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Chapter 1 describes the general properties of phthalocyanines, synthesis of metallo-
phthalocyanines, their photophysical features and their uses. The concepts of PDT and targeted 
therapeutics are also introduced. 
Chapter 2 describes the syntheses, characterization, photophysical studies and biological 
evaluation of cationic phthalocyanines. The trimethylaminophenoxy substituted phthalocyanines 
were synthesized through statistical condensation method, which gave a statistical mixture of 
isomers. Di-cationic phthalocyanines were found to be more cytotoxic. The amphiphilicity of the 
phthalocyanines played an important role. 
Chapter 3 covers the conjugation of phthalocyanines to peptides and is in pursuit of 
targeted therapeutics. The conjugation of two peptides, EGFR L1 (six amino acid residues) and 
EGFR L2 (twelve amino acid residues), gave conjugates with different charge, length, and 
hydrophobicity. The bioconjugates were synthesized via SPS method using typical peptide 
coupling agents. Cellular and animal studies are described for the conjugates. 
Chapter 4 is a description of the syntheses and characterization of pure regiomeric 
phthalocyanines. Previous chapters described, mostly, statistical mixture of Pcs. In this chapter, 
strategy to the synthesis of monomeric isomers and their characterization is presented.  
Chapter 5 describes the syntheses, characterization and cellular studies of a series of di-
cationic and pegylated phthalocyanines. Statistical condensation was used in the synthesis of 
macrocycles. Phthalocyanines with cationic charge at close proximity and on α-substitution 
position of the macrocycle were found to be more cytotoxic. In addition, Pc-antibody 
bioconjugates are discussed. The biological studies are described for both cationic Pcs and Pc-







1.1. Overview of Phthalocyanines 
Phthalocyanines (Pcs), also known as azaporphyrin derivatives, are a class of synthetic 
tetrapyrrolic compounds which are closely related to the naturally occurring porphyrin.
1
 The 
structural difference between the Pc and porphyrin macrocycles is that Pc has four extended 
benzo subunits and four nitrogen atoms at the meso position on the macrocycle; hence Pcs are 
often referred to as tetra-benzotetraazaporphyrins.
2
 The Pcs are a unique set of organic pigments 
that provide stable and strongly chromatic blues and greens. Pcs have strong absorbance at 
longer wavelengths than porphyrins and often have improved photophysical and photochemical 
properties.
3
 The first Pc was reported as a dark blue insoluble byproduct during the preparation 
of o-cyanobenzamide from phthalimide and acetic acid by Braun and Tcherniac in 1907.
4
 Von 
der Weid and Diesbach of Fribourg University, twenty years later, isolated Pc as an unexpected 




Since their discovery and identification (1900s), Pcs have been extensively used as dyes 
and pigments in paint, printing, textile and paper industries, due to their intense blue-green 
color.
6
 Owing to their increased stability, improved spectroscopic characteristics, diverse 
coordination properties, and architectural flexibility, Pcs have surpassed porphyrins in a number 
of applications.
7
 Most recently, Pcs have found high-tech applications in electrophotography and 
ink-jet printing and as photoconducting agents in photocopying devices.
8
 In addition, their 
novelty is rapidly growing in other fields where they are used as chemical sensors, liquid 
crystals, semiconductors, functional polymers and molecular metals, among others.
9





also found use in photodynamic therapy (PDT). Most of the photosensitizers used in PDT are 
tetrapyrrolic in nature; chlorin, porphyrin and bacteriochlorin. These cyclic tetrapyrrolic 
derivatives have an inherent similarity to naturally occurring porphyrins present in living matter; 
this probably gives them little or no toxicity in the absence of light.
10,11
 
1.2. Structure of Phthalocyanines 
The structure, charge and hydrophobicity of a photosensitizer determines its interactions 
with its biological surroundings and in turn determines its cellular uptake, subcellular 
localization and cytotoxicity.
12
 For instance, amphiphilic photosensitizers are often more 
photodynamically active than hydrophobic or hydrophilic molecules.
13
 Amphiphilicity, the 
element of having both hydrophobic and hydrophilic characteristics in different segments within 
the same molecule, permits distinct portions to interact differently with their biological 
environment and tend to enhance solubility, improve cellular uptake and intracellular targeting, 
and modulate aggregation. Though, it should be noted that strong amphiphilic photochemical 
internalization (PCI)-photosensitizers, including porphyrin, chlorin and phthalocyanine 




A number of functional groups have been added to Pc framework via the benzene rings to 
increase their utility. Functional groups such as alkyl chains, ethers, amines and thiols among 
others, have been introduced to enhance solubility.
15
 Instituting quaternized and sulfonated 
groups as substituents promotes solubility in aqueous media
16,17
 while organic functional groups 
such as thio and aryloxo promotes solubility in organic solvents.
18,19
 The substitutions can be 
made directly onto the Pc framework (Method S) or on the phthalonitrile precursor before 
condensation to form the Pc ring.
20





terms of degree of substitution; for example, a mono-substituted precursor leads to a 
tetrasubstituted Pc. Such substitutions can be carried out at any of the 16 available positions on 
the Pc framework (Figure 1.1). While the number and position of the substituents obtained by 
condensation is known, still constitutional isomers are obtained. Nevertheless, this method is 
preferred for adding substituents to the framework, giving Pcs with improved properties and 
desired chemical structures.
5
 The positions 1,4,8,11,15,18,22,25 are referred to as non-peripheral 








1.3. Synthesis of Phthalocyanines 
1.3.1. Synthesis via Tetramerization of a Single Precursor 
 A number of derivatives of ortho-substituted benzene can serve as precursors in the 
synthesis of Pc macrocycles (Figure 1.1). The precursors include phthalic anhydride, phthalic 
acid, phthalonitrile, phthalimide, diiminoisoindoline, o-cyanobenzamide, o-dibromobenzene and 
cyclohex-1-ene-1,2-dicarboxylic anhydride, among others. Phthalonitriles are popular for 
laboratory syntheses due to better yields, while phthalic anhydride is used in mass production, as 
it is relatively cheap.
22 
Phthalonitriles mostly require heating with a metal template in a high 





of phthalonitrile as a precursor is that it readily gives good yields of Pc complexes with most 
metals except mercury and silver, while other precursors such as phthalimide and other phthalic 




Scheme 1.1: Synthetic routes to metallophthalocyanines (MPcs) from various precursors. 
 Unsubstituted metal-free Pcs (H2Pcs) can be prepared using the Linstead method
24
 from 
phthalonitrile in refluxing lithium, sodium or magnesium alkoxide solution. The Pc can then be 
demetallated by adding a dilute acid to obtain H2Pc.  Tomoda method, a simple route to the 
synthesis of Pcs by heating phthalonitrile with catalytic amount of DBU or DBN, was reported in 
the 1980s.
25,26
 This route may yield up to 70% metal-free and 80% metallated Pcs. Strong 
organic bases such as DBU and DBN (Figure 1.2) generally promote the formation of Pcs in 





The use of these bases allows the reaction to proceed under milder conditions by promoting the 
formation of the alkoxide ion (Scheme 1.2). 
 
Figure 1.2: Structures of common organic bases used in Pc synthesis. 
Tomoda et al. proposed that the strong base is a proton acceptor, therefore, generating an 
alkoxide in the process (Scheme 1.2).
25
 The resulting alkoxide then acts both as the nucleophile 
and reducing agent as shown in Scheme 1.3.
27
 The alkoxide reacts with cyano group of a 
phthalonitrile, forming an alkoxyisoindoline intermediate, which rapidly tetracyclizes to form a 
Pc. 
 
Scheme 1.2: Formation of alkoxide anion (RO
-
) in preparation of Pcs.
25
 
The mechanism for the condensation of phthalonitriles to form Pcs (Scheme 1.3) 
probably involves a stepwise polymerization of the precursors or reactive intermediates, 
followed by coordination of the central metal ion (in case of MPcs) and finally ring closure to 
form the macrocycle.
28,29
 The ring closure is driven by aromatization, thermodynamic stability 
and inherent stabilization caused by metal coordination.  
 Metallated Pcs may also be prepared from metal-free Pcs through the addition of a metal 
salt into a reaction. The only limitation of this method is that large metals cannot be added into 
the cavity.
30
 Therefore, the metal salt must be added into a refluxing solution of the Pc or Pc 





Pc colorants is based on the methodology developed by Max Wyler at the ICI research center at 
Blackley, Manchester.
21
 The method involves heating inexpensive phthalic anhydride in the 
presence of a nitrogen source, such as urea and a catalyst such, as ammonium molybdate to 
obtain a Pc macrocycle. 
 





During cyclotetramerization of a 3-substituted phthalonitrile, a mixture of four isomers of 
C4h, C2v, Cs and D2h symmetry is obtained (Figure 1.3).
21 
In this case, due to the close proximity 
of the substituent to the core Pc ring, steric bulkiness of the substituents may be exploited to 





 synthesized. The enrichment of the C4h isomer reduces the D2h 
isomer.
31
 Electronic effects may also play a role in the formation of C4h isomer as the sterically 







methoxy group (strong electron donor) may deactivate the ‘ortho’ nitrile towards nucleophilic 
attack, leading to ‘meta’ nitrile selectivity. 
 




Similarly, statistical condensation of a 4-substituted phthalonitrile can lead to four 
constitutional isomers: C4h, C2v, Cs and D2h (Figure 1.4). Modification of the properties of 
substituents on the phthalonitrile and optimization of the reaction conditions can improve the 
formation of one or two of the major isomers. Unlike the 3-substituted phthalonitriles, there is no 
steric influence over the tetramerization reactions. Nonetheless, one case has been reported in 
which mild conditions gave a non-statistical mixture of Pc at room temperature;
36
 the electronic 
effect of the electron-rich alkoxy substituent may reduce the reactivity of the ‘para’ nitrile and 
not the ‘meta’ nitrile, so that nucleophilic attack takes place regioselectively. The major 












Bridged-Pcs or side-strapped Pcs, which may be obtained via bis-phthalonitriles, have 
been synthesized previously. Suitable bis(3-phthalonitriles) are prepared from 2,2-dialkyl 
propane-1,3-diols or chiral bis-naphthols, although many other bis(3-phthalonitriles) do not form 
side-strapped Pcs.
42
 The synthesis of these Pcs require highly dilute conditions for the 
cyclotetramerization of bis(3-phthalonitriles) or bis(4-phthalonitriles). This route results in D2h 
symmetry Pcs.
42-44
 A chiral side-strapped Pc with D2h symmetry has also been synthesized from 
bis(4-phthalonitrile) containing flexible linker (Scheme 1.4).
45
 A recent example is the synthesis 





Scheme 1.4: Chiral side-strapped Pc with D2h symmetry containing flexible linker.
45
 
 Non-peripherally substituted Pcs (with substituents on 1,4,8,11,15,18,22,25 positions) 
and peripheral Pcs (with substituents on 2,3,9,10,16,17,23,24 positions) have also been 
synthesized from appropriate single precursors. Octa-substituted non-peripheral Pcs are attractive 
because the substituents on the ring make them more soluble in organic solvents and the Pcs are 
obtained as single isomers.
47,48
 In addition, alkoxy groups at non-peripheral positions cause a 
large bathochromic shift of the Q-band into the IR region (above 750 nm).
49,50
 The octa-
substituted peripheral Pcs can be obtained by reacting 4,5-di-substituted phthalonitriles. If the 
two substituents are identical, then regiomerically pure Pcs are produced. Pre-formed Pc 





cleavage can give octahydroxy-substituted Pcs.
51,52





. Other Pcs in which substituents form a bridge between 2:3, 
9:10, 16:17, and 23:24 positions have been reported (Figure 1.5).
45
  Such Pcs form cyclic or 
macrocyclic units, with macrocyclic ones acting as ligands for metal cations and may form 
multiple metal ion arrays.
53
 Hexadeca-substituted Pcs (with substituents both at peripheral and 
non-peripheral positions) have also been synthesized.
48 
Others have been synthesized by means 








1.3.2. Synthesis via Tetramerization of Two or More Precursors 
The unsubstituted and many of the substituted Pcs reported in literature are symmetrical 
compounds. However, the inherent symmetry is a limitation for many purposes.
37
 The aim of the 
synthesis of Pcs with different substituents is to introduce different functional groups, which will 
provide coexistent features such as improved solubility and reactivity at the same time.
29,55-57
 
Many of the Pcs resulting from two or more different phthalonitriles is a statistical mixture of 
Pcs. However, if the precursors are symmetrical, then product ratios may change significantly.  
Various protocols for the tetramerization of two or more phthalonitriles have been 
reported in the past. Kobayashi and coworkers, in the late 1980s, developed a method to 





succinamide or diiminoisoindoline derivatives (Scheme 1.5).
35
 The ring expansion depends 
highly on the reactants’ properties and reaction conditions. The best yield could be achieved 
when a metal template is used and by selectively choosing the substituents on the precursors. For 
example, subphthalocyanines without substituents or with electron-withdrawing groups, and 
diiminoisoindoline derivatives with electron donating groups resulted in better yields.
6,58
 The 
only disadvantage of this approach, in many cases, is the fragmentation of the subphthalocyanine 




Scheme 1.5: Selective synthesis of A3B-type Pc.
60
 
Polymeric support in the synthesis of A3B-type Pcs (Scheme 1.6) was developed by 
Leznoff and coworkers in 1982, where a mono-functionalized diiminoisoindoline precursor (B) 
bound to solid polymer (P) reacts with another precursor (A).
61-63
  The soluble A4-type Pc and 
unreacted precursor-A are washed off and the desired Pc is cleaved under mild conditions. 
However, this is limited to easy on-off properties of the precursor bound to the solid support. 







Substituted Pcs (both symmetrical and unsymmetrical) resulting from two or more 
phthalonitriles can also be synthesized by statistical condensation of appropriate precursors, 
followed by chromatographic separation of the desired products. This may be achieved via 
Tomoda synthesis, just as those obtained from single phthalonitriles. This method, by 
optimization of reactant ratios and reaction conditions, may yield the desired compound in 
reasonable amounts, but still gives six (Figure 1.6) differently substituted Pcs, not including 
constitutional isomers.
35
 Modification of the properties of substituents on the phthalonitriles and 
optimization of the reaction conditions can improve the formation of one or two of the major 
isomers. The use of one of the phthalonitriles in excess is one such modification that may favor 
the formation A3B Pcs. In other cases, half Pcs have been used in the preparation of A2B2 Pcs.
64
 





Figure 1.6: Six differently substituted Pcs formed during mixed condensation of two                                                                                                  
differently substituted precursors, A and B.
35
 
1.4. Photophysical Properties of Phthalocyanines 
Photophysical processes are changes in the electronic states of a molecule and can affect 





wavelength is absorbed, may result in a variety of physical changes, but the chemical integrity of 
the molecule is retained. The absorbed light excites an electron from a lower (stable state) to a 
higher molecular quantum state (unstable with respect to the ground). The simplified Jablonski 
diagram (Figure 1.7) represents pathways of losing the energy to return to the ground state.
65-67
 
Absorption occurs from singlet ground state, S0, to a vibrationally excited level of first 
singlet excited state, S1, or sometimes to a second electronically excited state, S2. Through 
collisions with solvent molecules, vibrational relaxation occurs and the S2-excited molecules 
return to the first vibration level of S1, from which there are several possibilities: fluorescence, 
phosphorescence or heat generation. Fluorescence is a radiative process, which occurs when S1-
excited molecules lose energy and return to ground state directly. The S1→S0 transition which 




 sec).  
 
Figure 1.7: Jablonski Diagram illustrating electronic states of a molecule and transitions 







Phosphorescence process is preceded by internal conversion (IC) and intersystem 
crossing (ISC), which are non-radiative processes. Phosphorescence decay is comparable to 
fluorescence, except for the electron spin transition into a "forbidden" triplet state (T1) instead of 
the lowest singlet excited state. This transition is referred to as intersystem crossing. The decay 
from electronic level T1 occurs with lower energy relative to fluorescence. If this transition 
occurs within tissues, involved molecules may transfer energy to ground state molecular oxygen 
(in triplet state) to generate singlet oxygen, as one of the reactive oxygen species (ROS), that is 
capable of initiating oxidation of tissue. The concept of photodynamic therapy (PDT) is founded 
on this feature. 
1.4.1. Fluorescence Quantum Yield (Фf) 
The fluorescence quantum yield (Фf) of a compound is a measure of the efficiency of its 
molecules in the fluorescence process. It is the expression of the number of fluorescing 
molecules to the number of absorbed photons. It can be determined using a comparative 
method,
39
 and compared with ZnPc as reference in DMF solvent (Фf = 0.17).
68-70
 Other solvents, 
such as  DMSO and THF can also be used in fluorescence experiments, depending on the 
solubility of the Pcs under study. Fluorescence measurements in this project, gave fluorescence 
quantum yields ranging between 0.1 and 0.3 (in DMF solvent), which is in agreement with the 
literature for this type of Pc macrocycle.
69,70
 
1.4.2. Singlet Oxygen Quantum Yield (ФΔ) 
The singlet oxygen quantum yield is the measure of the efficiency of Pcs in the 
generation of singlet oxygen. The singlet oxygen quantum yield, ФΔ, value may be determined 
by means of photochemical or photophysical methods. A photochemical method was used in this 





scavenger is a sensitive compound that reacts quickly with singlet oxygen as soon as it is 
produced. The Pc is irradiated with light and the decay of the scavenger is measured 
spectroscopically. Some of the scavengers that may be used include guanine, furan and 1,3-
diphenylisobenzofuran (DPBF). In this study, the singlet oxygen quantum yields (Ф∆) were 
determined in DMF solvent through a relative method,
 
using ZnPc (Фf = 0.56) as reference and 
DPBF as a scavanger.
71
 
1.4.3. UV-vis Absorption Spectra 
All monomeric H2Pcs and MPcs exhibit a characteristic UV-vis absorption spectrum, 
which includes a Soret-band in the visible region at approximately 350 nm, and a major strong 
Q-band in the near-IR region (670 – 750 nm), as shown in Figure 1.8.
72
 The Pcs with four 
substituents at the α-position usually exhibit a bathochromic shift in their UV-vis absorption 
spectra.
73
 They exhibit approximately a 15 nm red-shift of their Q-bands, and 20 nm red-shift of 
their Soret-bands compared with the mono-substituted Pcs. Even within mono-substituted Pcs, 
those which have the substituent at α-position, show approximately 3 nm red-shift in their Soret-
bands, and approximately 3 nm hypsochromic shift in their Q-bands compared with β-substituted 
Pcs. This shows that both the number and the position of the substituents on the macrocycle 
affect the absorption spectra of Pcs.  
In addition, for the Pcs exhibiting narrow and intense Q-bands, and follow Beer-Lambert 




mol/L, it is usually 
believed that no aggregation has occurred within this range.
74
 The typical molar extinction 






. In this work, similar features were 
observed, in addition to the Stokes Shifts in the range 2 – 10 nm, which is in agreement with 








Figure 1.8: A typical absorption spectrum of a ZnPc in HPLC grade DMF solvent. 
1.5. Applications of Phthalocyanine 
Since their discovery and identification, Pcs have been extensively used as dyes and 
pigments in paint, printing, textile and paper industries due to their intense blue-green 
color.
72,77,78
 Most recently, Pcs have found high-tech applications in electrophotography and ink-
jet printing and as photoconducting agents in photocopying devices.
29
 In addition, their novelty 









 and molecular metals,
83
 among others. 
1.5.1. Applications in Photodynamic Therapy 
Pcs have also found use in the field of PDT, a therapeutic modality in which a dye used 
as a photosensitizer is administered to the patient. Following a time interval during which the dye 
localizes in the diseased tissue, the latter is exposed to light of appropriate wavelength and 
destroyed. The destruction of the tissues is caused by the excitation of the dye in the presence of 








Figure 1.9: Treatment of cancer using PDT.
86
                                                                           




a porphyrin derivative, as a PDT photosensitizer. 
However, it has synthetic reproducibility problems, long half-life in patients and low selectivity 
for tumors.
87,88
 Therefore, benzoporphyrin derivatives, chlorins, purpurins and Pcs have emerged 
as second generation photosensitizers, with Pcs having the most promising PDT applications in 
the treatment of cancer due to their strong absorptions at wavelengths > 660 nm and generally 
low dark toxicity and high stability. 
Pcs have been used in photobiology and PDT since 1985,
89
 with derivatives such as ZnPc 
(CGP55847), AlPcS4 (Photosense®) and Pc4 currently being used in clinical trials.
88,90,91
 The di-
substituted silicon-Pc, Pc4,  with an axial alkylsilyl ligand bearing a terminal amine (Figure 1.10) 









An ideal photosensitizer should be chemically pure and maintain a stable composition 
throughout the treatment. It should have preference for tumor cells. Its dark toxicity should be 
minimal but should have high phototoxicity. It should have a high 
1
O2 quantum yield and a large 
absorption coefficient in the range 600 – 800 nm wavelength. It is also important that the 
photosensitizer is rapidly cleared from the normal cells after treatment. The drugs should be 
amphiphilic.
10,12,88
 Various hydrophilic groups such as carboxylic acids, phosphonic acid, 
sulfonic acid, hydroxyl and quaternary ammonium salts have been added to the hydrophobic Pc 
ring to achieve this.  
 In addition, cell-targeted therapeutics has received significant attention and seems to 
define the future of PDT of cancers. Sibrian-Vasquez et al. recently reported the synthesis 
and biological evaluation of cancer cell-targeted Pc-peptide conjugates with high 
phototoxicity towards human carcinoma HEp2 cells.
93
 Positively charged macrocycles have 
also demonstrated a potential to interact with negatively charged tumor cell plasma 
membranes and bacterial surfaces, thus enhancing their cellular targeting ability.
94,95
 Cationic 









 They also bind to anionic DNA and RNA,
100,101
 which can enhance their 
overall PDT efficacy. In Chapters 2 and 5, the syntheses of cationic Pcs as potential 
candidates for PDT is described. 
1.5.2. Applications in Bioimaging 
Pcs have also been used as colorants or dyes.
29,72,78
 Nevertheless, till recently, not many 
Pcs have been reported as fluorescent agents, appropriate for bioconjugation applications.
102
 
Most Pcs are hydrophobic, and are inclined to aggregate in aqueous medium, or they do not have 





commercially available Pc dye. It has two axial polyethylene glycol moieties and two free 
carboxylic acids for bioconjugation.
103
 The axial glycol moieties make the dye water soluble and 
therefore, attractive as a biomarker. Different biomolecules such as peptides and proteins can 
bind to Pc dyes; the dyes are, therefore, applied in bioimaging and bioanalytical fields.
104-107
 
Another group of MPcs, which was synthesized by Renzoni, et al.,
108
 lacks the water soluble 
axial groups described in La Jolla blue, but contains both water soluble groups and another 
reactive group that is bound to the benzo-ring (Figure 1.11). The copper in this structure may 
also be replaced by another metal, such as silicon, which will allow it to bear two axial ligands. 
 
Figure 1.11: Structure of a) La Jolla Blue dye
TM 109
 and b) Copper sulfophthalocyanine dye.
108
 
The conjugation of Pcs with peptide  ligands or antibodies directed at specific receptors 
over-expressed in cancer cells, such as the human epidermal growth factor receptor (EGFR), is a 
remarkable strategy for increasing their biological efficacy.
110-114
 EGFR is over-expressed in 





which are believed to precede the development of cancer.
115-117
 In the development of selective 
delivery of cytotoxic drugs to the tumor sites,
118-124





 have proved attractive due to their ready-availability, 
low immunogenicity, ease of conjugation to other molecules, and a relatively superior EGFR-
targeting ability. Pcs conjugated to peptides via various linkers for colorectal cancer (CRC) 
diagnostic applications have been evaluated in vitro and in vivo.
125
 Chapters 3 and 5 of this work 
reports the syntheses, photophysical, and biological evaluation of Pc conjugates to either peptide 
ligands or a monoclonal antibody, which can serve as bioimaging agents.  
Polyethylene glycols (PEG) have been used as delivery vehicles
126,127
 and, in other cases, 
may be covalently-bound
128,129 
to Pcs for improved delivery to target tissues. Pegylation of 
photosensitizers increases their water-solubility, serum life, tumor accumulation, and also 
reduces their uptake by the reticuloendothelial system.
130,131
 Investigations were carried out to 
identify potential ZnPcs that may serve as photosensitizers with enhanced biological 
effectiveness. In Chapter 4, the syntheses, characterization and biological evaluation of a new 
series of regiomerically pure Pcs, containing at least a PEG group are described.  
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SYNTHESES AND BIOLOGICAL EVALUATION OF CATIONIC 
TRIMETHYLAMINOPHENOXY-SUBSTITUTED ZINC(II)-PHTHALOCYANINES 
2.1. Background 
 Photofrin was the first PDT drug approved for the treatment of thousands of 
patients worldwide since 1995. Nonetheless, it has some shortcomings ranging from being 
a complex mixture of compounds to having a limited tissue selectivity and absorbing only 
weakly in the red region of the spectrum (λmax = 630 nm),
1
 where light penetrates deeper 
into tissues.
2,3
 Therefore, intense research in the last 20 years, has focused on the 
developing PS with improved tumor-tissue selectivity and overall PDT efficiency. Pcs are 
predominantly promising PS owing to their long wavelength absorptions in the infra-red 
region of the spectrum (670 – 750 nm) with high extinction coefficients, high 
photochemical stability and superior ability to generate singlet oxygen.
4-7
 The major 
challenge in the use of the Pcs is the insolubility of the macrocycle in common organic 
solvents. 
 Different water-solubilizing and/or bulky groups have been attached to either the 
macrocycle periphery of Pcs or their central core, in order to improve their photophysical 
features such as their quantum yields and biological interactions or photodynamic 
efficacy.
7
 Of all the substituted Pcs, positively charged ones have received special 
attention due to their strong interactions with negatively charged tumor cell plasma 
membranes, thus enhancing their cellular targeting ability.
8-11
 Equally, cationic PS have 
been observed to target vulnerable subcellular units such as the mitochondria,
12-16
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 The photosensitizers can bind to anionic DNA and 
RNA,
21-24
 therefore, largely boosting their PDT efficacy.  
 Substantial variations in the cytotoxicity, cellular uptake and photodynamic 
capability of a series of porphyrins with similar cationic groups (-N(CH3)3
+
) have been 
reported recently.
15
 The features of a series of octa-cationic pyridyloxy-Pcs bearing 
different metal ions and axial ligands in human HEp2 cells have also been reported 
before.
19 
In addition, a Pc bearing a single quaternary ammonium group (-NH3
+
) was 
found to be ~20-fold more phototoxic than its corresponding tetra-ammonium Pc toward 
HEp2 cells.
25
 Although all the cationic porphyrins in this series targeted cell mitochondria, 
the mono-cationic was the most phototoxic, while the di-cationic accumulated the most 
within HEp2 cells. 
  In this chapter, the synthesis of cationic Pcs which will add to the library of 
photosensitizers with a potential to act as biomarkers or photosensitizing agents is reported. 
Lowery reported a simple synthesis of silicon-dichlorophthalocyanine in 1965.
26
 He used 
diiminoisoindoline as a starting material, which was reacted with silicon tetrachloride to 
obtain 71% yield of the silicon Pc. A similar synthesis has been reported by Li, H. et al.
19
 A 
direct way of synthesizing ZnPcs has also been reported, where zinc acetate acts as the source 
of metal.
16,19
 The starting phthalonitrile was refluxed in n-pentanol using a small amount of 
DBU as a catalyst to obtain 88% yield.  
Throughout this chapter, statistical condensation of phthalonitriles to Pcs is the main 
method of synthesis. Phthalonitriles were refluxed in DMAE using catalytic amounts of DBN 
to obtain Pcs in reasonable yields. This method of synthesis is known as ‘Tomoda method’ 





regiomeric Pc, all the other Pcs were mixtures of isomers. The cationic Pcs were achieved via 
trimethylation of the 4-aminophenoxy-substituents on the Pc core. In general, the mono-, di-, 
tetra- and octa-amino Pcs were synthesized and then trimethylated them to obtain 
corresponding positively charged analogues. As part of the continued investigation of cationic 
Pcs as potential photosensitizers, the quaternized Pcs were evaluated in vitro and the 
preliminary results are described.  
2.2. Synthesis 
2.2.1. Synthesis of Phthalonitriles  
The phthalonitriles used in the synthesis of Pcs were prepared according to the 
procedures established in literature, with slight modifications.
14,19
 The mono-, di-, tetra- and 
octa-cationic Pcs 2.5, 2.7, 2.12, 2.14, 2.16, 2.20, 2.22, 2.25 and 2.27 were synthesized 
according to strategies shown in Schemes 2.1 – 2.5. The key precursors: 3(4)-(p-N-Boc-
aminophenoxy)phthalonitrile 2.3 and 2.10 (Scheme 2.1 and 2.2) and 4,5-di(p-N-Boc-
aminophenoxy)phthalonitrile 2.10 (Scheme 2.3) were all obtained in >80% yields from 
commercially accessible 3-nitrophthalonitrile and 4-nitrophthalonitrile, or 4,5-
dichlorophthalonitrile and p-N-Boc-aminophenol in DMF at 80 ºC, in the presence of K2CO3, 
following known methodology.
27,28 
Another important precursor 2,2-bis(2,3-dicyanophenoxy) 
biphenyl 2.23 (Scheme 2.4 and 2.5), was obtained in 66% yield according to a known 
literature procedure.
29
 The use of unprotected p-aminophenol in these reactions, gave lower 
yields (60 – 70%) of the corresponding aminophenoxyphthalonitriles. This is due to the fact 
that the unprotected amino groups are more polar and thus, the Pcs got stuck in the column. 





aminophenol, which was reacted with either 3-nitrophthalonitrile or 4-nitrophthalonitrile to 
obtain the desire precursors.  
These phthalonitriles, alongside commercially accessible 4-tert-butylphthalonitrile, 
were used in the synthesis of cationic Pcs. The synthesis of mixture of isomers of Pcs, via 
statistical condensation, was accomplished using 4-tert-butylphthalonitrile or 2,2-bis(2,3-
dicyanophenoxy) biphenyl 2.23. In order to enhance the solubility of Pcs – which are 
infamous for their insolubility – 4-tert-butylphthalonitrile was used. The bulky tert-butyl 
groups on the Pc macrocycle, boosts the hydrophilicity and decrease the aggregation affinity 
of the Pc core. Notably, reduced aggregation may improve the uptake of the Pcs by the cells, 
causing higher photodynamic activities.
30
 
The molecular structures of four phthalonitriles crystals, which were grown from 
dichloromethane for X-ray analyses, are shown in Figure 2.1. The dicyanophenyl group in 
phthalonitrile 2.3 was essentially orthogonal to the central phenyl group and formed a dihedral 
angle of 89.83(3)º with it. Its CO2N plane was tilted considerably less from the central ring 
and formed a dihedral angle of 28.47(6)º with it. In phthalonitrile 2.10, the conformation was 
similar, with the dicyanophenyl and central phenyl rings formed a dihedral angle of 86.23(4)º. 
Its CO2N plane was almost coplanar with the central phenyl and had a dihedral angle 3(1)º. 
The dicyanophenyl plane was nearly orthogonal to both phenyl rings connected to it through 
O in phthalonitrile 2.18, with the dihedral angles being 79.22(2)º and 85.25(2)º. The tips of 
the two CO2N planes out of the phenyl groups to which they were bonded were midway 
between those seen in 2.3 and 2.10; 14.7(1)º and 14.9(1)º for this phthalonitrile. The tips of 
the carbonyl O were in opposite directions in 2.18; one toward the Ph (CN)2 and the other 





74.5(4)º about the bond connecting the two rings. Its dicyanophenyl groups were tilted by 
comparable amounts out of the phenyl groups they are bonded to, and formed dihedral angles 
of 70.68(7)º and 67.60(7)º with them. The dicyanophenyl groups formed a dihedral angle of 












Figure 2.1. X-ray structures of phthalonitriles 2.3, 2.9, 2.10, 2.18 and 2.23 obtained from 
single crystals (N atoms are blue, O atoms red and H atoms green; H atoms are white in 
2.23). Ellipsoids are drawn at the 50% probability level.  
2.2.2. Synthesis of Cationic ZnPcs 
 In order to enhance the solubility of the precursor Pcs and the target cationic 








with the appropriate p-N-Boc-aminophenoxyphthalonitrile. A mixture of N-Boc-protected 
phthalonitrile 2.3 and 3 equiv. 4-tert-butylphthalonitrile was reacted in the presence of 
Zn(II) acetate and a catalytic amount of DBN in DMAE (Schemes 2.1). After refluxing the 
reaction mixture for 5 h, a number of ZnPcs were obtained. The A4-type Pc was the major 
product, followed by the A3B- and A2B2-types ZnPcs, as confirmed by TLC and MS 
analyses. In order to purify the mixture, column chromatography using mixtures of hexane 
and ethyl acetate for elution gave the subsequent N-Boc-protected A3B-type ZnPcs in 15-
20% yields and the A2B2-type ZnPcs in 19-25% yields. The deprotection of the Boc 
groups under acidic conditions (using TFA/DCM) at room temperature, gave ZnPcs 2.4 
and 2.6 in quantitatiive yield. The yields of ZnPcs 2.4 and 2.6 were low when unprotected 
aminophenoxyphthalonitriles were used in the tetramerization reactions.  
 The free amino groups were quaternized using excess iodomethane and DIPA in 
DMF at room temperature.
15
 The subsequent trimethylaminophenoxy-substituted ZnPcs 
2.5 and 2.7 were obtained in 50-70% yields. The A3B- and A2B2-type ZnPcs 2.5 and 2.7 
were obtained mixtures of regioisomers as has been reported in literature before.
31-35
 The 
di-cationic ZnPcs 2.7 and 2.14 are particularly complex mixtures of up to 15 regioisomers 
of both trans-ABAB and cis-AABB types. Due to their exceedingly similar retention times 
on reversed-phase HPLC, isomers of these Pcs were not isolated. There are chances that 
the distribution of isomers may slightly be different for the α- and β-substituted Pcs, due 
to the higher steric hindrance resulting from the neighboring α-substituents during the 
macrocyclization step as reported previously in literature.
36
 The chromatograms for the 
cationic ZnPcs 2.7 and 2.14 obtained during reversed-phase HPLC using water/methanol 








Scheme 2.1.  Synthesis of mono- and di-cationic α-trimethylphenoxy-substituted ZnPcs 2.5 
and 2.7. Reagents and conditions: (a) K2CO3, DMF, 65 °C, 24 h (70%); (b) K2CO3, DMF, 80 
°C, 3 h (80%); (c) 4-tert-butylphthalonitrile, Zn(OAc)2, DMAE, 140 °C, 5 h (15-20%); (d) 
DCM/TFA, 0 °C, 4 h (quantitative); (e) CH3I, DIPA, DMF, 3 days, r.t. (50-70%). 
 The macrocyclization of 4-(p-N-Boc-aminophenoxy)phthalonitrile 2.10 under 
similar conditions as described above, followed by acidic deprotection of N-Boc  group 
using TFA, gave tetra-amino ZnPc 2.15 as a mixture of regioisomers, in 20 % yield 
(Scheme 2.2). The quaternization of amino groups using excess iodomethane gave ZnPc 
2.16 in 82% yield.  
 Using a similar strategy, the di-amino ZnPc 2.19 was synthesized from 4,5-di(N-
Boc-phenoxyl)phthalonitrile 2.18 and 4-tert-butylphthalonitrile (Scheme 2.3). The A3B-
type ZnPc 2.19 was isolated in 9% yield after TFA deprotection of N-Boc groups. The 
octa-amino ZnPc 2.21 was achieved in 50% yield from self condensation of phthalonitrile 
2.18. The quaternization of the amino groups on ZnPcs 2.19 and 2.21 using a large excess 








Scheme 2.2.  Synthesis of mono-, di- and tetra-cationic β-trimethylphenoxy-substituted ZnPcs 
2.12, 2.14, and 2.16. Reagents and conditions: (a) K2CO3, DMF, 65 °C, 24 h (87%); (b) 
K2CO3, DMF, 63 °C, 4 h (73%); (c) 4-tert-butylphthalonitrile, Zn(OAc)2, DMAE, 140 °C, 5 h 
(9-50%); (d) DCM/TFA, 0 °C, 4 h (quantitative); (e) CH3I, DIPA, DMF, 3 days, r.t. (50-
90%). 
 All the Pcs synthesized in this Chapter are a mixture of isomers, as discussed in 
Chapter 1, except Pc 2.21. In order to decrease the number of isomers, adjacent-
substituted di-aminophenoxy-Pcs 2.24 and 2.26 were synthesized (Schemes 2.4 and 2.5). 
The diphthalonitrile 2.23, linked via the ortho positions of biphenyl, was synthesized 
according to a literature procedure.
29
 The bis-phthalonitrile prevented the formation of the 







cyclotetramerization reaction from fifteen to only three. The trimethylation of the amino 
groups on ZnPcs 2.24 and 2.26 using excess of iodomethane gave the subsequent cationic 
ZnPcs 2.25 and 2.27 in 80-90% yields. 
 
Scheme 2.3. Synthesis of β-substituted di- and octa-cationic ZnPcs 2.20 and 2.22. Reagents 
and conditions: (a) K2CO3, DMF, 63 °C, 24 h (83%); (b) 4-tert-butylphthalonitrile, Zn(OAc)2, 
DMAE, 140 °C, 5 h (15-50%); (c) DCM/TFA, 0 °C, 4 h (quantitative); (d) CH3I, DIPA, 
DMF, 3 days, r.t. (50-70%). 
 
Scheme 2.4.  Synthesis of cis-A2B2 α-substituted di-cationic ZnPc 2.25. Reagents and 
conditions: (a) 3-(4-N-Boc-aminophenoxy)phthalonitrile, Zn(OAc)2, DMAE, 140 °C, 5 h 








Scheme 2.5.  Synthesis of cis-A2B2 β-substituted di-cationic ZnPc 2.27. Reagents and 
conditions: (b) 4-(4-N-Boc-aminophenoxy)phthalonitrile, Zn(OAc)2, DMAE, 140 °C, 5 h 
(11.4%); (b) DCM/TFA, 0 °C, 4 h (quantitative); (c) CH3I, DIPA, DMF, 3 days, r.t. 
(58.3%). 
2.3. Spectroscopic and Photophysical Characterization 
 The solubility in polar organic solvents such as DMSO, DMF, THF, and methanol 
of all cationic ZnPcs 2.5, 2.7, 2.12, 2.14, 2.16, 2.20, 2.22, 2.25 and 2.27 was investigated. 
They were all soluble in these solvents. Captivatingly, the solubility of these ZnPcs in 
organic solvents was observed to reduce with increase in cationic charge, whereas their 
solubilityin water increased with cationic charge (2.5 ~ 2.12 ~ 2.7 ~ 2.20 ~ 2.25 ~ 2.27 < 
2.14 < 2.16 < 2.22). The tetra- and octa-cationic ZnPcs 2.16 and 2.22 precipitated after 
quaternization reaction in DMF and DIPA and therefore, were easily isolated upon 
exhaustive methylation. After removal of reaction solvent, the solids were washed with 
acetone to remove the base and excess iodomethane. Only Pcs 2.14, 2.16 and 2.22 were 
water-soluble: Pc 2.22 at 2.69 × 10
-3
 M, Pc 2.16 at 4.75 × 10
-3
 and Pc 2.14 at 4.03 × 10
-3
 
M in distilled water. In addition, Pc 2.22 was highly hygroscopic. The other Pcs remained 
aggregated in water, even after sonicating them. Nevertheless, all the Pcs remained soluble 
when diluted from concentrated stocks in DMF or DMSO into PBS (final DMF or DMSO 
concentration of 1%) at 10 µM concentrations.  
 The N-Methylated Pcs are known to be sensitive to heat and therefore, require 
special handling.
37







removed at temperatures < 50 °C to avoid loss of N-methyls and immediately followed by 
their NMR and MS characterization. MS analyses revealed that the ZnPcs can be readily 
N-demethylated; for example, the mass spectrum of ZnPc 2.22 displayed a large number 
of fragments, dominated by a peak at m/z 1671.679 [M-8I-7CH3]
+
. N-Demethylation of 
these cationic ZnPcs was also observed upon prolonged storage at room temperature.
38
   
 The ZnPcs were  characterized by NMR, using mainly deuterated DMF solvent 




C-NMR spectra of ZnPcs 2.5, 
2.7, 2.12, 2.14 and 2.16 (Appendix A.2 – A.6), suggested the presence of various 
regioisomers (up to fifteen for the di-cationic ZnPcs), which was expected for the 
cyclotetramerization reaction of two mono-substituted phthalonitriles, and also in 
agreement with the observations from reversed-phase HPLC. The 
1
H-NMR of the N-Boc-
protected Pc precursors, gave two sets of signals were observed for the tert-butyl protons 
on the macrocycle (centered at ~ 1.9 ppm) and the N-Boc group(s) (centered at ~ 1.5 
ppm). Notably, the α-substituted N-Boc Pc-precursors had two sets of signals for the N-
Boc group (centered at 1.4 and 1.5 ppm), while the β-substituted N-Boc protected Pc 
precursors had only one set centered at 1.6 ppm. The N-Boc precursors of Pcs 2.24, and 
2.26 gave similar results. Equally, the mono- and di-cationic ZnPcs exhibited distinct 
variations in their chemical shifts of the -N(CH3)3 protons, possibly due to macrocycle 
distortion and/or hindered rotation. This is illustrated by the β-substituted ZnPc 2.12, 
which had only one singlet for the N(CH3)3 protons at 3.98 ppm, while the α-substituted 
ZnPc 2.5 (Figure 2.2) exhibited two singlets at 3.62 and 3.72 ppm. In the same way, the 
di-cationic β-substituted ZnPc 2.20 (Figure 2.3) showed only one singlet for the N(CH3)3 





















 The spectroscopic properties of cationic ZnPcs 2.5, 2.7, 2.12, 2.14, 2.16, 2.20, 
2.22, 2.25 and 2.27  in DMF and PBS at pH 7.4 were investigated and summarized in 
Tables 2.1 and 2.2 respectively. All the ZnPcs showed strong absorption Q-bands between 
680-686 nm and emissions between 682-689 nm in DMF solvent. In PBS (pH 7.4), the 
bands were broader and less intense. The fluorescence was also quenched, indicating 
aggregation (Figure 2.4). The Stokes’ shifts were in the range of 2-4 nm (Table 2.1 and 
2.2) in both DMF and PBS. Only minor red shifts (1-5 nm) were observed in the 
absorption bands of the α- versus the β-substituted ZnPcs. The Pcs did not aggregate at 
concentrrations up to 8.8 µM in DMF. Within this range, all the ZnPcs showed a Soret 
absorption band between 330 – 370 nm, a strong Q-band centered at ~ 684 nm and two 
vibrational bands at around 620 and 650 nm. The bands strictly followed the Lambert-




Figure 2.4. UV-Vis spectra for a) Pc 2.5 (blue), 2.12 (green), and 2.20 (orange) at 8.8 
µM in DMF; 2.5 (dotted blue), 2.12 (dotted green), and 2.20 (dotted orange) at 8.8 µM 
in PBS, pH 7.4. b) Pc 2.7 (red), 2.14 (brown), 2.16 (violet) and 2.22 (black) at 8.8 µM in 
DMF; 2.7 (dotted red), 2.14 (dotted brown), 2.16 (dotted violet) and 2.22 (dotted black) 








Figure 2.5. UV-Vis spectra for Pc 2.5, 2.7, 2.12, 2.14, 2.16, 2.20, 2.22, and 2.25 in DMF: 







 The ZnPcs at 1000 µM concentrations in DMF showed no evidence for colloidal 
solution formation, indicating that no large aggregates were formed.
40
 The fluorescence 
quantum yields for the ZnPcs were determined in the same solvent and all compounds 




 The determination of singlet oxygen quantum yields using ZnPc as the reference 
and 1,3-diphenylisobenzofuran (DPBF) as the scavenger of singlet oxygen was 
accomplished in DMF.
43
 The absorption decay of DPBF measured at 417 nm was used to 
calculate the singlet oxygen quantum yields, within accuracy of ~ 10% (Table 2.1). The 
mono-cationic ZnPc 2.5 (0.47) gave the highest quantum, yield while that of ZnPc 2.20 
(0.16) was the lowest. This suggests that synthesized series of ZnPcs consists of efficient 
producers of singlet oxygen and therefore, could find application as PDT 
photosensitizers. The di-cationic ZnPc 2.14 may find use in PDT due to its high 
1
O2 
quantum yields.  
Table 2.1. Spectral properties of ZnPcs 2.5, 2.7, 2.12, 2.14, 2.16, 2.20, 2.22, 2.25 and 
2.27 in DMF at room temperature. a: excitation at 640 nm; b: calculated using ZnPc (Фf = 














2.5 684 686 2 0.16 0.47 
2.7 686 689 3 0.21 0.31 
2.12 683 687 4 0.13 0.33 
2.14 683 686 3 0.18 0.44 
2.16 684 687 3 0.13 0.35 
2.20 684 687 3 0.19 0.16 
2.22 686 688 2 0.13 0.28 
2.25 685 687 2 0.11 0.33 








Table 2.2. Spectral properties of ZnPcs 2.5, 2.7, 2.12, 2.14, 2.16, 2.20, 2.21, 2.22, 2.25 
and 2.27 in PBS (pH = 7.4) at room temperature. 






Stokes shift (nm) 
2.5 679 681 2 
2.7 680 684 4 
2.12 677 680 3 
2.14 678 681 3 
2.16 679 682 3 
2.20 678 681 3 
2.21 682 685 3 
2.22 680 684 4 
2.25 680 683 3 
2.27 677 679 2 
a: excitation at 630 nm.
 
2.4. Cellular Studies 
 The in vitro properties including the time-dependent cellular uptake, cytotoxicity 
and intracellular localization for this series of cationic ZnPcs, were investigated in human 
carcinoma HEp2 cells. The cytotoxicity of the ZnPcs was evaluated using the Promega’s 
CellTiter Blue viability assay, as previously reported in litetrature,
15
 at concentrations up 
to 400 µM for each positively charged ZnPc and for the octa-amino-Pc 2.21. The results 
from these studies are summarized in Table 2.3. The IC50 values for the ZnPcs were 
calculated from dose-response curves. The cytotoxicity for ZnPcs is considerably varied 
and it depends not only on the number of charges but also on the Pc’s substitution site, 
i.e. on α- vs. β-substitution. While it has been previously reported that a mono-cationic 









gave high phototoxicities, this series of Pcs has di-cationic as the most phototoxic 







 The compounds showed low dark cytotoxicity with calculated IC50 > 150 µM. The 
mono- and di-cationic ZnPcs were phototoxic toward HEp2 cells at 1.5 J/cm
2
 light dose. 
The most phototoxic were the di-cationic ZnPcs 2.7 ~ 2.25 > 2.27 ~ 2.14 > 2.20 with 
determined IC50 of 2.7, 2.7, 12.1, 13.4 and 39.6 µM, respectively, followed by mono-
cationic ZnPc 2.5 with IC50 of 46.3 µM. The other Pcs showed IC50 > 100 µM at 1.5 
J/cm
2
, including the mono-cationic 2.12 and the octa-amino-Pc 2.21. There was no 
correlation between phototoxicity observed for the ZnPcs and the determined single 
oxygen quantum yields, because in addition to 
1
O2 other ROS can be involved in the 
observed photo-induced cytotoxicity, and their site(s) of generation will also determine the 
mechanisms and efficacy of cell death. It is very interesting to note that the α-substituted 
Pcs (i.e. 2.5, 2.7 and 2.25) were considerably more phototoxic (ca. 5-fold enhancement) 
than their β-substituted analogs.  
 Additionally, there was no major variation in the phototoxicity of the di-cationic 
ZnPcs 2.7 and 2.25, nor of ZnPcs 2.14 and 2.27, even if ZnPcs 2.7 and 2.14 were mixtures 
of about 15 regioisomers, containing both the cis-A2B2 and trans-ABAB macrocycles, 
while 2.25 and 2.27 were mixtures of 3 regioisomers of only the cis-A2B2 type. These 
results suggest that the cis-A2B2 ZnPcs were the most phototoxic of this series. Moreover, 
ZnPc 2.7 bearing the di-cationic charges on both adjacent and opposite benzene rings was 
15-fold more phototoxic than ZnPc 2.20 bearing di-cationic charges on the same benzene 
ring, further indicating the imortance of the α- vs. β-substitution on Pc phototoxicity. 
Amongst all the ZnPcs investigated, 2.7 and 2.25 were the most phototoxic and to had the 
highest dark cytotoxicity/phototoxicity ratio of > 120. This makes it the most promising 







Table 2.3. Dark and phototoxicity (at 1.5 J/cm
2
 light dose) of ZnPcs 2.5, 2.7, 2.12, 2.14, 
2.16, 2.20, 2.22, 2.25 and 2.27 toward HEp2 cells using the Cell Titer Blue assay. 





2.5 > 400 46.3 > 9 
2.7 344 2.7 128 
2.12 > 400 > 100 > 4 
2.14 156 13.4 12 
2.16 > 400 > 100 > 4 
2.20 > 400 39.6 > 10 
2.21 > 400 > 100 > 4 
2.22 > 400 > 100 > 4 
2.25 > 400 2.7 > 148 
2.27 > 400 12.1 > 33 
 Considerable differences were also observed in the cellular uptake of this series of 
ZnPcs, as shown in Figure 2.6. All the ZnPcs exhibited similar uptake patterns with rapid 
accumulation within a short period followed by a plateau, which was reached 1-2 h after 
Pc exposure. The octa-amino-Pc 2.21 accumulated the highest cellular uptake, possibly 
due to its higher hydrophobicity compared with the other cationic ZnPcs. Of all the 
postively charged ZnPcs, the di-cationic ZnPc 2.20 had the highest uptake values at all 
time points investigated, while the tetra-cationic Pc 2.16 had the lowest uptake. From 
these results, it can be concluded that the amphiphilicity of the cationic Pcs plays a 
crucial role on the extent of their cellular uptake, which is in concurrence with previous 
literature reports;
15,25,44
 in the porphyrin series, the di-cationic macrocycles were also 
found to accumulate the most within HEp2 cells. The two positive charges on the β-
positions of a single isoindole unit in ZnPc 2.20 confers higher amphiphilicity to the Pc 
compared with the regioisomeric mixtures in 2.7, 2.14, 2.25 and 2.27, which enhances 








Figure 2.6. Time-dependent uptake of cationic Pcs at 10 µM by HEp2 cells: Pc 2.5 
(black), 2.7 (orange), 2.12 (brown), 2.14 (green), 2.16 (light-blue), 2.20 (red), 2.21 
(purple), 2.22 (dark-green), 2.25 (blue) and 2.27 (pink). 
 The main sites of localization of the cationic ZnPcs within the cells were also 
examined by fluorescence microscopy, upon exposure of HEp2 cells to 10 µM Pc for 6 h. 
Figures 2.7 – 2.11 show the fluorescent patterns observed for each cationic ZnPc. The co-
localization investigations of the ZnPcs were accomplished using the organelle specific 
fluorescent probes: ER Tracker Blue/White (for endoplasmic reticulum, ER), MitoTracker 
Green (mitochondria), BODIPY Ceramide (golgi) and LysoSensor Green (lysosomes) to 
evaluate the main sites of localization within the cells. The di-cationic ZnPc 2.7 localized 







localized mostly in the ER and lysosomes, but not in mitochondria. In contrast, the tetra- 
and octa-cationic Pcs 2.16 and 2.22 were largely located in mitochondria and to a lower 
degree in the Golgi; it was not found in the ER.  
 The di-cationic ZnPcs 2.14 and 2.20 were found mostly in the lysosomes and 
Golgi, respectively, and to a lesser degree in the ER. ZnPc 2.27 was also found mostly in 
the Golgi and ER. Nevertheless, the mono-cationic ZnPcs 2.5 and 2.12 were found largely 
in the lysosomes and Golgi, respectively, and were also localized in the ER. These results 
exhibit very diverse subcellular distributions for these cationic ZnPcs. This is possibly due 
their varied interactions with membranes in addition to other biological substrates, and 
probably their diverse cellular uptake mechanisms.  
 It had been previously observed that a octa-cationic-Pcs localized intracellularly 
mainly in the lysosomes,
19
 and that cationic porphyrins bearing up to four charges were 
mainly found in mitochondria, ER and/or lysosomes.
13-15
 The high phototoxicity observed 
for the ZnPcs 2.5, 2.7, 2.14, 2.20, 2.25 and 2.27 might possibly be, in part, due to their 
localization in the ER; some of these Pcs were also found in the mitochondria and/or the 
lysosomes. All these organelles are key targets for PDT-induced cell apoptosis.
45-47
 It is 
interesting to note that the octa-amino Pc 2.21 was mainly found in mitochondria and 
Golgi, and to a lesser degree in lysosomes. No localization was observed for ZnPc 2.21 in 
the ER (Figure 2.12), in a similar case to the cationic ZnPcs 2.16 and 2.22. These 
incredible results show that cationic ZnPcs are attaractive photosensitizers, which can be 
tuned to obtain amphiphilic drug agents. Di-cationic Pcs, particulaly α-substituted ones, 
have been shown to be promising PDT candidates. The subcellular localization of the 








a)                                                                            b)  
Figure 2.7. Subcellular localization: a) Pc 2.5 in HEp2 cells at 10 µM for 6 h: (A) Phase 
contrast, (B) Overlay of 2.5 and phase contrast, (C) ER tracker Blue/White fluorescence, 
(E) MitoTracker Green fluorescence, (G) BoDIPY Ceramide, (I)  LysoSensor Green 
fluorescence, and (D, F, H, J) overlays of organelle tracers with compound fluorescence. 
Scale bar: 10 m. b) Pc 2.7 in HEp2 cells at 10 µM for 6 h: (A) Phase contrast, (B) 
Overlay of 2.7 and phase contrast, (C) ER tracker Blue/White fluorescence, (E) 
MitoTracker Green fluorescence, (G) BoDIPY Ceramide, (I)  LysoSensor Green 
fluorescence, and (D, F, H, J) overlays of organelle tracers with compound fluorescence. 








a)                                                                         b)  
Figure 2.8. Subcellular localization: a) Pc 2.12 in HEp2 cells at 10 µM for 6 h: (A) Phase 
contrast, (B) Overlay of 2.12 and phase contrast, (C) ER tracker Blue/White fluorescence, 
(E) MitoTracker Green fluorescence, (G) BoDIPY Ceramide, (I)  LysoSensor Green 
fluorescence, and (D, F, H,J) overlays of organelle tracers with compound fluorescence. 
Scale bar: 10 m. b) Pc 2.14 in HEp2 cells at 10 µM for 6 h: (A) Phase contrast, (B) 
Overlay of 2.14 and phase contrast, (C) ER tracker Blue/White fluorescence, (E) 
MitoTracker Green fluorescence, (G) BoDIPY Ceramide, (I)  LysoSensor Green 
fluorescence, and (D, F, H,J) overlays of organelle tracers with compound fluorescence. 








a)                                                                         b)  
Figure 2.9. Subcellular localization: a) Pc 2.16 in HEp2 cells at 10 µM for 6 h: (A) Phase 
contrast, (B) Overlay of 2.16 and phase contrast, (C) ER tracker Blue/White fluorescence, 
(E) MitoTracker Green fluorescence, (G) BoDIPY Ceramide, (I)  LysoSensor Green 
fluorescence, and (D, F, H,J) overlays of organelle tracers with compound fluorescence. 
Scale bar: 10 m. b) Pc 2.20 in HEp2 cells at 10 µM for 6 h: (A) Phase contrast, (B) 
Overlay of 2.20 and phase contrast, (C) ER tracker Blue/White fluorescence, (E) 
MitoTracker Green fluorescence, (G) BoDIPY Ceramide, (I)  LysoSensor Green 
fluorescence, and (D, F, H,J) overlays of organelle tracers with compound fluorescence. 








a)                                                                         b)  
Figure 2.10. Subcellular localization: a) Pc 2.21 in HEp2 cells at 10 µM for 6 h: (A) 
Phase contrast, (B) Overlay of 2.21 and phase contrast, (C) ER tracker Blue/White 
fluorescence, (E) MitoTracker Green fluorescence, (G) BoDIPY Ceramide, (I)  
LysoSensor Green fluorescence, and (D, F, H,J) overlays of organelle tracers with 
compound fluorescence. Scale bar: 10 m. b) Pc 2.22 in HEp2 cells at 10 µM for 6 h: (A) 
Phase contrast, (B) Overlay of 2.22 and phase contrast, (C) ER tracker Blue/White 
fluorescence, (E) MitoTracker Green fluorescence, (G) BoDIPY Ceramide, (I)  
LysoSensor Green fluorescence, and (D, F, H,J) overlays of organelle tracers with 








a)                                                                         b)  
Figure 2.11. Subcellular localization: a) Pc 2.25 in HEp2 cells at 10 µM for 6 h: (A) 
Phase contrast, (B) Overlay of 2.25 and phase contrast, (C) ER tracker Blue/White 
fluorescence, (E) MitoTracker Green fluorescence, (G) BoDIPY Ceramide, (I)  
LysoSensor Green fluorescence, and (D, F, H,J) overlays of organelle tracers with 
compound fluorescence. Scale bar: 10 m. b) Pc 2.27 in HEp2 cells at 10 µM for 6 h: (A) 
Phase contrast, (B) Overlay of 2.27 and phase contrast, (C) ER tracker Blue/White 
fluorescence, (E) MitoTracker Green fluorescence, (G) BoDIPY Ceramide, (I)  
LysoSensor Green fluorescence, and (D, F, H,J) overlays of organelle tracers with 









 The syntheses and characterizations of a series of nine cationic ZnPcs are 
described. All ZnPcs were synthesized by a one-step cyclotetramerization of one or two 
phthalonitriles and consequently are mixtures of regioisomers, except for the octa-cationic 
and symmetrical ZnPc 2.22. The positive charges conferred by the trimethylaminophenoxy 
substituents and the presence of bulky tert-butyl groups in Pcs 2.5, 2.7, 2.12, 2.14 and 
2.20 induced high solubility in polar organic solvents. In contrast, ZnPcs 2.25 and 2.27 
were obtained using a biphenyl-linked diphthalonitrile and consequently consist of only 
the cis-A2B2 Pc regioisomers. The cytotoxicity of this series of compounds was dependent 
both on the number of charges, and on their site of substitution (α vs. β) on the Pc 
isoindole units. 
 The amphiphilicity of the molecules strongly affected their uptake bby the cells; 
the amphiphilic di-cationic ZnPc 2.20 accumulated the most within cells, it had reasonable 
phototoxicity (IC50 = 39.6 µM at 1.5 J/cm
2
) and was preferentially locallized in the Golgi 
apparatus. Of all the ZnPcs synthesized, the di-cationic α-substituted ZnPcs 2.7 and 2.25 
exhibited the highest phototoxicity (IC50 = 2.7 µM at 1.5 J/cm
2
). The partial localization 
of the ZnPcs in the ER, and the highest ratio (> 120) for their dark 
cytotoxicity/phototoxicity, make them the most promising agents for PDT applications. 
 The tetra- and octa-cationic ZnPcs had very low cytotoxicities and were mainly 
found in the mitochondria, suggesting a possibility for application as mitochondria 
delivery vehicles for therapeutic agents. This Chapter presents a comprehensive study of 
cationic ZnPcs, with attractive features that may be exploited in imaging or PDT. Most of 







2.6. Experimental Section 
2.6.1. Chemistry 
All the reagents and solvents were obtained from commercial sources and used 
directly without further purification. Silica gel 60 (230×400 mesh) and alumina neutral 
(activity I, 50-200 µm) from Sorbent Technologies were used for column chromatography. 
Sephadex G-100 and LH-20 were obtained from Amersham Biosciences. Analytical thin-layer 
chromatography (TLC) was carried out using polyester backed TLC plates 254 (pre-coated, 
200 μm) from Sorbent Technologies. NMR spectra were recorded on an AV-400 LIQUID 
Bruker spectrometer (400 MHz for 
1
H, 100 MHz for 
13
C). Chemical shifts are reported in δ 
(ppm) using the following deuterated solvents as internal references: Acetone-d6 2.05 ppm 
(
1
H), 29.92 ppm (
13
C); DMF-d7 8.03 ppm (
1
H), 163.15 ppm (
13





C); D2O 4.80 ppm (
1
H); THF-d8 3.58 ppm (
1
H), 67.57 ppm (
13
C); CD2Cl2 5.32 
ppm (
1
H), 54.00 ppm (
13
C); CDCl3 7.27 ppm (
1
H), 77.23 ppm (
13
C). The HPLC analyses were 
performed on a Dionex system fitted with a P680 pump and UVD340U detector. Electronic 
absorption spectra were measured on a PerkinElmer, Lambda 35 UV-Vis spectrometer and 
emission spectra were measured on a Fluorolog® HORIBA JOBIN YVON (Model LFI-3751) 
spectrofluorimeter. Dithranol matrix was used for MALDI-TOF mass spectra measurement on 
a Bruker ProFlex III spectrometer; high-resolution ESI mass spectra (HRMS-ESI) were 
obtained using an Agilent Technologies 6210 Time-of-Flight LC/MS spectrometer. Melting 
points were obtained using MEL-TEMP electrothermal instrument.  
2.6.2. Synthesis of Phthalocyanines and Their Precursors 
Mono-N-Boc-amino-phthalonitrile 2.3. A 3-nitrophthalonitrile 2.1 (2 g, 11.6 mmol) 







carbonate (2.5 g, 18.0 mol) was added to the solution in five portions and the mixture heated 
to 80 °C for 3 h. The reaction mixture was cooled to room temperature, poured into ice-cold 
water and filtered to obtain a solid. The solid was purified using alumina column 
chromatography, eluted with DCM to afford a white solid (3.1 g, 80.0%), mp 165 – 166 °C.
 
1
H NMR (acetone-d6): δ 8.58 (br, 1H, NH), 7.80 (t, J = 8.2 Hz, 1H, Ar-H), 7.70 -7.66 (m, 3H, 
Ar-H), 7.25 – 7.14 (m, 3H, Ar-H), 1.48 (s, 9H, C(CH3)3). 
13
C NMR (acetone-d6): δ 162.1, 
153.7, 149.4, 138.6, 136.2, 128.1, 121.7, 121.5, 120.7, 117.4, 116.2, 113.8, 105.9 (Ar-C, CN), 
80.2, 28.4 (C(CH3)3). HRMS-ESI: m/z 336.1340 [M+H]
+





, calcd. for [C19H19N3O4]
+
 353.1376; 358.1163 [M+Na]
+
, calcd. for 
[C19H17N3O3Na]
+
 358.1168.  
 Mono-α-amino-ZnPc 2.4. A mixture of 4-tert-butylphthalonitrile (770.0 mg, 4.1 
mmol), phthalonitrile 2.3 (462.0 mg, 1.4 mmol) and zinc(II) acetate (509.4 mg, 2.8 mmol) 
was dissolved in DMAE (6.0 mL). Catalytic amount of DBN was added and reaction refluxed 
for 5 h. The solvent was removed and the residue purified by silica column chromatography 
using hexane/ethyl acetate 4:1 for elution. The N-Boc protected ZnPc was isolated as a blue 




H NMR (acetone-d6): δ 9.51-8.07 (m, 11H, Ar-H), 
7.78-7.23 (m, 5H, Ar-H), 1.86-1.82 (m, 27H, C(CH3)3), 1.51-1.48, 1.41 (m, 9H, C(CH3)3). 
13
C 
NMR (acetone-d6): δ 171.0 (C=O), 155.7, 155.0, 154.0, 153.9, 152.8, 151.9, 141.2, 139.3, 
136.9, 135.6, 134.9, 134.8, 130.3, 127.7, 127.6, 127.3, 123.0, 122.4, 120.7, 120.5, 119.2, 
119.0, 117.5, 117.5, 117.4, 117.3, 79.8, 79.7 (N-Boc-C(CH3)3), 60.6 (N-Ar-C), 36.5, 32.7, 
32.5 (Ar-C, C(CH3)3), 28.7, 28.6 (N-Boc-C(CH3)3). MS (MALDI-TOF) m/z 952.389 [M+H]
+
, 
calcd for C55H54N9O3Zn, 952.3641. The N-Boc group was removed using DCM/TFA, 1:1 (8 









UV–Vis (DMF): λmax (log ε) 349 nm (5.09), 614 nm (4.82), 682 nm (5.58). 
1
H NMR (DMF-
d7): δ 9.58-9.29 (m, 7H, Ar-H), 8.41-8.28 (m, 4H, Ar-H), 7.28-7.24 (m, 2H, Ar-H), 6.69-6.63 
(m, 2H, Ar-H), 4.65-5.05 (br, 2H, NH2), 1.80-1.65 (m, 27H, C(CH3)3). 
13
C NMR (DMF-d7): δ 
156.6, 155.2, 155.0, 154.9, 154.8, 154.7, 154.6, 154.6, 154.1, 154.1, 153.9, 152.9, 150.1, 
148.9, 145.7, 145.0, 142.1, 142.1, 139.8, 139.7, 139.4, 137.4, 137.3, 137.0, 131.5, 128.5, 
128.4, 128.3, 127.5, 123.2, 123.0, 121.4,  119.7, 119.6, 119.4, 118.4, 117.6, 116.5, 116.4, 32.3 
(Ar-C, C(CH3)3). MS (MALDI-TOF) m/z 852.341 [M+H]
+
, calcd for C50H46N9OZn 852.312. 
 Mono-α-(trimethylamino)-ZnPc 2.5. Pc 2.4 (20 mg, 0.023 mmol), DIPA (0.2 mL, 
1.44 mmol) and CH3I (0.5 mL, 8.0 mmol) were dissolved in dry DMF (0.3 mL) and the 
mixture was stirred at 25 °C for 3 days and the excess solvents was removed. The solid was 
dissolved in DCM (15 mL), washed with water (20 mL × 2) and the organic layer was 
concentrated and purified on Sephadex G-100 column using DCM/methanol 5:1 for elution. 
The product was obtained as a blue solid (18.2 mg, 75.8%), mp 204-206 
o
C. UV–Vis (DMF): 
λmax (log ε) 351 nm (4.11), 620 nm (4.13), 684 nm (4.97). 
1
H NMR (acetone-d6): δ 9.47-9.16 
(m, 6H, Ar-H), 8.85-7.82 (m, 8H, Ar-H), 7.50 (br, 2H, Ar-H), 3.72 (s, 4H, N-CH3), 3.62 (s, 
5H, N-CH3), 1.80-1.71 (m, 27H, C(CH3)3). 
13
C NMR (acetone-d6): δ 162.2, 156.0, 153.9, 
150.4, 142.8, 140.3, 137.9, 130.9, 128.0, 123.2, 123.0, 122.8, 122.6, 119.9, 118.2, 117.7 (Ar-
C), 71.3 (N-Ar-C), 58.0, 57.9 (N-CH3), 36.5, 32.6 (C(CH3)3). MS (MALDI-TOF) m/z 894.434 
[M-I]
+
, calcd for C53H52N9OZn 894.359. 
 Di-α-amino-ZnPc 2.6. A procedure related to that described for Pc 2.4 was used and 
the purification via silica column chromatography using hexane/ethyl acetate 1:1 gave the N-




H NMR (DMF-d7): δ 







4H, Ar-H), 1.81-1.77 (m, 18H, C(CH3)3), 1.57, 1.51, 1.50, 1.46, 1.46, 1.42 (s, 18H, CH3). 
13
C 
NMR (acetone-d6): δ 169.5, 169.2, (C=O), 155.9, 155.7, 155.3, 155.0, 154.9, 154.7, 154.6, 
154.4, 154.2, 154.0, 153.9, 153.8, 153.7, 153.5, 153.5, 153.3 153.0, 153.0, 152.9, 151.9, 
151.6, 150.6, 142.0, 141.9, 141.4, 141.3, 141.0, 140.0, 139.9, 139.7, 139.5, 139.4, 139.2, 
137.6, 137.3, 137.0, 136.7, 135.8, 135.6, 135.5, 135.0, 134.9, 130.4, 130.1, 129.7, 129.6, 
129.2, 128.8, 128.6, 128.0, 127.6, 127.5, 127.3, 127.2, 123.7, 123.4, 123.3, 122.8, 122.7, 
122.4, 122.1, 121.5, 121.3, 120.7, 120.1, 119.9, 119.4, 119.3, 119.1, 118.8, 118.4, 118.1, 
117.6, 117.5, 117.4, 117.2 (Ar-C), 80.0, 79.8, 79.7 (N-Boc, C(CH3)3), 36.5, 36.4, 32.7, 32.5, 
31.6, 31.4 (Ar-C, C(CH3)3), 28.9, 28.7, 28.6 (N-Boc, C(CH3)3). MS (MALDI-TOF) m/z 
1102.455 [M]
+
, calcd for C62H58N10O6Zn 1102.383. The protected ZnPc was dissolved in 
DCM/TFA, 1:1 (8 mL) and the solution was stirred for 2 h to afford Pc 2.6 (163.1 mg, 
93.1%), mp > 250 
o
C. UV–Vis (DMF): λmax (log ε) 350 nm (4.55), 618 nm (4.31), 686 nm 
(5.07). 
1
H NMR (DMF-d7): δ 9.57-8.99 (m, 6H, Ar-H), 8.41-8.16 (m, 4H, Ar-H), 7.93-7.69 
(m, 2H, Ar-H), 7.35 (br, 4H, Ar-H), 6.82 (br, 4H, Ar-H), 1.83-1.67 (m, 18H, C(CH3)3). 
13
C 
NMR (DMF-d7): δ 156.2, 156.1, 155.6, 155.3, 155.1, 155.0, 154.8, 154.6, 154.5, 154.4, 154.1, 
153.9, 153.5, 153.3, 153.2, 152.4, 150.9, 143.3, 142.3, 141.6, 140.2, 140.0, 139.8, 137.8, 
137.6, 137.4, 132.5, 131.8, 131.5, 129.9, 129.2, 128.7, 128.5, 128.1, 123.9, 123.4, 122.2, 
121.3, 120.0, 119.6, 119.5, 118.5, 118.1, 118.1, 117.5 (Ar-C), 32.6 (Ar-C, C(CH3)3). MS 
(MALDI-TOF) m/z 903.352 [M+H]
+
, calcd for C52H43N10O2Zn 903.286. 
 Di-α-(trimethylamino)-ZnPc 2.7. ZnPc 2.6 (20 mg, 0.022 mmol), DIPA (0.15 mL, 
1.07 mmol) and CH3I (0.2 mL, 3.21 mmol) mixture was dissolved in dry DMF (0.5 mL) and 
stirred at room temperature for 3 days. Excess iodomethane was removed and the residue 







(16.2mg, 58.9% yield), mp 195-197 
o
C. UV–Vis (DMF): λmax (log ε) 350 nm (4.64), 622 nm 
(3.79), 686 nm (5.25). 
1
H NMR (acetone-d6): δ 9.55-9.36 (m, 4H, Ar-H), 9.04-8.93 (m, 1H, 
Ar-H), 8.72-8.59 (m, 1H, Ar-H), 8.33-8.04 (m, 7H, Ar-H), 7.91-7.75 (m, 2H, Ar-H), 7.66-7.54 
(m, 4H, Ar-H), 3.85-3.65 (m, 18H, N-CH3), 1.79-1.64 (m, 27H, C(CH3)3). 
13
C NMR (acetone-
d6): δ 162.1, 161.7, 154.1, 153.7, 150.4, 143.0, 141.8, 140.5, 140.1, 138.1, 137.7, 132.1, 
131.4, 130.3, 129.8, 128.2, 127.8, 123.8, 123.4, 123.0, 121.3, 119.8, 118.3, 117.7, (Ar-C), 
66.3 (N-Ar-C), 57.9 (N-CH3), 36.4, 32.7, 32.3 (C(CH3)3). MS (MALDI-TOF) m/z 973.373 
[M-2I-CH3]
+
, calcd for C57H53N10O2Zn
 
973.364. 
 Monoaminophenoxyphthalonitrile 2.9. A mixture of 4-nitrophthalonitrile (1 g, 5.8 
mmol) and 4-aminophenol (0.7 g, 6.4 mmol) was dissolved in DMF (15 mL) and heated to 
63°C. Then K2CO3 (2.63 g, 20 mmol) was added in six portions after every five minutes and 
the mixture stirred 4 h under argon. It was cooled to room temperature and poured into ice-
cold water (500 mL). The filtered crude product (brown solid) was purified via silica column 
chromatography using DCM/methanol (98:2). Organic solvents were removed to obtain a 
yellow solid (1.0 g, 73.3%), mp 130 - 131°C.  
1
H NMR (d-CD2Cl2, 400 MHz): δ 7.70 (d, J =  
8.6 Hz, 1H, Ar-H), 7.23 (t, J = 8.8 Hz, 2H, Ar-H), 6.87 (d, J =  7.8 Hz, 2H, Ar-H), 6.73 (d, J = 
7.8, 2H, H-Ar), 3.86 (br, 2H, NH2). 
13
C NMR (d-CDCl3, 100 MHz): δ 162.89, 145.32, 144.96, 
135.36, 121.71, 120.98, 120.82, 117.31, 116.16, 115.84, 115.40, 107.96 (Ar-C, CN). MS 
(MALDI-TOF) m/z 236.0813 [M+H]
+
, calcd for, C14H9N3O, 23.0818.  
Mono-N-Boc-aminophenoxyphthalonitrile 2.10. A procedure related to that 
described for phthalonitrile 2.3 was used the product obtained in 87.8% yield, mp 169-171 °C. 
1
H NMR (CD2Cl2): δ 7.73 (d, J = 8.7 Hz, 1H, Ar-H), 7.47 (d, J = 8.8 Hz, 2H, Ar-H), 7.27 (d, J 







N-H),  1.51 (s, 9H, C(CH3)3). 
13
C NMR (CDCl3): δ 162.2, 152.6, 148.5, 136.8, 135.4, 121.3, 
121.2, 121.1, 117.5, 115.6, 115.2, 108.6 (Ar-C, CN), 80.7 (C=O), 28.0 (C(CH3)3). MS 
(HRMS-ESI) m/z 336.1351 [M+H]
+
, calcd for C19H18N3O3 336.1348; 358.1189 [M+Na]
+
, 
calcd for C19H17N3O3Na 358.1162. 
 Mono-β-amino-ZnPc 2.11. A mixture of 4-tert-butylphthalonitrile (385 mg, 2.09 
mmol), phthalonitrile 2.10 (231 mg, 0.69 mmol) and zinc(II) acetate (254.7 mg, 1.4 mmol) 
was refluxed for 5 h, cooled and purified as described above for Pc 2.4 to afford a blue solid 




H NMR (acetone-d6): δ 9.31-8.55 (m, 8H, Ar-H), 8.40-8.12 
(m, 4H, Ar-H), 8.10-7.85 (m, 2H, Ar-H), 7.75-7.60 (m, 2H, Ar-H), 1.95-1.87 (m, 27H, 
C(CH3)3), 1.62 (d, J = 7.6, 9H, C(CH3)3). 
13
C NMR (acetone-d6): δ 159.9, 159.8, 159.3, 159.2, 
154.1, 154.0, 153.7, 153.4, 153.0, 152.7, 152.4, 139.2, 138.9, 138.8, 138.7, 138.4, 138.2, 
137.1, 137.0, 136.8, 136.7, 136.4, 136.2, 127.3, 125.9, 124.0, 123.8, 123.6, 122.9, 122.6, 
122.4, 121.9, 121.5, 121.3, 121.0, 120.8, 120.7, 119.6, 119.2, 112.2, 111.4, 110.8 (Ar-C), 80.2 
(N-Boc-C(CH3)3), 55.5 (N-Ar-C), 36.4, 32.6 (Ar-C, C(CH3)3), 28.9 (N-Boc-C(CH3)3). MS 
(MALDI-TOF) m/z 952.395 [M+H]
+
, calcd for C55H54N9O3Zn 952.364. The product was 
dissolved in DCM/TFA, 1:1 (8 mL) and stirred for 2 h to afford product 2.11 (94.7 mg, 93.7 
%), mp > 250 
o
C. UV–Vis (DMF): λmax (log ε) 349 nm (5.01), 610 nm (4.71), 677 nm (5.46). 
1
H NMR (Pyridine-d5): δ 10.02-9.70 (m, 6H, Ar-H), 9.63-9.41 (m, 1H, Ar-H), 8.44-7.96 (m, 
4H, Ar-H), 7.47-7.39 (m, 2H, Ar-H), 7.18-7.10 (m, 2H, Ar-H), 5.09 (br, 2H, N-H), 1.72-1.65 
(m, 27H, C(CH3)3). 
13
C NMR (DMSO-d6): δ 160.6, 160.6, 160.3, 160.3, 152.4, 152.2, 152.0, 
151.9, 151.8, 151.7, 151.6, 151.4, 151.1, 147.2, 147.0, 146.5, 146.4, 146.2, 145.0, 143.9, 
139.6, 139.5, 138.2, 138.0, 137.9, 137.7, 135.8, 135.7, 135.6, 135.5, 135.4, 131.9, 131.7, 







119.7, 118.7, 118.3, 115.9, 115.6, 115.0, 109.6, 109.4, 108.5, 108.3, (Ar-C), 59.8 (N-Ar-C), 
35.6, 31.4 (Ar-C, C(CH3)3). MS (MALDI-TOF) m/z 852.348 [M+H]
+
, calcd for C50H46N9OZn 
852.312. 
 Mono-β-(trimethylamino)-ZnPc 2.12. ZnPc 2.11 (20 mg, 0.023 mmol), DIPA (0.2 
mL, 1.44 mmol) and CH3I (0.5 mL, 8.0 mmol) were dissolved in dry DMF (0.3 mL). The 
excess CH3I was removed and the resultant residue purified as described above to give a blue 
solid (15.7 mg, 65.4%), mp 201-203 
o
C. UV–Vis (DMF): λmax (log ε) 355 nm (4.22), 618 nm 
(3.90), 683 nm (4.80). 
1
H NMR (DMF-d7): δ 9.54-9.23 (m, 7H, Ar-H), 8.95 (br, 1H, Ar-H), 
8.41-8.34 (m, 5H, Ar-H), 7.97-7.70 (m, 4H, Ar-H), 3.99 (s, 9H, N-3CH3), 1.82-1.76 (m, 27H, 
C(CH3)3). 
13
C NMR (DMF-d7): δ 160.2, 159.4, 157.9, 155.32, 154.8, 154.2, 154.1, 153.9, 
143.7, 141.3, 140.1, 139.9, 137.7, 137.5, 132.5, 128.3, 125.3, 124.0, 123.8, 123.3, 122.3, 
120.7, 120.3, 119.9, 115.9, 113.8, 113.6 (Ar-C), 71.3 (N-Ar-C), 57.3 (N-CH3), 32.6 
(C(CH3)3). MS (MALDI-TOF) m/z 894.442 [M-I]
+
, calcd for C53H52N9OZn
 
894.359. 
 Di-β-amino-ZnPc 2.13. A procedure related to that described for Pc 2.11 was used 
and purification via silica column chromatography using hexane/ethyl acetate 1:1 gave the 




H NMR (DMF-d7): δ 9.67-
9.59 (m, 2H, Ar-H), 9.39-8.40 (m, 9H, Ar-H), 8.00-7.81 (m, 5H, Ar-H), 7.64-7.60 (m, 4H, Ar-
H), 1.88-1.82 (m, 18H, C(CH3)3), 1.61-1.59 (m, 18H, N-Boc-C(CH3)3). 
13
C NMR (DMF-d7): 
δ 164.9, 161.1, 161.0, 160.7, 154.5, 154.3, 153.9, 153.8, 153.6, 153.4, 153.3, 153.0, 152.8, 
150.5, 141.2, 139.8, 138.7, 138.0, 139.7, 137.4, 136.8, 134.1, 128.3, 127.6, 126.2, 124.8, 
123.1, 122.2, 121.9, 121.8, 121.6, 121.5, 121.3, 121.1, 120.9, 119.8, 112.3, 111.4, 110.9, (Ar-
C), 80.2 (C=O), 60.9 (N-Ar-C), 36.8, 32.7 (Ar-C, C(CH3)3), 29.0, 28.8 (N-Boc-C(CH3)3). MS 
(MALDI-TOF) m/z 1103.463 [M+H]
+







protected ZnPc was dissolved in DCM/TFA, 1:1 (8 mL) and stirred for 2 h to obtain ZnPc 
2.13 (73.8, 92.0% yield), mp > 250 
o
C. UV–Vis (DMF): λmax (log ε) 351 nm (4.90), 611 nm 
(4.59), 679 nm (5.32). 
1
H NMR (DMSO-d6): δ 9.40-8.82 (m, 9H, Ar-H), 8.56-8.18 (m, 5H, 
Ar-H), 7.87-7.60 (m, 4H, Ar-H), 7.28-6.77 (m, 7H, Ar-H), 5.20-5.00 (br, 3H, N-H), 1.82-1.77 
(m, 18H, C(CH3)3). 
13
C NMR (DMSO-d6): δ 160.7, 152.4, 152.2, 146.0, 139.6, 138.0, 135.4, 
132.0, 131.8, 127.1, 123.8, 123.6, 121.5, 120.9, 118.8, 115.4, 114.9, 109.6, 108.3 (Ar-C), 
35.6, 31.9, 31.5, 31.0, 30.7 (Ar-C, C(CH3)3). MS (MALDI-TOF) m/z 903.587 [M+H]
+
, calcd 
for C52H43N10O2Zn 903.286. 
 Di-β-(trimethylamino)-ZnPc 2.14. ZnPc 2.13 (20 mg, 0.022 mmol), DIPA (0.15 mL, 
1.07 mmol) and CH3I (0.2 mL, 3.21 mmol) were used to synthesize the title compound 
following the same procedure described above for Pc 2.7. Product 2.14 was obtained as a blue 
solid (14.6 mg, 53.1% yield), mp > 218-220 
o
C. UV–Vis (DMF): λmax (log ε) 355 nm (4.41), 
618 nm (4.08), 683 nm (4.96). 
1
H NMR (DMF-d7): δ 9.60-9.9.06 (m, 9H, Ar-H), 8.36-8.24 
(m, 6H, Ar-H), 7.66-7.57 (m, 4H, Ar-H), 7.40-7.37 (m, 1H, Ar-H), 7.05-7.02(m, 1H, Ar-H), 
3.98-3.93 (m, 18H, N-6CH3), 1.78-1.71 (m, 18H, C(CH3)3). 
13
C NMR (DMF-d7): δ 160.1, 
158.1, 155.4, 154.0, 149.4, 143.7, 141.9, 140.4, 137.9, 136.4, 128.2, 125.3, 124.0, 123.1, 
122.3, 122.1, 120.3, 119.9, 119.8, 115.1, 113.6, (Ar-C), 71.3 (N-Ar-C), 58.0 (N-CH3), 41.5, 
32.5 (C(CH3)3). MS (MALDI-TOF) m/z 973.654 [M-2I-CH3]
+
, calcd for C57H53N10O2Zn  
973.364. 
 Tetra-β-amino-ZnPc 2.15. A mixture of phthalonitrile 2.10 (0.5 g, 1.49 mmol) and 
zinc(II) acetate (0.095 g, 0.5 mmol) was dissolved in DMAE (5.0 mL) and refluxed under 
argon. Two drops of DBN were added and the solution refluxed for another 6 h. The solvent 







DCM/methanol 95:5 for elution. The product was further purified via a second alumina 
column using DCM/methanol 9:1 for elution to isolate a dark green solid (105.6 mg, 20.2%), 




H NMR (THF-d8): δ 9.12-8.66 (m, 12H, Ar-H), 7.93-7.68 (m, 8H, Ar-H), 7.46-
7.31 (br, 8H, Ar-H), 7.16 (br, 8H, Ar-H), 1.55 (s, 36H, C(CH3)3). 
13
C NMR (THF-d8): δ 
160.9, 154.6, 154.1, 153.2, 152.8, 141.5, 137.6, 137.1, 134.4, 124.9, 121.2, 120.6, 112.1, 
111.5 (Ar-C), 79.9 (N-Boc-C(CH3)3), 62.9, 59.1, 45.9 (N-Ar-C), 28.87 (N-Boc, C(CH3)3). MS 
(MALDI-TOF) m/z 1405.819 [M+H]
+
, calcd for C76H69N12O12Zn 1405.445. The solid was 
dissolved in DCM/TFA, 1:1 and stirred at 0 C for 3 h. The solvent was removed and the 
resulting residue was treated with 2 N NaOH (1 mL). The product was re-dissolved in 20 mL 
DCM/methanol and washed with water (2 x 50 mL). The organic phase was concentrated to 
obtain a green solid (72.4 mg, 96.1%), mp > 250 
o
C. UV-Vis (DMF): λmax (log ε) 352 nm 
(4.63), 613 nm (4.31), 682 nm (5.01). 
1
H NMR (DMF-d7): δ 9.89 (br, 1H, Ar-H), 9.34-9.28 
(m, 3H, Ar-H), 8.88-8.70 (m, 3H, Ar-H), 7.46-7.31 (m, 8H, Ar-H), 7.83 (br, 7H, Ar-H), 7.47 
(br, 4H, Ar-H), 7.21 (br, 4H, Ar-H), 6.93 (br, 4H, Ar-H). 
13
C NMR (DMF-d7): δ 160.0, 159.5, 
155.2, 154.0, 147.5, 142.0, 137.3, 135.4, 134.9, 134.3, 131.6, 124.8, 122.5, 121.2, 120.0, 
116.5, 111.4, 110.1 (Ar-C), 63.4, 59.2, 154.5, 46.3 (N-Ar-C), 28.9 (N-Boc, C(CH3)3). MS 
(MALDI-TOF) m/z 1004.313 [M+H]
+
,  calcd for C56H36N12O4Zn 1004.227.  
 Tetra-β-trimethylamino-ZnPc 2.16. ZnPc 2.15 (24.4 mg, 0.023 mmol) was 
dissolved in DMF (0.4 mL). Methyl iodide (3 mL, 48.2 mmol) and DIPA (0.2 mL, 1.42 
mmol) were added and the mixture was stirred at 25 °C for 3 days. Excess iodomethane was 
removed, acetone added to triturate the product and then solution centrifuged to isolate title 
compound as a blue-green solid (31.9 mg, 82.4%), mp 194-196 
o
C. UV–vis (DMF): λmax (log 
ε) 358 nm (4.62), 620 nm (4.31), 684 nm (5.08). 
1







H), 9.00-8.89 (m, 2H, Ar-H), 8.34 (br, 5H, Ar-H), 7.85-7.75 (m, 7H, Ar-H), 7.71-7.64 (m, 7H, 
Ar-H), 7.53-7.47 (m, 6H, Ar-H), 4.07-4.01 (m, 36H, N-CH3). 
13
C NMR (DMSO-d6): δ 158.2, 
156.9, 153.1, 152.2, 151.8, 142.5, 142.3, 140.1, 139.9, 135.4, 134.9, 134.5, 133.5, 124.45, 
124.3, 124.2, 123.0, 122.9, 122.7, 121.3, 121.1, 120.4, 120.1, 119.9, 119.5, 119.2, 119.1, 
114.2, 112.8, 112.1 (Ar-C), 64.2 (N-Ar-C), 58.1, 56.8, 53.2 (N-CH3). MS (MALDI-TOF) m/z 
1131.406 [M-4I-3CH3]
+
, calcd for C65H55N12O4Zn 1131.3761.  
 4,5-Di-N-Boc-amino-phthalonitrile 2.18. The compound was obtained by reacting 
4,5-dichlorophthalonitrile and N-Boc-4-aniline in DMF and isolated in 82.6% yield, following 
the procedure described above for phthalonitrile 2.3; mp 203-205 °C. 
1
H NMR (CDCl3): δ 
7.47 (d, J =  8.8 Hz, 4H, Ar-H), 7.15 (s, 2H, Ar-H), 7.05 (d, J =  8.8 Hz, 4H, Ar-H), 6.66 (br, 
2H, N-H), 1.51 (s, 18H, 2×C(CH3)3). 
13
C NMR (CDCl3): δ 152.8, 152.2, 148.9, 136.9, 136.5, 
121.0, 120.9, 120.5, 115.6, 115.01, 110.0, 101.5 (Ar-C, CN), 81.0 (C=O), 28.3 (C(CH3)3). MS 
(ESI) m/z 565.2036 [M+Na]
+
, calcd for C30H30N4O6Na 565.2058. 
 Di-β-amino-ZnPc 2.19. A mixture of 4-tert-butylphthalonitrile (385 mg, 2.09 mmol), 
phthalonitrile 2.18 (374 mg, 0.69 mmol) and zinc(II) acetate (254.7 mg, 1.4 mmol) was used 
and a procedure related to that described for Pc 2.4 was followed to obtain a blue solid (81 




H NMR (DMF-d7): δ 9.56 - 9.24 (m, 7H, Ar-H), 9.12 - 9.02 (m, 
1H, Ar-H), 8.91 – 8.83 (m, 2H, Ar-H), 8.42 – 8.31 (m, 3H, Ar-H), 7.89 – 7.79 (m, 4H, Ar-H), 
7.52 – 7.40 (m, 4H, Ar-H), 1.85 -1.79 (m, 27H, C(CH3)3), 1.58 – 1.53 (m, 18H, Boc- 
C(CH3)3). 
13
C NMR (DMF-d7): δ 154.5, 154.2, 154.0, 153.3, 152.7, 152.2, 151.6, 151.4, 
151.1, 150.6, 150.4, 139.6, 137.5, 137.3, 137.0, 135.6, 135.2, 128.5, 123.2, 121.0, 120.6, 
120.4, 120.3,  119.7, 119.5, 119.4, 119.2, 115.5, 113.7, 80.2 (C=O), 80.0 (C=O), 32.6 (Ar-C, 
C(CH3)3), 29.9 (C(CH3)3), 28.9 (C(CH3)3). MS (MALDI-TOF) m/z 1158.465 [M]
+







C66H66N10O6Zn 1158.446. The product was dissolved in DCM/TFA, 1:1 and for 2 h to obtain 
the product as a blue solid (61 mg, 9.2% overall yield), mp > 250 
o
C. UV–vis (DMF): λmax 
(log ε) 353 nm (4.98), 611 nm (4.65), 677 nm (5.43). 
1
H NMR (DMSO-d6): δ 9.34-9.13 (m, 
6H, Ar-H), 9.07-8.97 (m, 1H, Ar-H), 8.74-8.71 (m, 1H, Ar-H), 8.31-8.26 (m, 1H, Ar-H), 8.16-
8.11 (m, 2H, Ar-H) 7.17-7.11 (m, 3H, Ar-H), 6.94-6.88 (m, 3H, Ar-H), 6.70-6.58 (br, 2H, Ar-
H), 4.93 (br, 4H, N-H), 1.79-1.71 (m, 27H, C(CH3)3). 
13
C NMR (DMSO-d6): δ 152.9, 151.5, 
147.1, 138.6, 136.2, 136.1, 133.8, 133.3, 127.6, 122.4, 121.1, 121.0, 120.1,  119.9, 118.8, 
116.1, 115.8, 110.7, 32.3 (Ar-C, C(CH3)3). MS (MALDI-TOF) m/z 959.34 [M+H]
+
, calcd for 
C56H51N10O2Zn 959.35. 
 Di-β-trimethylamino-ZnPc 2.20. A mixture of ZnPc 2.19 (20 mg, 0.023 mmol), 
DIPA (0.2 mL, 1.44 mmol) and CH3I (1.0 mL, 16.0 mmol) was dissolved in dry DMF (0.4 
mL) and stirred at 25 °C for 3 days. Excess iodomethane was removed and the residue 
purified as described above for Pc 2.5. The product was isolated as a blue solid (19.5 mg, 
72.0%), mp 190 
o
C (decomp). UV–vis (DMF): λmax (log ε) 357 nm (4.50), 619 nm (4.16), 684 
nm (5.01). 
1
H NMR (DMF-d7): δ 9.56-9.23 (m, 9H, Ar-H), 8.45-8.28 (m, 7H, Ar-H), 7.60 (br, 
3H, Ar-H), 3.96 (s, 18H, N-6CH3), 1.78-1.71 (m, 27H, C(CH3)3). 
13
C NMR (DMF-d7): δ 
159.8, 156.2, 155.5, 154.8, 154.1, 152.3, 149.0, 143.7, 140.3, 137.9, 137.1, 128.2, 123.9, 
123.0, 119.8, 119.4, 119.1, 117.2, 116.3 (Ar-C), 71.3 (N-Ar-C), 58.0 (CH3), 32.6 (C(CH3)3). 
MS (MALDI-TOF) m/z 1029.416 [M-2I-CH3]
+
, calcd for C61H61N10O2Zn 1029.427. 
 Octa-β-amino-ZnPc 2.21. A mixture of phthalonitrile 2.18 (0.745 g, 1.37 mmol) and 
zinc(II) acetate (0.420 g, 2.29 mmol) was dissolved in DMAE (6.0 mL) under argon. Catalytic 
amount of DBN was added and the solution was refluxed for 6 h. The solvent was removed 











H NMR (DMSO-d6): δ 
8.97 (s, 4H, Ar-H), 8.55 (s, 4H, Ar-H), 7.55 (s, 16H, Ar-H), 7.16 (s, 16H, Ar-H), 1.52 (s, 72H, 
C(CH3)3).
 13
C NMR (DMSO-d6): δ 154.6, 154.0, 151.7, 136.9, 135.9, 120.4, 120.0, 119.5, 
115.3, (Ar-C), 79.8 (C=O), 63.1, 62.9, 59.4, 59.3 (N-Ar-C), 46.1, 28.9 (N-Boc, C(CH3)3). MS 
(MALDI-TOF) m/z 2277.901 [M]
+
, C123H129N16O24Zn 2277.866. The compound was 
dissolved in DCM/TFA, 1:1 and the solution was stirred for 2 h. The title product was isolated 
as a green solid (246.4 mg, 84.8%), mp > 250 
o
C. UV–vis (DMF): λmax (log ε) 361 nm (4.62), 
615 nm (4.22), 689 nm (5.06).
 1
H NMR (DMSO-d6): δ 7.52 (br, 8H, Ar-H), 7.16-6.60 (m, 
32H, Ar-H).
 13
C NMR (DMSO-d6): δ 153.6, 152.3, 145.7, 134.5, 120.0, 119.8, 115.2, (Ar-C), 
61.7, 57.7, 53.1, 45.3 (N-Ar-C). MS (MALDI-TOF) m/z 1432.383 [M]
+
, calcd for 
C80H56N16O8Zn 1432.376. 
 Octa-β-trimethylamino-ZnPc 2.22. ZnPc 2.21 (18.0 mg, 0.0126 mmol) was 
dissolved in DMF (8 mL). Methyl iodide (3 mL, 48.2 mmol) and DIPA (0.2 mL, 1.42 mmol) 
were added and the mixture stirred at 25 °C for 3 days. Excess solvents were removed, 
acetone (5 mL) added to triturate the product and the solution centrifuged to obtain the 
product as a green solid (31.9 mg, 90.9%), mp 188-190 
o
C. UV–vis (DMF): λmax (log ε) 365 
nm (4.57), 620 nm (4.24), 686 nm (5.17). 
1
H NMR (D2O): δ 7.96-7.47 (m, 40H, Ar-H), 3.80-
3.30 (m, 72H, N-CH3). 
13
C NMR (D2O): δ 158.1, 152.1, 142.0, 136.01, 134.8, 122.7, 120.1, 
118.2, 117.6, 116.3, 114.4, (Ar-C), 64.1 (N-Ar-C), 62.6, 58.0, 56.7, 53.1, 42.2, 16.2 (N-CH3). 
MS (MALDI-TOF) m/z 1671.679 [M-8I-7CH3]
+
, calcd for C97H91N16O8Zn 1671.650. 
Di-α-amino-ZnPc 2.24. A mixture of 2,2’-bis(2,3-dicyanophenoxy)biphenyl 2.23
29
 
(302.3 mg, 0.69 mmol), phthalonitrile 2.3 (480.0 mg, 1.43 mmol) and zinc acetate (254.7 mg, 







mixture refluxed at for 5 h. The solvent was removed and the residue purified via silica gel 
column chromatography using ethyl acetate solvent for elution. Further purification via a 
second silica column using hexane/ethyl acetate 1:1 for elution, gave a blue solid (112.2 mg, 




H NMR (DMF-d7): δ 9.53-9.07 (m, 5H, Ar-H), 8.41-8.06 (m, 4H, Ar-
H), 7.80-7.15 (m, 19H, Ar-H), 1.56 - 1.49 (m, 18H, C(CH3)3). 
13
C NMR (DMF-d7): δ 
161169.6, 168.0 (C=O), 159.0, 156.3, 156.2, 156.1, 154.9, 154.7, 154.6, 154.5, 154.4, 154.3, 
154.2, 154.1, 154.0, 153.8, 153.6, 153.4, 153.0, 152.5, 152.4, 151.0, 150.8, 138.7, 137.4, 
137.1, 136.6, 136.3, 135.5, 133.2, 132.0, 131.6, 131.3, 131.0, 130.8, 130.6, 130.3. 129.9, 
129.3, 129.0, 128.9, 128.2, 126.5, 126.3, 125.7, 124.7, 124.2, 122.3, 122.2, 122.1, 121,6, 
121.5, 121.3,121.2, 121.0, 120.9, 120.8, 119.7, 119.6, 119.2, 118.2, 118.1, 117.5, 117.0, 
116.4, 112.9 (Ar-C), 80.3, 80.1, 80.0 (O-C(CH3)3), 28.94, 28.86 (C(CH3)3). MS (MALDI-
TOF) m/z 1173.440 [M+H]
+
, calcd for C66H49N10O8Zn 1173.303. The N-Boc-protected ZnPc 
(85.06 mg, 0.073 mmol) was dissolved in a 1:1, mixture of DCM/TFA (6 mL) and the 
solution was stirred at 0 C for 3 h. The work-up as described above, gave a blue-greenish 
solid (65.4 mg, 92.1 %). UV-Vis (DMF): λmax (log ε) 336 nm (4.37), 624 nm (4.13), 691 
(4.89) nm. 
1
H NMR (DMF-d7): δ 9.41-6.27 (m, 28H, Ar-H), 4.12 (br, 4H, NH2). 
13
C NMR 
(DMF-d7): δ 159.0, 155.2, 155.0, 154.1, 153.0, 152.3, 150.9, 148.5, 146.5, 146.2, 142.8, 
140.4, 133.1, 131.0, 129.9, 129.6, 129.3, 127.9, 126.3, 122.2, 122.0, 121.8, 121.1, 117.9, 
117.3, 116.6, 116.3, 112.9 (Ar-C). MS (MALDI-TOF) m/z 973.210 [M+H]
+
, calcd for 
C56H33N10O4Zn, 973.1978.  
Di-α-(trimethylamino)-ZnPc 2.25. ZnPc 2.24 (20 mg, 0.021 mmol), DIPA (0.15 mL, 
1.07 mmol) and CH3I (0.2 mL, 3.21 mmol) were added to dry THF (0.5 mL) and the mixture 







Pc 2.25 as a pale-green solid (14.7 mg, 53.3%), mp > 250 
o
C. UV–Vis (DMF): λmax (log ε) 
337 nm (4.61), 613 nm (4.51), 685 nm (5.26). 
1
H NMR (DMF-d7): δ 9.52-9.36 (m, 3H, Ar-H), 
8.79-8.63 (m, 1H, Ar-H), 8.44-8.36 (m, 2H, Ar-H), 8.30-8.18 (m, 6H, Ar-H), 8.10-7.95 (m, 
2H, Ar-H), 7.78-7.72 (m, 5H, Ar-H), 7.58-7.55 (m, 2H, Ar-H), 7.33-7.06 (m, 7H, Ar-H), 3.95 
(s, 8H, N-CH3), 3.85-3.81 (m, 10H, N-CH3). 
13
C NMR (DMF-d7): δ 161.5, 160.0, 159.0, 
154.5, 154.3, 153.8, 153.5, 153.2, 152.7, 151.0, 150.7 143.9, 143.2, 143.1, 142.7, 133.2, 
132.4, 131.8, 131.2, 129.9, 129.3, 126.7, 126.5, 126.2, 124.2, 124.0, 123.6, 123.4, 122.1, 
121.9 121.4, 121.0, 119.7, 118.5, 118.3, 112.9 (Ar-C), 66.29 (N-Ar-C), 58.1, 58.0 (N-CH3). 
MS (MALDI-TOF) m/z 1045.304 [M-2I-CH3+2H]
+
, calcd for C61H45N10O4Zn
+
 1045.2917. 
Di-β-amino-ZnPc 2.26. A mixture of 2,2’-bis(2,3-dicyanophenoxy)biphenyl 2.23
29
 
(302.3 mg, 0.69 mmol), phthalonitrile 2.10 (480.0 mg, 1.43 mmol) and zinc acetate (254.7 
mg, 1.4 mmol) was dissolved in DMAE (100.0 mL). Catalytic amount of DBN was added and 
the reaction refluxed for 15 h. The product was purified as described above for 2.24 to give N-





(DMF-d7): δ 9.59-9.54 (m, 2H, Ar-H), 9.26-9.06 (m, 2H, Ar-H), 8.67-8.26 (m, 3H, Ar-H), 
810-8.05 (m, 1H, Ar-H), 7.98-7.14 (m, 19H, Ar-H), 1.59 - 1.51 (m, 18H, C(CH3)3). 
13
C NMR 
(DMF-d7): δ 169.6, 168.0 (C=O), 161.3, 161.2, 161.14, 161.06, 159.11, 159.07, 154.9, 154.5, 
154.3, 154.0, 153.6, 153.1, 152.9, 152.8, 152.5, 151.6, 150.8, 15.7, 142.7, 142.4, 141.2, 137.9, 
137.8, 137.4, 136.4, 133.6, 133.2, 131.3, 131.2, 130.8, 130.7, 130.3, 129.9, 129.4, 126.3, 
126.2, 125.7, 125.0, 124.9, 124.8, 122.1, 121.7, 121.5, 121.3, 121.1, 120.9, 118.2, 112.9, 
111.9 (Ar-C), 80.2 (O-C(CH3)3), 28.9, 28.8 (C(CH3)3). MS (MALDI-TOF) m/z 1173.419 
[M+H]
+
, calcd for C66H48N10O8Zn 1173.303. The N-Boc-protected ZnPc (51.6 mg, 0.044 







isolated as a blue-greenish solid (38.2 mg, 89.2 %). UV-Vis (DMF): λmax (log ε) 350 nm 
(4.29), 616 nm (3.99), 684 (4.72) nm. 
1
H NMR (DMF-d7): δ 9.84-6.34 (m, 28H, Ar-H), 4.30 
(br, 4H, NH2). 
13
C NMR (DMF-d7): δ 159.1, 156.2, 155.0, 154.3, 153.0, 150.9, 150.6, 148.8, 
143.0, 142.2, 140.4, 134.2, 133.2, 131.2, 131.0, 130.9, 129.9, 129.6, 129.3, 126.2, 125.7, 
125.4, 122.2, 122.0, 121.2, 116.9, 112.8, 109.8h (Ar-C). MS (MALDI-TOF) m/z 973.228 
[M+H]
+
, calcd for C56H33N10O4Zn, 973.1978.  
Di-β-(trimethylamino)-ZnPc 2.27. A mixture of ZnPc 2.26 (20 mg, 0.021 mmol), 
DIPA (0.15 mL, 1.07 mmol) and iodomethane (0.2 mL, 3.21 mmol) was added to dry THF 
(0.5 mL) and stirred at 25 °C for 3 days. The ZnPc 2.27 was isolated as a blue-green solid 
(16.1 mg, 58.3%), mp > 250 
o
C. UV–Vis (DMF): λmax (log ε) 350 nm (4.72), 613 nm (4.48), 
680 nm (5.23). 
1
H NMR (DMF-d7): δ 9.27-8.66 (m, 3H, Ar-H), 8.37-8.30 (m, 5H, Ar-H), 
8.15-8.06 (m, 1H, Ar-H), 7.91-7.55 (m, 9H, Ar-H), 7.41-7.25 (m, 7H, Ar-H), 4.02-3.97 (m, 
18H, N-CH3). 
13
C NMR (DMF-d7): δ 159.9, 158.9, 158.4, 158.2, 154.4, 154.0, 153.6, 150.8, 
143.9, 143.8, 141.8, 141.4, 136.2, 135.9, 135.6, 133.3, 131.6, 131.3, 131.0, 130.0, 129.3, 
126.2, 125.3, 124.1, 122.5, 122.1, 121.1, 120.6, 120.2, 114.2, 113.8, 113.0 (Ar-C), 66.29 (N-










2.6.3. Phthalonitrile Molecular Structures  
X-ray structure analyses of phthalonitriles 2.3, 2.9, 2.10, 2.18 and 2.23 were based on 
data collected at T=90K on either a Nonius KappaCCD diffractometer equipped with MoKα 
radiation (compound 2.3) or a Bruker Kappa Apex-II CCD diffractometer with CuKα 
radiation (compounds 2.10, 2.18 and 2.23). The crystals were grown by slow evaporation of 







successful syntheses. Crystal data: 2.3, C19H17N3O3, Mr = 335.36, monoclinic space group 
P21/c, a = 16.266(4), b = 11.114(3), c = 9.8401(16) Å,  = 101.629(13)°, V = 1742.4(7) Å
3
, Z 
= 4, Dx = 1.278 Mg m
−3
 , max = 30.0°, R = 0.047 for 5047 data and 232 refined parameters, 
CCDC 810389; 2.10, C19H17N3O3, Mr = 335.36, orthorhombic space group Pca21, a = 
10.139(2), b = 8.597(2), c = 20.157(5) Å, V = 1757.0(7) Å
3
, Z = 4, Dx = 1.268 Mg m
−3
 , max = 
68.1°, R = 0.032 for 2507 data and 233 refined parameters, CCDC 810390; 2.18, C30H30N4O6, 
Mr = 542.58, triclinic space group P-1, a = 10.0348(5), b = 12.0728(6), c = 13.3158(10) Å,  
= 110.460(5),  = 102.622(4),  = 101.132(4)°, V = 1409.38(15) Å
3
, Z = 2, Dx = 1.279 Mg 
m
−3
, max = 68.6°, R = 0.037 for 4972 data and 373 refined parameters, CCDC 810391. 2.23, 
C28H14N4O2, 2.4(CH2Cl2), Mr = 642.25, triclinic space group P-1, a = 8.9371(4), b = 
10.3208(5), c = 16.1899(7) Å,  = 77.863(2),  = 81.983(2),  = 78.622(2)°, V = 1423.75(11) 
Å
3
, Z = 2, Dx = 1.498 Mg m
−3
 , max = 69.4°, R = 0.066 for 5068 data and 334 refined 
parameters, CCDC 835347. 
2.6.4. Spectroscopic Studies  
The absorption spectra for the ZnPcs were measured on a PerkinElmer, Lambda 35 
UV-Vis spectrometer. The solvents used in these measurements were HPLC grade. The stock 
solutions of 0.1-1 mM of each ZnPc in DMF were prepared and successive dilutions were 
obtained by spiking 20 – 250 µL of the corresponding stock solution into 10 or 18 mL of 
DMF solvent. The emission spectra were recorded on a Fluorolog
®
-HORIBA JOBIN YVON 
(Model LFI-3751) spectrofluorimeter. The optical densities for the solutions used in emission 
measurements ranged between 0.05 – 0.10 at excitation wavelengths. All the measurements 
were performed within 2 h of solution preparation at 25 °C, using a 10 mm path length 







using a secondary standard method,
33
 and ZnPc (Фf = 0.17) used as reference.
40,41,48
 The 
singlet oxygen quantum yields (Ф∆) were measured in DMF using a relative method,
43
 where 
ZnPc (Фf = 0.56) served as reference and DPBF as a scavenger. The samples, both the stock 
and dilutions, were prepared in the dark. The concentration of DPBF was kept at ~ 3.0 × 10
-5
 
mol/l to avoid multiple reactions. The monitoring of DPBF absorption decay at 417 nm was 
used to calculate the singlet oxygen quantum yields for the ZnPcs within ~ 10% accuracy 
2.6.5. Cell Studies  
 The human carcinoma HEp2 cells used in this study were maintained in a 50:50 
mixture of DMEM:AMEM (Invitrogen) supplemented with 5% FBS (Invitrogen), Primocin 
antibiotic (Invitrogen) and 5% CO2 at 37 
o
C. By subculturing the cells twice weekly, 




 passage cells were used for all the 
measurements. 
 Time-Dependent Cellular Uptake: The HEp2 cells for cellular uptake experiments 
were plated at 7500 cells per well in a Costar 96-well plate. They were then allowed to grow 
for 48 h. The ZnPc stock solutions were prepared at 32 mM in DMSO. Subsequent dilution 
gave 20 µM in medium (a 2X stock). Further dilution into the cells of the 96-well plate gave a 
final concentration of 10 µM, with a maximum DMSO concentration of 1%. The uptake of the 
ZnPcs was allowed to continue for 0, 1, 2, 4, 8, 12 and 24 h. The termination of the uptake 
was achieved by removing the loading medium and washing the wells with PBS. The 
concentration of the ZnPcs was calculated from standard curves using intrinsic fluorescence 
as measured with a BMG FLUOstar plate reader fitted with a 355 nm excitation and a 650 nm 
emission filter, as it has been previously described.
15







CyQuant cell proliferation assay (Invitrogen) as per manufactures instruction, and the uptake 
was expressed in terms of nM compound per cell. 
 Dark Cytotoxicity: The plating of the HEp2 cells was performed as described above 
for the uptake measurements. The ZnPcs were diluted into medium to a 400 µM 
concentration. Then 2-fold serial dilutions were prepared to 50 µM, and the cells incubated 
overnight. The cell toxicity was obtained using Promega’s Cell Titer-Blue Viability assay 
according to manufacturer’s instructions. The untreated cells were considered 100% viable 
while those treated with 0.2% saponin were considered 0% viable. The IC50 values were 
calculated from dose-response curves, which were obtained using GraphPad Prism software. 
 Phototoxicity: The plating of the HEp2 cells was achieved as described above with 
compounds concentration range from 6.25-100 µM. After overnight loading, the medium was 
replaced with the medium containing 50 mM HEPES at pH 7.2. The cells were then exposed 
to a NewPort light system with 175 W halogen lamp for 20 min and filtered through a water 
film to provide approximately 1.5 J/cm
2
 light dose. The cells were cooled by placing the 
culture on a 5 
o
C Echotherm chilling/heating plate (Torrey Pines Scientific, Inc.) and the plate 
was incubated overnight. The cell viability was then calculated as described above for the 
dark cytotoxicity. 
Microscopy: The cells for microscopy were incubated in a glass bottom 6-well plate 
(MatTek) and allowed to grow for 48 h. They were then exposed to 10 µM of each ZnPc 
overnight. Organelle tracers from Invitrogen were used at the following concentrations: 
LysoSensor Green 50 nM, MitoTracker Green 250 nM, ER Tracker Blue/white 100 nM, and 
BODIPY FL C5 ceramide 1 µM. The organelle tracers diluted in medium and the cells were 







PBS and microscopy. The microscopy images were obtained using a Leica DMRXA 
microscope with 40× NA 0.8dip objective lens and DAPI, GFP and Texas Red filter cubes 
(Chroma Technologies). 
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SYNTHESES, CHARACTERIZATION AND BIOLOGICAL EVALUATION OF 
PHTHALOCYANINE-PEPTIDE CONJUGATES FOR EPIDERMAL GROWTH 
FACTOR RECEPTOR TARGETING IN COLON CANCER 
3.1. Background 
Colorectal cancer (CRC) is currently the second leading cause of cancer-related deaths 
among both men and women in the US.
1
 It typically develops over several years from 
adenomatous polyps to carcinoma. Routine colon screening, detection and removal of polyp 
adenomas and early stage cancer reduces the incidence of CRC. However, most cancers are 
detected at a stage where they may become terminal because they lack outward signs or 
symptoms.
2
 The current methods of detection for CRC such as flexible sigmoidoscopy, standard 
colonoscopy, radiography, and computer tomography (CT) colonoscopy frequently miss small 
adenomas (< 5 mm) and flat lesions, the two early stages of CRC.
2
 Early detection of small 
adenomas and flat lesions could prevent the development of the malignant tumors.  
The new detection methods currently being employed to accomplish this goal include 
chromoendoscopy, narrow band imaging, and blue light auto-fluorescence.
3
 Chromoendoscopy 
utilizes an absorptive or contrast dye, such as methylene blue, to stain the mucosa for standard 
white light colonoscopy, enhancing tissue characterization, differentiation, and diagnosis of 
small adenomas.
2,3
 Narrow band imaging uses a blue and green filter to narrow the white 
colonoscopic light to illuminate the mucosa, and blue light auto-fluorescence involves a UV light 
source to generate mucosal auto-fluorescence. In addition, confocal laser endomicroscopy (CLE) 
has been employed to image the mucosa, with fluorescein, acriflavine, or cresyl violet as the 
                                                
 This chapter originally appeared in Ongarora, B. G.; Fontenot, K. R.; Hu, X.; Sehgal, I.; 
Satyanarayana-Jois, S. D.; Vicente, d. G. H., Phthalocyanine–Peptide Conjugates for Epidermal 
Growth Factor Receptor Targeting. Journal of Medicinal Chemistry 2012, 55 (8), 3725-3738.
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fluorescent dyes. The drawbacks of these dyes are their poor selectivity for CRC, residual 
toxicity, and emission wavelengths in the visible region of the optical spectrum.
5
  
On the other hand, phthalocyanines (Pcs) are tetrapyrrolic macrocycles with extended π-
conjugated systems that typically emit at long wavelengths (> 670 nm) with high fluorescence 
quantum yields.
6,7
 Near-IR fluorescence for bioimaging applications has several advantages: low 
Raman scattering cross-sections associated with the use of low energy excitation photons, larger 
Raman-free observation windows and reduced absorption and fluorescence from other 
compounds.
8
 Pcs have been extensively investigated in the last decades for a variety of 
applications, including as colorant dyes, catalysts, sensors, and as photosensitizers for 
photodynamic therapy (PDT) of cancers.
9-11
  
As pointed out in Chapter 1, PDT involves the administration of a photosensitizer 
followed by activation with red light to produce cytotoxic oxygen species that destroy malignant 
cells.
12,13
 Due to their low dark toxicity, high photostability and ability to preferentially 
accumulation within tumor tissue, Pcs are promising cancer diagnostic and treatment agents. 
Furthermore, conjugation of Pcs with peptide ligands directed at specific receptors over-
expressed in cancer cells, such as the human epidermal growth factor receptor (EGFR), is an 
attractive strategy for increasing their biological efficacy.
14-18
 EGFR is over-expressed in CRC, 




Among the EGFR-targeting biomolecules recently reported for selective delivery of 
cytotoxic drugs to the tumor sites,
22-26
 two small peptides with sequences LARLLT (designated 
EGFR-L1)
27
 and YHWYGYTPQNVI (designated EGFR-L2)
28
 are particularly attractive due to 







superior EGFR-targeting ability. EGFR-L1 was selected from computational screening of an 
EGFR peptide ligand virtual library, and shown to target EGFR both in vitro (in EGFR over-
expressing H1299 cells) and in vivo (in H1299 tumor-bearing mice following intravenous (iv) 
administration).
27
 On the other hand, EGFR-L2 was identified from screening of a phage display 
peptide library and also shown to bind to EGFR both in vitro (SMMC-7721 cells) and in vivo 
(SMMC-7721 tumor bearing mice following iv injection).
28
  
In the continuing pursuit for tumor-selective fluorescent imaging and PDT agents, a Pc 
conjugated to a bifunctional nuclear localizing sequence and cell-penetrating peptide containing 
32 amino acid residues, via either a short (5-atom) or a PEG (20-atom) linker, has been shown to 
display higher fluorescence quantum yield and increased cellular uptake compared with non-
conjugated Pc.
29
 In this Chapter, the synthesis, photophysical, and biological evaluation of Pc 
conjugates to either EGFR-L1 or EGFR-L2 peptide ligands is described.  
3.2. Results and Discussion 
3.2.1. Synthesis and Characterization 
The Pc-peptide conjugates described in this Chapter were designed to specifically target 
EGFR. The synthetic routes to conjugates 3.5, 3.6, 3.9 and 3.11 are shown in Schemes 1 and 2. 
Pcs 3.1 and 3.7 were prepared by statistical condensation
 
of 3- or 4-(p-N-Boc-aminophenoxy)-
phthalonitrile and 4-tert-butylphthalonitrile (in 1:3 ratio) in DMAE at 140 ºC for 5 h, and in the 
presence of Zn(II) acetate and DBN, followed by TFA deprotection of the Boc groups, as 
described in Chapter 1 and also in literature.
30
 Reaction of Pc 3.1 with diglycolic anhydride in 
DMF gave the corresponding α-substituted carboxy-terminated Pc 3.2, in 86.6% yield, following 
reported literature procedure.
29,31
 The coupling of Pc 3.2 with commercially available tert-butyl 







afforded the Pc 3.4 in 68.3% overall yield;
31
 lower yields were obtained when TBTU was used in 
place of EDCI, due to a more difficult purification of the target Pc-PEG compounds. Solid-phase 
conjugation of Pc 3.4 to the two peptide sequences LARLLT
27
 (EGFR-L1) and 
GYHWYGYTPQNVI
28
 (EGFR-L2) using DIEA, HOBt and TBTU or HATU in DMF and at 
room temperature, gave the targeted Pc-peptide conjugates 3.5 and 3.6 in 40-80% yields, after 
cleavage from the solid support and reversed-phase chromatographic purification. A glycine 
residue at the N-terminus of the EGFR-L2 peptide was meant to enhance the conjugation 
reaction yields.
31,32
 Coupling reactions with Pc 3.3 gave traces of the product (MALDI-TOF). 
 
Scheme 3.1: Synthesis of mono-peptide α-substituted ZnPc. Conditions: (a) 1,4-dioxane-2,6-
dione, DMF, r.t., (86.6%). (b) DIEA, HOBt, TBTU, EGFR-L1/L2, DMF, 24 h, r.t., 40-79% (c) 
tert-butyl-12-amino-4,7,10-trioxadodecanoate, DIEA, HOBt, EDCI, DMF, 48 h, r.t., (76.5%). (d) 







 Reaction of Pc 3.7 with diglycolic anhydride in DMF gave the corresponding β-
substituted carboxy-terminated Pcs 3.8, in 92.2% yield, following the procedure for Pc 3.2 
above. The coupling of Pc 3.8 with commercially available tert-butyl protected PEG using 
HOBt, EDCI and DIEA, following by deprotection of the tert-butyl group afforded Pc 3.10 in 
72.7% overall yield. Lower yields were also obtained when TBTU was used in place of EDCI, 
just as in Pc 3.2 above.  Solid-phase conjugation of Pcs 3.8 and 3.10 to the two peptides 
EGFR-L1 and EGFR-L2 using DIEA, HOBt and TBTU or HATU in DMF and at room 
temperature, gave the targeted Pc-peptide conjugates 3.9 and 3.11 in 35-84% yields, after 
cleavage and purification. Reacting EGFR-L2 with Pc 3.10 gave traces Pc 3.12 (MALDI-TOF). 
 
Scheme 3.2: Synthesis of mono-peptide β-substituted ZnPc. Conditions: (a) 1,4-dioxane-2,6-
dione, DMF, r.t., (92.2%). (b) DIEA, HOBt, TBTU, EGFR-L1/L2, DMF, 24 h, r.t., 35-84% (c) 
tert-butyl-12-amino-4,7,10-trioxadodecanoate, DIEA, HOBt, EDCI, DMF, 48 h, r.t., (82.3%). (d) 







The synthesize of di-peptidic conjugates was attempted using Pc 3.13, which was 
prepared as described in Chapter 1 (Scheme 3). The reaction of Pc 3.13 with diglycolic 
anhydride in DMF gave the corresponding β-substituted di-carboxy-terminated Pc 3.14, in 
87.6% yield. The coupling of Pc 3.14 with commercially available tert-butyl protected PEG 
using HOBt, EDCI and DIEA afforded Pc 3.15 in trace amounts and therefore, conjugation to 
peptides was not possible. Solid-phase conjugation of Pc 3.14 to EGFR-L1 and EGFR-L2 using 
DIEA, HOBt and TBTU or HATU in DMF and at room temperature, was not successful either. 
 
Scheme 3.3: Synthesis of di-peptide-conjugated ZnPc. Conditions: (a) 1,4-dioxane-2,6-dione, 
DMF, r.t., (87.6%). (b) DIEA, HOBt, TBTU, EGFR-L1/L2, DMF, 24 h, r.t. (c) tert-butyl-12-







A Pc macrocycle has previously been conjugated to a lysine-rich bifunctional peptide 
sequence containing 32 amino acid residues, via a similar short (5-atom) and a long (20-atom) 
PEG linker, and observed that the PEG linker increased cellular uptake into human HEp2 cells, 
and decreased cytotoxicity of the Pc conjugate.
29
 On the other hand, the short linker Pc conjugate 
showed higher fluorescence quantum yield, probably as a result of its lower conformational 
flexibility compared with the PEG group. In the current work, a short (5-atom) and a low 
molecular weight PEG (13-atom) linker between the Pc and the peptide ligand were investigated; 
the smaller PEG group has the advantages of being commercially available and potentially less 
flexible than the penta(ethylene glycol) previously used. In addition, the PEG linker is believed 
to favor an extended conformation for conjugates 3.5 and 3.6 and 3.11,
31
 which might favor 
EGFR target binding, and to increase their aqueous solubility compared with conjugate 3.9 (vide 
infra). 
EGFR over-expression has been found in a variety of human cancers, including breast, 
ovarian, prostate, pancreatic, and colorectal;
33
 for this reason EGFR has been an important target 
for cancer treatment.
14-18
 Monoclonal antibodies (mAbs), such as cetuximab and trastuzumab, 
and tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, are HER1/EGFR-targeted 
agents currently in clinical development, or already approved, for use in several countries. 
Peptides EGFR-L1 and EGFR-L2
 
were designed to act as a substitute for the natural ligand EGF, 
which has reported mitogenic and neoangiogenic activity, and has been shown to specifically 
target EGFR over-expressing tumor cells both in vitro and in vivo.
27,28
 Advantages of using small 
peptide ligands as target units include their easy synthesis and coupling to fluorophores, their 
low immunogenicity and high binding affinity for the biological target. The EGFR-L1 







All Pcs in this series were characterized by MS, NMR, UV-Vis and fluorescence 
spectroscopy; MALDI-TOF was used to confirm the amino acid sequence in the Pc-peptide 
conjugates. The spectroscopic properties for Pcs 3.4, 3.5, 3.6, 3.9, 3.10 and 3.11 are summarized 
in Table 3.1 and Figure 3.1). All Pcs showed strong Q absorption bands between 677 - 680 nm in 
DMF, and emissions between 680 - 683 nm in the same solvent, with fluorescence quantum 
yields in the range 0.10-0.13 and Stokes’ shifts of 2 – 4 nm, characteristic of this type of 
compound.
29,30 
All Pc-peptide conjugates were soluble in polar organic solvents, such as DMSO 
and DMF, up to 1.0 mM concentrations, though, precipitation was observed upon dilution into 
aqueous solutions. Cremophor EL, a non-ionic solubilizer and emulsifier was, therefore, added to 
all Pc stock solutions used in the biological experiments. The cell studies were conducted in 
PBS/DMSO/Cremophor (94:1:5) and the mice studies in PBS/DMSO/Cremophor (85:10:5).
 
 
a)                                                                                          b) 
Figure 3.1. (a) Absorption spectra for Pc conjugates at 8.0 μM and, (b) Emission spectra for Pc 








The solubility of the Pcs decreased in the order Pc-PEG (3.4 and 3.10) > Pc-EGFR-L1 
(3.5 and 3.11) > Pc-EGFR-L2 (3.6) > Pc-EGFR-L2 (3.9), due to the high hydrophobicity of the 
longer EGFR-L2 sequence (containing 11 hydrophobic amino acids and only two polar), 
compared with EGFR-L1 (containing 4 hydrophobic amino acids, one polar and one cationic). 
Indeed, the uncharged Pc conjugates 3.9 and 3.6 exhibited low solubility in polar protic solvents 
such as methanol, compared with the positively charged Pc conjugates 3.5 and 3.11. The least 
soluble was the Pc-EGFR-L2 conjugate 3.9 bearing a short 5-atom linker. 
Table 3.1. Spectroscopic Properties of Pcs in DMF. 
Pc Absorption (nm) Emission
a









3.4 678 682 4 5.35 0.10 
3.5 680 683 3 5.33 0.12 
3.6 680 683 3 4.60 0.13 
3.8 677 680 3 5.19 0.13 
3.9 677 681 4 4.85 0.10 
3.11 680 682 2 5.27 0.11 
a
 Excitation at 670 nm. 
b
 Calculated using ZnPc (Фf = 0.17) as the standard.  
3.2.2. Docking  
To model the interaction of peptides EGFR-L1 and EGFR-L2, docking studies were 
carried out using Autodock.
34,35
 EGFR-L1 is known to bind to a pocket away from the EGF 
binding pocket in EGFR,
27
 while EGFR-L2 binds to the EGF binding pocket.
28
 Hence, for 
EGFR-L1 grid box for docking calculations were around Glu71, Asn134, Gly177. The low 
energy docked structure (docking energy of -6.06 kcal/mol) of EGFR-L1 is shown in Figure 
3.2a. The Leu4 backbone carbonyl and Thr6 side chain hydroxyl groups form hydrogen-bonding 
interaction with EGFR. The RLLT sequence of the peptide acquired a β-turn conformation when 








Figure 3.2. Low energy docked structure of (i) EGFR-L1 and (ii) EGFR-L2 peptides with EGF 
receptor. EGFR is shown in surface and the peptide is shown as dark sticks. The EGF binding 
pocket is also shown. 
The low energy docked structure of EGFR-L2 peptide is shown in Figure 3.2b. EGFR-L2 
peptide binds to EGF binding pocket with docking energy of -5.96 kcal/mol. Tyr1 and Ile12 
residues from the peptide formed hydrogen-bonding interactions with the EGFR stabilizing the 
peptide-receptor interaction. Overall, the peptide did not have any particular secondary structure 
as shown in the Figure 3.2b. Peptide was bound in the cavity of EGF binding pocket of EGFR. 
These results indicate that both peptides EGFR-L1 and EGFR-L2 can bind to EGFR. 
3.2.3. Cell Culture 
Four cell lines with different EGFR expressions were used to investigate the cytotoxicity, 
uptake and subcellular distribution of Pc-peptide conjugates 3.5, 3.6, 3.9 and 3.11: human 
squamous cell carcinoma HEp2,
29-32
 human epidermoid carcinoma A431,
36-38
 cercopithecus 
aethiops kidney Vero (as negative control),
39









 The model human HEp2 cells are often used in the investigation of peptide-fluorophore 
conjugates, while the human A431 cells are a positive control for high EGFR expression (~1-3 
million EGFR per cell), and the African green monkey Vero cells are a negative control (lowest 
expression of EGFR). The human colorectal adenocarcinoma HT-29 cells over-express EGFR, 
although to a lower degree (~9000 EGFR per cell) than the A431 cells.
39-41
  
Cytotoxicity. The dark- and photo-cytotoxicity for Pc-PEG 3.4 and Pc-peptide 
conjugates 3.5, 3.6, 3.9 and 3.11 were evaluated in all cell lines at concentrations up to 125 µM, 
using the Cell Titer Blue Assay, and the results are summarized in Table 3.2, and shown in 
Figures 3.3 and 3.4. None of the Pcs was found to be toxic in the dark, with determined IC50 
values for all Pcs above 125 µM, the highest concentration investigated. Upon exposure to a low 
light dose (1 J/cm
2
), only Pc 3.5 bearing the EGFR-L1 peptide was found toxic to A431, HEp2 
and Vero cells (IC50 = 16, 17 and 47 µM, respectively).  
In human carcinoma HEp2 cells, Pc conjugate 3.5 was significantly more phototoxic than 
3.11 (IC50 ~ 100 µM), and was in agreement with our observations in Chapter 1, showing that α-
substituted Pcs tend to be more phototoxic than the corresponding β-substituted Pcs.
30
 On the 
other hand, none of the Pcs were phototoxic to human HT-29 cells, suggesting that this type of 
conjugate could potentially be used for imaging of colorectal tumors.  
Low toxicity is an important feature of potential new imaging agents to be employed in 
conjunction with CLE. The Pc-EGFR-L1 conjugate 3.5 was significantly more phototoxic than 
the corresponding Pc-EGFR-L2 conjugate 3.6, which might be a result of its higher uptake into 
cells due to its cationic charge (vide infra). The presence of the PEG linker did not have any 









Figure 3.3. Dark toxicity of conjugates Pc 3.4 (blue), 3.5 (purple), 3.6 (red), 3.9 (tangerine), and 
3.11 (turquoise) at 10 μM toward (i) A431, (ii) Vero, (iii) HEp2 and (iv) HT-29 cells, using the 
Cell Titer Blue assay. 
 
Figure 3.4. Phototoxicity of conjugates Pc 3.4 (blue), 3.5 (purple), 3.6 (red), 3.9 (tangerine), and 
3.11 (turquoise) at 10 μM toward (i) A431, (ii) Vero, (iii) HEp2 and (iv) HT-29 cells, using the 







Table 3.2. Dark and photo cytotoxicity for Pc conjugates using the Cell Titer Blue assay. 












3.4  >100/>125 >100/>125 >100/>125 >100/>125 
3.5  15.8/>125 47.0/>125 17.0/>125 >100/>125 
3.6  >100/>125 >100/>125 >100/>125 >100/>125 
3.9  >100/>125 >100/>125 >100/>125 >100/>125 
3.11  >100/>125 >100/>125 >100/>125 >100/>125 
Time-Dependent Uptake. The time-dependent cellular uptake for all Pcs was performed 
at the non-toxic concentration of 10 μM in all cell lines, and the results are shown in Figure 3.5. 
There were marked differences in the cellular uptake of the Pc-EGFR-L1 conjugates compared 
with the Pc-EGFR-L2 conjugates, which might be due to their different overall charge, solubility 
and tendency for aggregation. While the highly hydrophobic and uncharged Pc-EGFR-L2 
conjugates 3.6 and 3.9 were poorly taken up by all cell lines, in particular by A431 and HT-29 
cells which over-express EGFR, the positively charged Pc-EGFR-L1 conjugates 3.5 and 3.11 
accumulated within cells to a much higher extent. Cells with higher EGFR expression showed 
higher uptake of the Pc conjugates, about 4-fold increase in A431 vs Vero cells, and a 3- or 2-
fold increase in HT-29 colorectal and HEp2 cancer cells, respectively. This result shows that Pc 
conjugates 3.5 and 3.11 can indeed target cancer cells over-expressing EGFR, in particular CRC 
cells. Very different Pc uptake into Vero cells, with low expression of EGFR was observed; Pc 
conjugate 3.11 accumulated the fastest, followed by 3.5 and precursor Pc-PEG 3.4.  
The Pc-EGFR-L2 conjugates 3.9 and 3.6 were taken up by Vero cells to a much lower 
extent than the Pc-EGFR-L1 conjugates 3.5, 3.6 and 3.11 bearing a PEG linker accumulated ~ 2-
fold higher than 3.9. These results show that the Pc macrocycle has a natural tendency to 







compounds tend to be taken up to a higher extent. The conjugation of the Pc to a small cationic 
peptide sequence (EGFR-L1) changes the uptake kinetics, as seen in Figure 3.5b, and as 
previously observed.
32
 In EGFR over-expressing cells, Pc conjugates 3.5 and 3.11 clearly were 
taken up the most of all Pcs investigated. For example, in A431 cells, conjugates 3.5 and 3.11 
accumulated ~15-fold more than Pc-PEG 3.4 and than the Pc-EGFR-L2 conjugates 3.6 and 3.9 
(Figure 3.5a). Similarly in HT-29 and HEp2 cells, 3.5 and 3.11 were taken up to a higher extent 
than Pcs 3.4, 3.6 and 3.9.  
 
Figure 3.5. Time-dependent uptake of Pcs 3.4 (blue), 3.5 (purple), 3.6 (red) 3.9 (orange) and 
3.11 (turquoise) at 10 μM by (i) A431, (ii) Vero, (iii) HEp2 and (iv) HT-29 cells. 
These results indicate that the peptide sequence has a marked effect on the cell targeting 







peptides EGFR-L1 and –L2 can bind to EGFR, EGFR-L2 to the EGF binding site and EGFR-L1 
to an outside pocket, as previously reported.
27,28
 Although Pc-EGFR-L2 conjugates could 
potentially bind to EGFR with high specificity and be retained at the cell surface rather than 
internalized, their low uptake into Vero cells with low expression of EGFR suggests that their 
low solubility and high tendency for aggregation are responsible for their observed low cellular 
uptake. Indeed, the least soluble Pc 3.9 accumulated the least within cells compared with all Pcs 
investigated. On the other hand, the Pc-EGFR-L1 conjugates bearing an arginine residue and 
overall +1 charge were readily taken up by all cells, as previously observed for porphyrin-
peptide conjugates bearing 1 to 4 positively charged residues.
43
 Positively charged molecules 
have been observed to have enhanced ability for crossing negatively charged plasma membranes, 
in particular those containing arginine due to the unique ability of the protonated guanidinium 
group to form bidentate hydrogen bonds.
43-47
  
Table 3.3. Main subcellular sites of localization for Pc conjugates in human cells. 
ZnPc A431 cells HEp2 cells HT-29 cells 
3.4  Lyso, Golgi, Mito Lyso, Golgi Lyso 
3.5  Lyso, Golgi, Mito, 
ER 
Lyso, Golgi, Mito, 
ER 
Lyso, Mito 
3.6  Lyso, Golgi, Mito Lyso, Golgi, Mito Lyso, ER 
3.9  Lyso, Golgi, Mito Lyso, Golgi, Mito Lyso, Golgi, Mito 
3.11  Lyso, Golgi, Mito Lyso, Golgi, Mito Lyso, Golgi, Mito 
Of all Pc-peptide conjugates investigated, 3.11 accumulated the fastest within all cell 
lines, followed by 3.5, which was found in the highest amount within A431 and HT-29 cells, at 
times > 8 h after Pc exposure. Due to its rapid and efficient uptake into cells and low 







Subcellular Localization. The preferential sites of intracellular localization of Pc-
peptide conjugates 3.5, 3.6, 3.9 and 3.11 and Pc-PEG 3.4 were evaluated using fluorescence 
microscopy, in the three human cell lines over-expressing EGFR, i.e. A431, HT-29 and HEp2 
cells. The results are summarized in Table 3.3 and shown in Figures 3.6 – 3.11 for conjugates 
3.5, 3.6, 3.9 and 3.11. Co-localization experiments were performed using the organelle-specific 
probes LysoTracker Green (lysosomes), ER Tracker Blue/White (ER), MitoTracker Green 
(mitochondria) and BODIPY Ceramide (Golgi). 
All conjugates localized in multiple sites within the cells. The Pc-EGFR-L1 conjugate 
3.11 was found in the lysosomes, mitochondria and Golgi of all cell lines; in addition its 
regioisomer 3.5 was also observed in the ER, which might in part explain its higher phototoxicity 
compared with 3.11.
48,49
 Pc-EGFR-L2 conjugates 3.6 and 3.9 were also found in lysosomes, 
Golgi and mitochondria. Lysosomal localization might result from an endocytic pathway of this 
type of molecules, as previously observed.
29,43
 
The potential fluorescence from the Pc conjugates on the plasma membrane was also 
investigated, in order to detect any non-internalized EGFR-bound conjugate. However, no 
fluorescence was detected by microscopy, indicating that the Pc conjugates do not localize on the 
plasma membrane. No co-localization was observed with fluorescent probe 1-(4-
trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene p-toluenesulfonate (TMA-DPH) that 
specifically labels the plasma membrane. This result indicates that the Pc-EGFR-L2 conjugates 
have poor EGFR targeting ability, probably because of their low solubility and high tendency for 
aggregation. On the other hand, the Pc-EGFR-L1 conjugates 3.5 and 3.11 efficiently targeted 









a)                                                                    b) 
Figure 3.6. Subcellular localization of (a) Pc 3.5 in A431 cells at 10 µM for 6 h. (A) Phase 
contrast, (B) Overlay of 3.5 fluorescence and phase contrast, (C) ER Tracker Blue/White 
fluorescence, (E) MitoTrack green fluorescence, (G) BoDIPY Ceramide, (I) LysoSensor green 
fluorescence, and (D, F, H, J) overlays of organelle tracers with 3.5 fluorescence. Scale bar: 10 
m. (b) Pc 3.6 in A431 cells at 10 µM for 6 h. (A) Phase contrast, (B) Overlay of 3.6 
fluorescence and phase contrast, (C) ER Tracker Blue/White fluorescence, (E) MitoTrack green 
fluorescence, (G) BoDIPY Ceramide, (I) LysoSensor green fluorescence, and (D, F, H, J) 








a)                                                                    b) 
Figure 3.7. Subcellular localization of (a) Pc 3.9 in A431 cells at 10 µM for 6 h. (A) Phase 
contrast, (B) Overlay of 3.9 fluorescence and phase contrast, (C) ER Tracker Blue/White 
fluorescence, (E) MitoTrack green fluorescence, (G) BoDIPY Ceramide, (I) LysoSensor green 
fluorescence, and (D, F, H, J) overlays of organelle tracers with 3.9 fluorescence. Scale bar: 10 
m. (b) Pc 3.11 in A431 cells at 10 µM for 6 h. (A) Phase contrast, (B) Overlay of 3.11 
fluorescence and phase contrast, (C) ER Tracker Blue/White fluorescence, (E) MitoTracker 
green fluorescence, (G) BODIPY Ceramide, (I) LysoSensor green fluorescence, and (D, F, H, J) 








a)                                                                    b) 
Figure 3.8. Subcellular localization of (a) Pc 3.5 in HEp2 cells at 10 µM for 6 h. (A) Phase 
contrast, (B) Overlay of 3.5 fluorescence and phase contrast, (C) ER Tracker Blue/White 
fluorescence, (E) MitoTrack green fluorescence, (G) BoDIPY Ceramide, (I) LysoSensor green 
fluorescence, and (D, F, H, J) overlays of organelle tracers with 3.5 fluorescence. Scale bar: 10 
m. (b) Pc 3.6 in HEp2 cells at 10 µM for 6 h. (A) Phase contrast, (B) Overlay of 3.6 
fluorescence and phase contrast, (C) ER Tracker Blue/White fluorescence, (E) MitoTrack green 
fluorescence, (G) BoDIPY Ceramide, (I) LysoSensor green fluorescence, and (D, F, H, J) 








a)                                                                    b) 
Figure 3.9. Subcellular localization of (a) Pc 3.9 in HEp2 cells at 10 µM for 6 h. (A) Phase 
contrast, (B) Overlay of 3.9 fluorescence and phase contrast, (C) ER Tracker Blue/White 
fluorescence, (E) MitoTrack green fluorescence, (G) BoDIPY Ceramide, (I) LysoSensor green 
fluorescence, and (D, F, H, J) overlays of organelle tracers with 3.9 fluorescence. Scale bar: 10 
m. (b) Pc 3.11 in HEp2 cells at 10 µM for 6 h. (A) Phase contrast, (B) Overlay of 3.11 
fluorescence and phase contrast, (C) ER Tracker Blue/White fluorescence, (E) MitoTrack green 
fluorescence, (G) BoDIPY Ceramide, (I) LysoSensor green fluorescence, and (D, F, H, J) 








a)                                                                    b) 
Figure 3.10. Subcellular localization of (a) Pc 3.5 in HT-29 cells at 10 µM for 6 h. (A) Phase 
contrast, (B) Overlay of 3.5 fluorescence and phase contrast, (C) ER Tracker Blue/White 
fluorescence, (E) MitoTrack green fluorescence, (G) BoDIPY Ceramide, (I) LysoSensor green 
fluorescence, and (D, F, H, J) overlays of organelle tracers with 3.5 fluorescence. Scale bar: 10 
m. (b) Pc 3.6 in HT-29 cells at 10 µM for 6 h. (A) Phase contrast, (B) Overlay of 3.6 
fluorescence and phase contrast, (C) ER Tracker Blue/White fluorescence, (E) MitoTrack green 
fluorescence, (G) BoDIPY Ceramide, (I) LysoSensor green fluorescence, and (D, F, H, J) 








a)                                                                    b) 
Figure 3.11. Subcellular localization of (a) Pc 3.9 in HT-29 cells at 10 µM for 6 h. (A) Phase 
contrast, (B) Overlay of 3.9 fluorescence and phase contrast, (C) ER Tracker Blue/White 
fluorescence, (E) MitoTrack green fluorescence, (G) BoDIPY Ceramide, (I) LysoSensor green 
fluorescence, and (D, F, H, J) overlays of organelle tracers with 3.9 fluorescence. Scale bar: 10 
m. (b) Pc 3.11 in HT-29 cells at 10 µM for 6 h. (A) Phase contrast, (B) Overlay of 3.11 
fluorescence and phase contrast, (C) ER Tracker Blue/White fluorescence, (E) MitoTrack green 
fluorescence, (G) BoDIPY Ceramide, (I) LysoSensor green fluorescence, and (D, F, H, J) 







3.2.4. Mouse Studies  
Pc-peptide conjugate 3.11 was chosen for further evaluation in mouse studies, due to its 
low cytotoxicity and rapid accumulation within cells in vitro. Following iv administration of 10 
mg/kg of Pc 3.11, nude mice showed the emergence of tumor-selective fluorescence indicating 
that the conjugate was taken up into both A431 and HT-29 s.c. tumors. Fluorescence signal 
which exceeded the background of adjacent skin regions became apparent at 24 h in both tumor 
types (representative mice shown in Figure 3.12). Microscopically, the deposition of 3.11 in the 
tumor tissue was not homogeneous, but rather seemed to occur in a multifocal pattern perhaps 
reflecting regions of greater vascularity (Figure 3.13); however, sufficient Pc 3.11 accumulated 
within the entire tumor to result in a near-IR fluorescence signal distinguishing tumor above 
adjacent normal tissue.  
 
Figure 3.12. Fluorescent images (exc 630 nm/em 700 nm) of nude mice bearing subcutaneous 
tumor implants of A431 (top) or HT-29 (bottom) cancer cells at various times following iv 
administration of Pc 3.11. The tumor positions are circled and the left panel of HT-29 mouse 
shows the eGFP tumor fluorescence (exc 490 nm/em 535 nm).  
Quantitatively, the signal in the HT-29 tumors declined from 24 to 96 h and could not be 
readily differentiated from adjacent regions without tumor at 96 h. Preliminary studies with the 







signal needed to be at least 1.2-fold greater than adjacent regions of the mouse. The fluorescence 
signal emission in the A431 tumor continued to increase to 96 h (Figure 3.14) suggesting 
continued uptake of the Pc conjugate over a longer time period in cells over-expressing EGFR.  
For purposes of comparison, the two tumor groups were not significantly different in tumor size 
(A431= 133.3 ± 28.7 cm
3
 and HT-29 = 141.9± 21.4 cm
3 
at 96 h). Neither tumor demonstrated 
auto-fluorescence at the 630/700 nm spectra window at time 0 when compared with adjacent 
skin surfaces. 
 
Figure 3.13. Deposition of Pc 3.11 in the HT-29 tumor xenograph, 24 h following iv injection. 
Images show (A) eGFP indicating HT-29 tumor regions, (B) Pc 3.11 fluorescence, and (C) 
overlap of tumor and Pc deposition. 
 
Figure 3.14. Emission signal of Pc 3.11 at 700 nm in the s.c. human tumor xenographs, over the 
adjacent (background) skin regions, expressed as a percent. To visually distinguish tumors by 







In vivo, tumor-associated fluorescence excitable at 630 and emitted at 700 nm was 
detectable at 24 h. Correspondence of these wavelengths to the Pc conjugate spectra indicates 
uptake of the conjugate by the two subcutaneous human tumor xenografts. While both HT-29 
and A431 cells over-express EGFR, there is a vast difference in the degree of receptor 
expression, with A431 ~ 200 times higher EGFR expression than HT-29.
40-42
 If the Pc conjugate 
homed to the tumor tissue based solely on the presence of the EGFR ligand, then the comparable 
levels of fluorescence observed from both tumors at 24 h would not have been expected. 
Therefore, in addition to tumor attraction based on EGFR-peptide binding, our results suggest 
significant tumor homing by the Pc macrocycle itself, in agreement with the in vitro results 
(Figure 3.5b) and previous observations.
9
 The extended fluorescence-time within the A431 
tumor over the HT-29 tumor suggests that with greater quantities of EGFR, comes longer 
retention and/or greater capacity for selective uptake or re-uptake. At times prior to 24 h, there 
was either weak or no signal, suggesting a prolonged time period of plasma circulation with 
gradual tumor accumulation. A similar pattern of tumor uptake was recently described in a 
xenograph breast cancer model imaged following administration of a chiral porphyrazine,
50
 
which showed increasing signal over background up to 48 h post administration. On the other 
hand, chlorin e6-HSA nanoparticles were recently used for PDT of HT-29 tumor xenograph,
51
 
and shown to have higher tumor-targeting ability and accumulation than free chlorin e6 as a 





 were recently shown to accumulate within tumor-bearing 
mice, reaching maximum accumulation levels at 24 h post-administration. 
There was no signal detected in adjacent non-tumor regions indicating a high degree of 







fluoresced at the near-IR spectral window required for this Pc-conjugate. This background 
fluorescence is difficult to remove in mice since prolonged fasting is not feasible. For imaging of 
colon or urogenital malignancies, it would likely be necessary to remove fecal material prior to 
tumor detection. 
In order to evaluate the in vivo stability of conjugate 3.11, the HT-29 tumors were 
harvested at 24 and 96 h following iv injection and extracted using acetone/methanol mixture. 
The UV-vis spectra of both the 24 and 96 h tumor extracts in methanol showed the characteristic 
Q band absorption of the Pc (Figure  3.15), indicating that the Pc macrocycle has high stability in 
vivo, allowing for prolonged and selective accumulation within tumor tissue. MALDI-TOF MS 
indicated that at 24 h, intact conjugate 3.11 was still present in the tumor extract, while at 96 h 
the major Pc species detected was Pc-PEG-LARL (Figures 3.16).  
 
Figure 3.15. Absorption spectrum for Pc-conjugate 3.11 in methanol, extracted from HT-29 mice-
tumor. 
This result suggests that the EGFR-L1 peptide in Pc 3.11 is slowly degraded within 
tumor tissue by proteolytic enzymes, mainly losing the two terminal amino acids 96 h after iv 
injection. This result is in agreement with previous observations that this type of peptide 












Four Pc-peptide conjugates (3.5, 3.6, 3.9 and 3.11) were designed and synthesized to 
target EGFR, and investigated as potential florescence imaging agents for cancers over-
expressing EGFR, such as CRC. Two peptide ligands for EGFR containing 6 (LARLLT) and 13 
(GYHWYGYTPQNVI) amino acid residues, were conjugated to the Pc via a short 5-atom, or a 
13-atom PEG linker. The PEG group enhances the solubility of the Pc-peptide conjugates and 
tends to increase their cellular uptake. Using Autodock both peptide ligands were found to bind 
to EGFR, giving low energy (ca. - 6 kcal/mol) docking structures. The short EGFR-L1 peptide 
conjugates 3.5 and 3.11 are positively charged and were efficiently internalized by all cell lines 
(A431, HT-29, HEp2 and Vero cells), localizing preferentially in lysosomes, Golgi and 
mitochondria. However, the 13-residue EGFR-L2 peptide produced highly hydrophobic Pc 
conjugates 3.6 and 3.9 that poorly targeted EGFR and were poorly internalized. The amount of 
Pc-EGFR-L1 conjugates, 3.5 and 3.11, taken up by cells was dependent on their degree of EGFR 
expression. While 3.5 and 3.11, as well as Pc-PEG 3.4 also accumulated within the low EGFR 
expressing Vero cells, increased uptake was observed with increasing EGFR expression in the 
human cell lines (A431 > Ht-29 > HEp2). The observed uptake into low EGFR expressing cells 
indicates that the Pc-PEG has a natural tendency to target and accumulate within cancer cells. 
All conjugates were found to be non-toxic (IC50 > 100 µM) to both low- and over-
expressing EGFR cells, with exception of conjugate 3.5 that showed moderate phototoxicity 
toward A431, HEp2 and Vero cells (IC50 = 16, 17 and 47 µM, respectively). None of the 
conjugates were toxic towards human colorectal HT-29 cells (IC50 > 100 µM). This result, in 
addition to the observed near-IR fluorescence emissions of all Pc conjugates at ca. 682 nm with 





cells, makes these Pc-EGFR-L1 conjugates highly promising fluorescent contrast agents for 
CRC, and potentially other EGFR over-expressing cancers, in particular the least phototoxic 
(IC50 > 100 µM at 1 J/cm
2
) β-substituted Pc-peptide conjugate 3.11. 
Conjugate 3.11 was further investigated in nude mice bearing A431 and HT-29 human 
tumor xenografts. Twenty four hours after iv administration of 3.11, a clearly near-IR 
fluorescence signal (exc 630 nm/ em 700 nm) was seen over background adjacent tissues, in both 
tumor types. While the fluorescence signal decreased in HT-29 tumors after 24 h, it continued to 
increase in the A431 tumors up to 96 h, the longest time investigated. The MS analysis of tumor 
extracts 96 h after iv injection of Pc-peptide 3.11 indicated partial degradation of the conjugate, 
by proteolytic enzymes, mainly leading to the cleavage of the last two amino acids of EGFR-L1. 
Our studies show that Pc-peptide conjugates can be used for near-IR fluorescence 
imaging of cancers over-expressing EGFR, such as CRC. Due to the hydrophobic nature of the 
Pc macrocycle, a low molecular PEG linker and a polar or charged peptide ligand are required 
for adequate aqueous solubility and receptor targeting ability. In addition, a β-substituted Pc 
macrocycle appears to be the most suitable for imaging applications due to its lower 
phototoxicity compared with the corresponding α-substituted macrocycle. 
3.4. Experimental Section 
3.4.1. General Chemistry  
All reagents and solvents were purchased from commercial sources and used directly 
without further purification. Silica gel 60 (230×400 mesh) and C18 (200×400), both from 
Sorbent Technologies, were used for column chromatography. Analytical thin-layer 
chromatography (TLC) was carried out using polyester backed TLC plates 254 (precoated, 200 





spectrometer (400 MHz for 
1
H, 100 MHz for 
13
C). The chemical shifts are reported in δ ppm 





C); DMF-d7 8.03 ppm (
1
H), 163.15 ppm (
13
C); Pyridine-d5 7.58 ppm (
1
H), 135.91 ppm 
(
13
C). HPLC analyses were carried on a Dionex system equipped with a P680 pump and 
UVD340U detector. Photophysical (absorption) spectra were measured on a UV-VIS NIR 
Scanning Spectrometer, using UV-3101PC SHIMADZU (Cell positioned)–CPS-260 lamp and 
emission spectra were obtained on a Fluorolog® - HORIBA JOBINVYON (Model LFI-3751) 
spectrofluorimeter. MALDI-TOF mass spectra were recorded on a Bruker ProFlex III mass 
spectrometer using dithranol as the matrix or Bruker UltrafleXtreme (MALDI-TOF/TOF) using 
4-chloro-α-cyanocinnamic acid as the matrix; high resolution ESI mass spectra were obtained on 
an Agilent Technologies 6210 Time-of-Flight LC/MS. The melting points (mp) were determined 
using MEL-TEMP electrothermal instrument. HPLC separation was carried out on a Waters 
system including a 2545 quaternary gradient module pump, 2489 UV/Visible detector, and a 
fraction collector III. Analytical HPLC was carried out using a XBridge C18 300Å, 5μm, 4.6 x 
250 mm (Waters, USA) column using a stepwise gradient. Semipreparative HPLC was carried 
out using a XBridge C18 300Å, 5 μm, 10 x 250 mm (Waters, USA) column using a stepwise 
gradient. The solvent system for peptides consisted of millipure water and HPLC grade 
acetonitrile, while it consisted of millipure water and HPLC grade methanol for the EGFR-L1 
conjugates. Pcs 3.1, and 3.7 were synthesized as previously described.
30
 
3.4.2. Peptide Synthesis and Conjugations 
 Applied Biosystems Pioneer, Peptide Synthesis System was used to synthesize peptide 
sequences. Each peptide was synthesized using Fmoc-PAL-PEG-PS on 0.2 mmol scale using 





acids were coupled using HOBt and TBTU as the coupling agents. The peptide sequences, 
prepared using this methodology, were as follows: LARLLT and GYHWYGYTPQNVI. 
Removal of the Fmoc group from the last amino acid was the final step for each synthesis. This 
was followed by washing the peptide several times with DMF/DCM and dried under high 
vacuum for 24 h.  The Pc-peptide conjugates were synthesized as previously described.
29
  
In summary, resin containing either GYHWYGYTPQNVI or LARLLT was dissolved in 
DMF and soaked for 2 h. The Pcs were dissolved in DMF, the base and coupling reagents (HOBt 
and TBTU) added to the Pc solutions. The activated mixture was transferred into the reaction 
vessel containing the resin and left to shake for 4 days.  The resin was washed under vacuum 
several times using DMF, then methanol and finally DCM. A cleavage cocktail – 
TFA/phenol/TIS/H2O (88:5:2:5) – was added with constant shaking for 4 h. The solution was 
washed with TFA (2 × 2 mL) into a flask and concentrated under vacuum. Cold diethyl ether was 
added to the residue and the mixture centrifuged. The Pc-EGFR-L1 conjugates were purified 
using reverse-phase HPLC using a Waters system including a 2545 quaternary gradient module 
pump, 2489 UV/Visible detector, and a fraction collector III. Analytical HPLC was carried out 
using a XBridge C18 300Å, 5μm, 4.6 x 250 mm (Waters, USA) column using a stepwise 
gradient. Semi-preparative HPLC was carried out a XBridge C18 300Å, 5 μm, 10 x 250 mm 
(Waters, USA) column using a stepwise gradient. The solvent system consisted of millipure 
water and HPLC grade methanol (30:70 → 0:100). The purity of the conjugates was > 95% as 
obtained from HPLC.  
ZnPc 3.2: A mixture of Pc 3.1
30
 (80.0 mg, 0.096 mmol) and 1,4-dioxane-2,6-dione (18.0 
mg, 0.16 mmol) was dissolved in DMF (1.0 mL) and the solution stirred overnight at room 





filtered under vacuum and washed with water and hexane. The solid was dried under vacuum for 
2 days to afford the pure blue solid (80.4 mg, 86.6%), mp 235 – 236 °C. 
1
H NMR (Pyridine-d5): 
δ 10.78-10.71 (s, 1H, -COOH), 10.17 - 9.41 (m, 7H, Ar-H), 8.44 - 8.23 (m, 6H, Ar-H), 8.01 - 
7.71 (m, 3H, Ar-H), 6.04 (br, 1H, N-H), 4.55 (d, J = 12.4 Hz, 2H, CH2O), 4.47 (d, J = 10.5 Hz, 
2H, CH2O), 1.73 – 1.59 (m, 27H, C(CH3)3). 
13
C NMR (Pyridine-d5): δ 168.3, 168.2, 156.6, 
155.9, 155.8, 154.7, 154.3, 154.0, 152.9, 150.6, 150.4, 150.1, 149.8, 142.4, 140.1, 140.0, 137.8, 
137.7, 136.2, 136.0, 135.8, 135.5, 134.3, 134.8, 131.54, 128.46, 128.3, 124.8, 124.2, 124.0, 
123.7, 123.4, 122.8, 122.5, 121.4, 120.6, 120.5, 120.4, 120.2,  119.4, 118.1, (Ar-C) 73.1, 70.5 
(OCH2), 35.8, 32.4 (Ar-C, C(CH3)3). MS (MALDI-TOF) m/z 968.319 [M+H]
+
, calcd for 
C54H50N9O5Zn 967.323. UV-vis (DMF): λmax (log ε) 346 nm (5.04), 614 nm (4.80), 680 nm 
(5.50). 
ZnPc 3.4: Pc 3.2 (30.0 mg, 0.032 mmol) was dissolved in DMF (400 µL). Et3N (4.0 mg, 
0.041 mmol), HOBt (4.6 mg, 0.034 mmol) and tert-butyl-12-amino-4,7,10-trioxadodecanoate 
(10.8 mg, 0.039 mmol) were added to the reaction mixture. EDCI (5.3 mg, 0.034 mmol) was 
then added in one portion. The reaction solution was stirred for 3 days at room temperature, 
diluted using ethyl acetate (10 mL) and washed subsequently with water (20 mL × 2). The 
organic layer was dried over anhydrous sodium sulfate. The solvent was evaporated and the 
crude product purified on silica column eluted with mixed solvents of DCM/methanol (98:2→ 
96:4) to afford a blue solid (30.0 mg, 76.5%). 
1
H NMR (DMF-d7): δ 9.60 - 9.01 (m, 7H, Ar-H), 
8.45 - 8.15 (m, 5H, Ar-H), 8.00 – 7.77 (m, 3H, Ar-H), 7.63 – 7.49 (m, 2H, Ar-H), 4.27 – 4.15 
(m, 4H, CH2O), 3.62 – 3.57 (m, 3H, CH2O), 3.54 – 3.47 (m, 9H, CH2O), 3.42 – 3.37 (m, 2H, 
CH2O), 2.44 – 2.39 (m, 2H, CH2CO), 1.82 – 1.78 (m, 27H, C(CH3)3), 1.40 (s, 9H, C(CH3)3). 
13
C 





154.7, 154.6, 154.4, 154.3, 154.20, 154.16, 154.0, 153.4, 153.3, 153.2, 152.4, 152.1, 152.04, 
151.96, 142.3, 140.03, 139.98, 139.9, 139.6, 137.64, 137.57, 137.5, 137.2, 135.10, 135.06, 143.5, 
131.7, 131.6, 130.1, 129.4, 128.7, 128.6, 128.4, 123.6, 123.5, 123.3, 122.6, 122.4, 122.3, 122.0, 
120.3, 120.1, 120.0, 119.8, 119.6, 119.0, 118.9, 117.5 (Ar-C), 80.8 (O-C(CH3)3), 72.4, 72.1, 
71.20, 71.18, 71.15, 71.1, 71.0, 70.5, 70.32, 70.30, 67.2 (OCH2), 39.64, 39.61, (COCH2), 32.7, 





calcd for C63H66N10O9Zn 1170.431. The protected Pc 3.4 conjugate was dissolved in a mixture of 
DCM/TFA (4 mL/4 mL) and stirred at 0° C for 3 h. The solvent was evaporated, the residue 
treated with 2N NaOH (2 mL) and then extracted by ethyl acetate (15 mL). The product was 
dried under vacuum to afford blue product (24.0 mg, 89.3%), mp 191 – 192 °C. 
1
H NMR (DMF-
d7): δ 10.15-10.13 (s, 1H, -COOH), 9.59 - 9.08 (m, 7H, Ar-H), 8.42 - 8.10 (m, 5H, Ar-H), 7.95 - 
7.82 (m, 3H, Ar-H), 7.61 – 7.52 (m, 2H, Ar-H), 4.25 – 4.11 (m, 4H, CH2O), 3.79–3.57 (m, 12H, 
CH2O), 3.41–3.37 (m, 2H, CH2O), 2.51–2.48 (m, 2H, CH2CO), 1.79 (s, 27H, C(CH3)3). 
13
C 
NMR (Pyridine-d5): δ 173.7, 170.5, 168.7, 156.9, 156.2, 155.4, 154.5, 153.7, 152.6, 145.6, 142.6, 
140.2, 139.8, 137.6, 135.2, 134.6, 131.7, 128.7, 123.5, 122.7, 122.4, 120.0, 119.1, 117.7 (Ar-C), 
72.5, 72.2, 71.3, 70.4, 67.8 (OCH2), 35.5 (COCH2), 32.6 (Ar-C, C(CH3)3). MS (MALDI-TOF) 
m/z 1170.485 [M]
+
, calcd for C63H66N10O9Zn 1170.431. UV-vis (DMF): λmax (log ε) 349 nm 
(4.90), 612 nm (4.61), 678 nm (5.35).   
ZnPc conjugate 3.5: Resin (25.7 mg, 0.0052 mmol) containing LARLLT, was 
transferred into a reaction vial. DMF was added (5:1, DMF/resin) and left to soak for 4 h, after 
which it was washed four times with DMF. Pc 3.4 (10.0 mg, 0.010315 mmol) was weighed into 
a 2.0 mL vial and DMF (200 μL) added. DIEA (6.4 µL, 0.036745 mmol) was added to the 





mmol) were added to the Pc solution. The mixture was added to the resin and left to shake for 4 
days. The resin was washed under vacuum using DMF, followed by methanol and finally DCM. 
A cleavage cocktail – TFA/phenol/TIS/H2O (88:5:2:5) – was added and shaken constantly for 4 
h and the solution washed with TFA (2 × 2 mL) into a 50 mL flask under vacuum. Cold 
diethylether was added to the residue and the mixture centrifuged. The precipitate was purified 
using reverse-phase HPLC eluted by water/methanol (30:70 → 0:100) to afford a blue solid (7.6 
mg, 79.2%), mp 151-152 °C. 
1
H NMR (DMF-d7): δ 10.18, 10.13 (s, 1H, N-H), 9.67-9.20 (m, 5H, 
Ar-H), 8.55-8.45 (m, 3H, Ar-H), 8.25-8.15 (m, 2H, Ar-H), 8.13-8.05 (m, 1H, Ar-H), 7.97-7.86 
(m, 5H, Ar-H), 7.85-7.79 (m, 2H, Ar-H), 7.61-7.47 (m, 5H, Ar-H), 7.20 (s, 1H, Ar-H), 7.13 (s, 
1H, Ar-H), 4.39-4.01 (m, 26H, CH2O/CH2NH), 3.77-3.70 (m, 3H, CH2O), 3.56-3.50 (m, 12H, 
CH2O), 3.43-3.31 (m, 3H, CH2O), 2.55-2.41 (m, 2H, CH2CO), 2.01-1.92 (m, 3H, CH2), 1.85-
1.71 (m, 27H, C(CH3)3/7H, CH2), 1.69-1.62 (m, 3H, CH2), 1.43-1.35 (m, 4H, CH2), 1.21-1.15 
(m, 4H, CH2), 0.94-0.87 (m, 20H, CH3). 
13
C NMR (DMF-d7): δ 175.5, 175.3, 174.10, 174.07, 
173.7, 173.4, 170.5, 168.8, 168.7, 160.3, 159.9, 158.7, 156.8, 156.2, 155.6, 155.3, 155.1, 154.4, 
152.4, 152.1, 140.0, 137.9, 137.6, 135.1, 134.5, 131.7, 128.6, 123.4, 122.6, 122.4, 120.0, 119.0, 
117.5, 116.1 (Ar-C), 72.3, 72.0, 71.3, 71.2, 71.0, 70.9, 70.3, 68.2, 68.0, 66.3 (OCH2), 60.1, 55.2, 
54.6, 54.0, 53.5. 51.8, 41.9, 41.3, 41.2, 39.5, 37.2 (CH2) 32.6 (Ar-C, C(CH3)3), 29.4, 26.5, 25.6, 
25.5, 24.0, 23.8, 23.5, 22.3, 22.0, 21.8, 20.7, 17.5 (CH3). MS (MALDI-TOF) m/z 1837.907 
[M+H]
+



























C93H124N19O14Zn 1794.887, C90H117N18O13Zn 1721.834, C83H106N17O11Zn 1580.755, 
C72H83N12O10Zn 1339.565, C69H78N11O9Zn 1268.528, C68H78N11O8Zn 1240.533,  
C63H67N10O8Zn 1155.444. UV-vis (DMF): λmax (log ε) 348 nm (4.79), 612 nm (4.56), 680 nm 
(5.33). 
ZnPc conjugate 3.6: Resin (60.0 mg, 0.0052 mmol) containing GYHWYGYTPQNVI 
was transferred into a reaction vial. DMF was added (5:1, DMF/resin) and left to soak for one 
hour, after which it was washed four times with DMF. Pc 3.4 (12.1 mg, 0.010315 mmol) was 
weighed into a 2.0 mL vial and DMF (200 μL) added. Then HOBt (1.4 mg, 0.010315 mmol), 
HATU (3.9 mg, 0.010315 mmol) and DIEA (5.39 μL, 0.030946 mmol) were added to the Pc 
solution. The mixture was stirred for five minutes, transferred into the reaction chamber 
containing the resin and left to shake for 3 days. The resin was washed under vacuum using 
DMF (till DMF was clear), followed by methanol and finally DCM. A cleavage cocktail – 
TFA/phenol/TIS/H2O (88:5:2:5) – was added and shaken constantly for 4 h. The solution was 
then washed with TFA (2 × 2 mL) into a 50 mL flask under vacuum. Cold diethylether was 
added to the residue and the mixture centrifuged. The precipitate was then sonicated in water and 
centrifuged several times to give the title compound (11.5 mg, 40.5%, mp 208 – 209 °C). 
1
H 
NMR (DMF-d7): δ 10.40, 10.35 (s, 1H, COOH), 9.51-9.20 (m, 6H, Ar-H), 8.45-8.10 (m, 10H, 
Ar-H), 7.80-7.75 (m, 2H, Ar-H), 7.70-7.50 (m, 2H, Ar-H), 7.45-7.20 (m, 30H, Ar-H), 7.15-6.95 
(m, 14H, Ar-H), 6.90-6.78 (m, 4H, Ar-H), 6.74-6.65 (m, 9H, Ar-H), 4.75-4.10 (m, 16H, 
CH2O/CH2NH), 4.04-3.65 (m, 7H, CH2O/CH2NH), 2.25-2.04 (m, 6H, CH2CO), 2.01-1.75 (m, 
21H, C(CH3)3/CH2), 1.43 (s, 4H, , CH2), 1.31 (s, 3H, CH2), 1.21-1.15 (m, 4H, CH2), 1.05-1.00 
(m, 8H, CH2), 0.94-0.85 (m, 19H, CH3). MS (MALDI-TOF) m/z 2748.17 [M]
+
, calcd for 


























, calcd for C140H165N29O27Zn 2748.17, 
C140H164N28O27Zn 2733.16, C139H164N28O26Zn 2705.17, C115H123N21O19Zn 2165.86, 
C90H95N17O12Zn 1669.66, C79H85N15O11Zn 1483.58, C73H78N12O10Zn 1346.53, C65H70N12O9Zn 
1226.47,  C63H67N10O8Zn 1155.44. UV-vis (DMF): λmax (log ε) 345 nm (3.84), 612 nm (4.25), 
680 nm (4.60). 
ZnPc 3.8: A mixture of Pc 3.7
30
 (50.0 mg, 0.06 mmol) and 1,4-dioxane-2,6-dione (11.3 
mg, 0.1 mmol) was dissolved in DMF (0.5 mL) and the solution stirred overnight at room 
temperature. The mixture was purified as 3.2 above to afford the pure blue solid (53.5 mg, 
92.2%), mp 249 – 250 °C. 
1
H NMR (Pyridine-d5): δ 10.84-10.77 (s, 1H, -COOH), 10.01 - 9.35 
(m, 8H, Ar-H), 8.50 - 8.21 (m, 5H, Ar-H), 8.10 - 7.90 (m, 1H, Ar-H), 7.54 – 7.41 (m, 2H, Ar-H), 
6.74 (br, 1H, N-H), 4.69 (d, J = 5.4 Hz, 2H, CH2O), 4.60 (d, J = 5.6 Hz, 2H, CH2O), 1.75 – 1.64 
(m, 27H, C(CH3)3). 
13
C NMR (Pyridine-d5): δ 173.9, 168.43, 168.38, 160.0, 159.7, 154.8, 154.7, 
154.6, 154.5, 154.3, 153.9, 153.8, 153.5, 153.4, 153.0, 150.6, 150.4, 150.1, 140.8, 139.4, 139.2, 
137.0, 136.8, 134.2, 134.0, 131.0, 127.7, 124.7, 122.0, 120.8, 120.7, 120.3, 119.8, 112.5, 111.6 
(Ar-C) 72.5, 69.9 (OCH2), 35.8, 31.7 (Ar-C, C(CH3)3). MS (MALDI-TOF) m/z 968.314 [M+H]
+
, 
calcd for C54H50N9O5Zn 968.323. UV-vis (DMF): λmax (log ε) 351 nm (4.86), 611 nm (4.58), 679 
nm (5.33). 
ZnPc conjugate 3.9: Resin (60.0 mg) containing 0.0052 mmol GYHWYGYTPQNVI 
was transferred into a reaction vial. DMF was added (5:1, DMF/resin) and soaked for 2 h. The 





vial and DMF (200 μL) added. Then HOBt (1.4 mg, 0.010315 mmol), TBTU (3.3 mg, 0.010315 
mmol) and DIEA (5.39 μL, 0.030946 mmol) were added to the Pc solution. The mixture was 
stirred for 30 min, transferred into the vial containing the resin and left to shake for 3 days.  The 
resin was washed under vacuum using DMF (till DMF was clear), followed by methanol and 
finally DCM. A cleavage cocktail – TFA/phenol/TIS/H2O (88:5:2:5) – was added and shaken 
constantly for 4 h. The solution was then washed with TFA (2 × 2 mL) into a 50 mL flask under 
vacuum. Cold diethylether was added to the residue and the mixture centrifuged. The precipitate 
was then sonicated in water and centrifuged several times to give the title compound (9.2 mg, 
35.0%), mp 211 – 212 °C. 
1
H NMR (DMF-d7): δ 9.51-9.20 (m, 5H, Ar-H), 8.45-8.10 (m, 9H, 
Ar-H), 7.80-7.75 (m, 2H, Ar-H), 7.70-7.50 (m, 2H, Ar-H), 7.35-7.20 (m, 24H, Ar-H), 7.07-6.91 
(m, 14H, Ar-H), 6.80-6.70 (m, 4H, Ar-H), 6.65-6.53 (m, 9H, Ar-H), 4.68-4.30 (m, 12H, 
CH2NH), 4.24-3.65 (m, 4H, CH2O/CH2NH), 3.45-3.30 (m, 4H, CH2O/CH2NH), 2.25-2.04 (m, 
2H, CH2CO), 2.01-1.75 (m, 21H, C(CH3)3/CH2), 1.33 (s, 5H, , CH3), 1.26 (s, 2H, CH2), 1.18-
1.10 (m, 4H, CH2), 1.00-0.94 (m, 8H, CH2), 0.85-0.75 (m, 18H, CH3). MS (MALDI-TOF) m/z 
2545.04 [M]
+
, calcd for C131H148N28O23Zn 2545.0563. UV-vis (DMF): λmax (log ε) 351 nm 
(4.44), 610 nm (4.07), 677 nm (4.87). 
ZnPc 3.10: Pc 3.8 (30.0 mg, 0.032 mmol) was dissolved in DMF (400 µL). Et3N (4.0 
mg, 0.041 mmol), HOBt (4.6 mg, 0.034 mmol) and tert-butyl-12-amino-4,7,10-
trioxadodecanoate (10.8 mg, 0.039 mmol) were added to the reaction solution and the solution 
was stirred for 20 min. EDCI (5.3 mg, 0.034 mmol) was added to the reaction solution in one 
portion. The reaction was then treated as 3.4 above to afford a blue solid (32.2 mg, 82.3%). 
1
H 
NMR (Acetone-d6): δ 9.87 - 9.77 (m, 1H, Ar-H), 9.07 – 7.40 (m, 16H, Ar-H), 3.99 (s, 2H, 





CH2O), 3.22 (s, 2H, CH2O), 2.36 – 2.33 (m, 2H, CH2CO), 1.88 – 1.78 (m, 27H, C(CH3)3), 1.37 
(s, 9H, C(CH3)3). 
13
C NMR (DMF-d7): δ 171.8, 170.7, 169.3, 169.2, 162.4, 160.8, 160.4, 155.0, 
154.8, 154.3, 154.2, 141.4, 140.0, 139.8, 137.6, 136.7, 136.4, 134.5, 128.6, 125.2, 123.4, 123.0, 
121.4, 121.3, 120.9, 120.0, 112.8, 111.7 (Ar-C), 81.0 (O-C(CH3)3), 72.6, 72.4, 71.5, 71.43, 
71.36, 71.3, 70.6, 67.8 (OCH2), 32.8 (Ar-C, C(CH3)3), 28.7 (N-Boc C(CH3)3). MS (MALDI-






, calcd for C67H75N10O9Zn 1227.501, 
C63H66N10O9Zn 1170.431. The protected Pc conjugate was then deprotected as 3.4 above to 
afford a blue solid (25.3 mg, 88.3%), mp 161 – 163 °C.
 1
H NMR (DMF-d7): δ 10.42-10.33 (s, 
1H, COOH), 9.57 - 9.32 (m, 6H, Ar-H), 9.09 - 8.75 (m, 1H, Ar-H), 8.55 - 8.20 (m, 4H, Ar-H), 
8.15 - 8.00 (m, 2H, Ar-H), 7.99 – 7.81 (m, 1H, Ar-H), 7.65 – 7.50 (m, 2H, Ar-H), 4.36 (d, J = 7.2 
Hz, 2H, CH2O), 4.28 (d, J = 5.1 Hz, 2H, CH2O), 3.65 – 3.57 (m, 12H, CH2O), 3.41 – 3.37 (m, 
2H, CH2O), 2.55 – 2.48 (m, 2H, CH2O), 1.85 – 1.74 (m, 27H, C(CH3)3). 
13
C NMR (DMF-d7): δ 
173.7, 170.6, 169.2, 169.1, 160.64, 160.58, 160.25, 160.18, 155.3, 155.22, 155.16, 155.1, 155.0, 
154.9, 154.8, 154.7, 154.3, 154.2, 1154.15, 154.11, 153.0, 153.9, 153.4, 153.3, 153.2, 153.1, 
141.5, 141.4, 140.1, 140.0, 139.8, 137.7, 137.64, 137.55, 137.5, 136.5, 136.2, 134.8, 134.7, 
134.6, 128.3, 128.2, 126.2, 125.0, 123.3, 123.2, 122.8, 122.0, 121.2, 121.11, 121.06, 120.8, 
120.7, 119.9, 119.8, 112.7, 111.6, (Ar-C), 72.4, 72.1, 71.28, 71.25, 71.14, 71.10, 70.4, 68.3, 67.7 
(OCH2), 39.7, 36.8 (COCH2), 32.6 (Ar-C, C(CH3)3). MS (MALDI-TOF) m/z 1170.508 [M]
+
, 
calcd for C63H66N10O9Zn 1170.431. UV-vis (DMF): λmax (log ε) 350 nm (4.65), 610 nm (4.41), 
676 nm (5.19).  
ZnPc conjugate 3.11: Resin (25.7 mg, 0.0052 mmol) containing LARLLT, was 
transferred into a reaction vial. DMF was added (5:1, DMF/resin) and left to soak for 4 h, after 





a 2.0 mL vial and DMF (200 μL) added. DIEA (6.4 µL, 0.036745 mmol) was added to the 
solution and stirred for 1 h. Then HOBt (1.8 mg, 0.013321 mmol), HATU (4.0 mg, 0.010521 
mmol) were added to the Pc solution. The mixture was added to the resin and left to shake for 4 
days. It was then cleaved and purified as described above for Pc 3.5 to afford a blue solid (8.1 
mg, 84.4%, mp 167 – 168 °C). 
1
H NMR (DMF-d7): δ 10.40, 10.35 (s, 1H, N-H), 9.67-9.20 (m, 
5H, Ar-H), 8.57-8.45 (m, 3H, Ar-H), 8.30-8.25 (m, 2H, Ar-H), 8.13-8.05 (m, 2H, Ar-H), 7.97-
7.86 (m, 3H, Ar-H), 7.85-7.79 (m, 2H, Ar-H), 7.61-7.47 (m, 5H, Ar-H), 7.18 (s, 1H, Ar-H), 7.12 
(s, 1H, Ar-H), 4.37 (d, J = 7.6, 4H, CH2O), 4.29-4.21 (m, 9H, CH2NH), 3.77-3.70 (m, 16H, 
CH2NH), 3.65-3.57 (m, 12H, CH2O), 3.54-3.43 (m, 2H, CH2NH), 3.37-3.29 (m, 3H, CH2NH), 
2.61-2.56 (m, 2H, CH2CO), 2.01-1.92 (m, 2H, CH2), 1.91-1.71 (m, 27H, C(CH3)3/7H, CH2), 
1.69-1.58 (m, 5H, CH2), 1.39-1.36 (m, 4H, CH2), 1.17-1.15 (m, 4H, CH2), 0.95-0.86 (m, 20H, 
CH3). 
13
C NMR (DMF-d7): δ 175.5, 175.3, 174.1, 174.0, 173.7, 173.6, 173.4, 170.6, 169.2, 
169.1, 160.2, 159.9, 158.8, 154.6, 154.2, 153.7, 140.2, 139.8, 136.7, 136.3, 128.6, 128.4, 122.8, 
122.2, 121.4, 120.9, 119.3, 116.3 (Ar-C), 72.4, 72.2, 71.3, 71.1, 71.0, 70.4, 68.2, 68.1, 66.3 
(OCH2), 60.1, 55.2, 54.6, 54.0, 53.5. 51.8, 41.9, 41.34, 41.29, 39.7, 37.2 (CH2) 32.6 (Ar-C, 
C(CH3)3), 29.4, 26.5, 25.7, 25.6, 25.5, 24.0, 23.8, 23.5, 22.4, 22.0, 21.8, 20.7, 17.6 (CH3). MS 
(MALDI-TOF) m/z 1837.925 [M+H]
+
, calcd for C94H125N20O15Zn 1837.892. MS-MS (MALDI-





















, calcd for C94H125N20O15Zn 1837.892, C94H124N19O15Zn 
1822.882, C93H124N19O14Zn 1794.887, C90H117N18O13Zn 1721.834, C83H106N17O11Zn 1580.755, 





C63H67N10O8Zn 1155.444. UV-vis (DMF): λmax (log ε) 352 nm (4.79), 610 nm (4.52), 677 nm 
(5.29). 
ZnPc 3.14. A mixture of Pc 3.13
30
 (50 mg, 0.05 mmol) and 1, 4-dioxane-2, 6-dione (17.4 
mg, 0.15 mmol) was dissolved in DMF (0.5 mL) and the solution stirred overnight at room 
temperature. The reaction solution was evaporated to dry. The residue was dissolved in THF (1 
mL) and water (20 mL) added to precipitate the product. The solid was filtered under vacuum, 
and washed with water and hexane. The solid was dried under vacuum for 2 days to afford a blue 
solid (52.1 mg, 87.6%). 
1
H NMR (d-Pyridine, 400 MHz): δ 10.74 (s, 2H, -COOH), 10.07 - 9.50 
(m, 7H, Ar-H), 8.39 - 8.10 (m, 8H, Ar-H), 7.50 – 7.40 (m, 4H, Ar-H), 6.56 (br, 2H, N-H), 4.63 
(d, J = 3.5 Hz, 4H, CH2O), 4.56 (d, J = 4.5 Hz, 4H, CH2O), 1.71 – 1.58 (m, 27H, C(CH3)3). MS 
(MALDI-TOF) m/z 1191.360 [M+H]
+
, calcd for C64H59N10O10Zn 1191.371.  
ZnPc 3.15. Pc 3.14 (20 mg, 0.017 mmol) was dissolved in DMF (500 µL). DIEA (26 mg, 
0.2 mmol), HOBt (4.6 mg, 0.034 mmol) and TBTU (10.6 mg, 0.034 mmol) were added to the 
reaction solution and the solution was stirred for 2 min. Tert-butyl-12-amino-4,7,10-
trioxadodecanoate (10.8 mg, 0.032 mmol) was added to the reaction solution in one portion. The 
reaction solution was stirred for 72 h at room temperature. The reaction solution was poured into 
20 mL of ice-cold water and filtered under gravity. The residue was dissolved in ethyl acetate 
(10 mL). The organic solution washed subsequently with water (20 mL), saturated aqueous 
NaHCO3 solution (20 mL) and water (20 mL). The organic layer was dried over anhydrous 
sodium sulfate. The solvent was evaporated and the crude product purified by silica column (1 
cm in height) with the elution of mixed solvents of methanol/dichloromethane (1/9), eluting the 





afford a blue solid in trace amounts. MS (MALDI-TOF) m/z 1711.720 [M+H]
+
, calcd for 
C90H109N12O18Zn 1711.729. 
3.4.3. Spectroscopic Studies 
All absorption spectra were measured on UV-VIS NIR Scanning Spectrometer UV-
3101PC SHIMADZU (Cell positioned) equipped with a CPS-260 lamp. The DMF solvent used 
was HPLC grade and it was the solvent of choice since it dissolved all the Pcs relatively good. 
Stock solutions (1000 µM, 1.0 mL) of all Pcs were prepared and the dilutions were prepared by 
spiking 20 – 80 µL of the corresponding stock solution into 10.0 mL of solvent. Emission spectra 
were obtained on a Fluorolog
®
-HORIBA JOBINVYON (Model LFI-3751) spectrofluorimeter. 
The optical densities of the solutions used for emission studies ranged between 0.04 – 0.05 at 
excitation wavelengths. All experiments were carried out within 4 h of solution preparation at 
room temperature (23-25 °C) with 10 mm path length spectrophotometric cell. The fluorescent 
quantum yields (Фf) were determined using a secondary standard method.
55
 By comparison with 
ZnPc (Фf = 0.17) as a reference, the values of fluorescence were obtained in DMF solvent.
56
 
3.4.4. Computational Studies 
Docking of EGFR-L1 and –L2 peptides to EGFR protein extracellular domain was 
performed using AUTODOCK 4 software.
34,35
 EGFR crystal structure was obtained from a 
protein databank (PDB code: 1nql).
57
 Solvent molecules were removed from the pdb file. Polar 
hydrogen atoms were added to the structure. For EGFR-L1 peptide docking a grid box was 
created with amino acid residue on EGFR Asn134 as center of the grid box, and for EGFR-L2 
docking a grid box was created near EGF binding site on EGFR.
27,28
 A grid box with dimensions 
of 128×128×128 Å
3
 was used for calculations. Three dimensional structures of peptide EGFR-L1 





subjected to 300 K and molecular dynamics (MD) followed by simulated annealing MD.
58
 The 
final structure from simulated MD was energy minimized and used for docking studies. In 
peptides EGFR-L1 and EGFR-L2 rotatable bonds were allowed to rotate during docking 
calculations. For docking 50 runs with 10 million energy evaluations were carried out using 
Lamarkian genetic algorithm. Docking calculations were performed on Linux cluster on high 
performance supercomputers at LSU Baton Rouge. Docked structures were listed in increasing 
order of energy, and low energy clusters were used as the most probable binding models. 
Structures from low energy docking were displayed and analyzed using PyMol software. 
3.4.5. Cell Studies  
All tissue culture medium and reagents were purchased from Invitrogen (Carlsbad, CA). 
Human carcinoma HEp2 cells, human epidermoid carcinoma A431, human colorectal 
adenocarcinoma HT-29, and cercopithecus aethiops kidney Vero cells, were purchased from 
ATCC. HT-29 cells were cultured and maintained in McCoy’s 5A Medium Modified 
supplemented with 10% FBS and 1% antibiotic (Penicillin Streptomycin). HT-29 cells were 
infected with a lentivirus containing the enhanced green fluorescent protein (eGFP; virus 
purchased from Biogenova, Ellicott City, MD). Green fluorescent cells were sorted by flow 
cytometry and expanded to generate a line termed “HT-29 eGFP”. Both A431 and Vero cells 
were cultured and maintained in ATCC formulated DMEM supplemented with 10% FBS and 
1% antibiotic (Penicillin Streptomycin). HEp2 cells were cultured and maintained in 50:50 
ATCC formulated DMEM/Advanced MEM containing 10% FBS and 1% antibiotic (Penicillin 
Streptomycin). The cells were split twice weekly to maintain a sub-confluent stock. All 
compound solutions were filter-sterilized using a 0.22 μm syringe filter. A 32 mM stock solution 





emulsifier), to avoid compound precipitation upon dilution into media. From this solution, a 400 
μM stock was also prepared in desired medium and filter-sterilized using a 0.22 μm syringe 
filter.  
 Time-Dependent Cellular Uptake: HEp2 cells and A431 cells were plated at 7,500 per 
well in a Costar 96 well plate and allowed to grow for 48 h. Vero cells were plated at 7,500 per 
well in a Costar 96 well plate and allowed to grow for 24 h. HT-29 cells were plated at 7,500 per 
well in a Costar 96 well plate and allowed to grow for 96 h. Pc stock solutions (32 mM) were 
diluted to 10 μM Pc solutions in media and added to the cells at different time periods of 0, 1, 2, 
4, 8, and 24 h. Uptake of the compounds was stopped by removing loading medium and washing 
once with PBS. Cells were solubilized by adding 0.25% Triton X-100 in PBS. The Pc 
concentration was determined by reading its fluorescence emission at 650/700 nm 
(excitation/emission) using a BMG FLUOstar plate reader (Cary, NC). Cell number was 
quantified using CyQuant reagent. 
 Dark Cytotoxicity: The cells were plated and allowed to grow as described above. Pc 
stock solutions (32 mM) were diluted to concentrations of 25, 50, 100 and 125 μM in medium, 
and added to cells for 24 h. The loading medium was removed and medium containing Cell Titer 
Blue was added to determine the toxicity of the compounds (viable cells were measured 
fluorescently at 570/615 nm); untreated cells were considered 100% viable and cells treated with 
0.2% saponin as 0% viable. 
 Phototoxicity: The cells were plated and allowed to grow as described above. The Pc 
stock solutions (32 mM) were diluted to concentrations of 6.25, 12.5, 25, 50 and 100 μM in 
medium and added to cells for 24 h. The loading medium was removed and fresh medium was 
added. The conjugates were exposed to light using a light system (Newport) at 1 J/cm
2





min. The plates were chilled at 5 °C using a cooling block. Water was used as a filter for IR 
radiation. The plates were then incubated for another 24 h followed by removing medium and 
adding medium containing Cell Titer Blue to determine the toxicity of the compounds. 
 Microscopy: The cells were inoculated in a glass-bottom 6-well plate (MatTek) and 
allowed to grow for 48 h. The cells were then exposed to 10 µM for each Pc for 6 h. Organelle 
tracers were obtained from Invitrogen and used at the following concentrations: LysoSensor 
Green 50 nM, MitoTracker Green 250 nM, ER Tracker Blue/white 100 nM, and BODIPY FL C5 
ceramide 1 µM. Images were acquired using a Leica DMRXA microscope with 40× NA 0.8dip 
objective lens and DAPI, GFP and Texas Red filter cubes (Chroma Technologies). 
3.4.6. In Vivo Uptake Studies  
For the animal studies, Nu/nu mice were purchased from Charles Rivers Laboratories at 6 
weeks of age. After approximately 2 weeks of quarantine, mice were implanted with tumor cells 
subcutaneously in the upper flank. For these injections, each cell line was cultured to 
approximately 75% confluence, then dissociated with trypsin, and concentrated by 
centrifugation. Since the two tumor lines were found to grow at different rates in nude mice, 1 x 
10
6
 A431 cells and 2 x 10
6
 HT-29 eGFP cells were implanted in a volume of 100 µL. The 
injection material consisted of 4 parts DMEM and 1 part MatriGel basement membrane matrix 
(BD biosciences). Tumors were allowed to develop until palpable (approximately 6 days for 
A431 cells and 9 days for HT-29 eGFP cells), after which mice were imaged for time = 0, then 
injected through the tail vein with 20 µL of a 10 mM solution of Pc 3.11 in 10% DMSO and 5% 
Cremophor EL in PBS, for a dose of ~ 10 mg/kg. The mice were then observed for acute adverse 
responses to the injected Pc and returned to their box until imaged. Prior to imaging at selected 





imaged individually for 30 s at excitation 630 nm and emission 700 nm (x630/m700) in a Kodak 
In Vivo FX whole animal imager. All animal experiments were conducted by adherence to a 
protocol approved by the LSU IACUC committee.   
To quantify relative fluorescence within the image of the tumor region, a region-of-
interest (roi) was drawn around the tumor and the mean pixel intensity (mpi) of this roi was 
divided by the mpi’s of 3 adjacent skin areas to obtain a percent of tumor fluorescence over 
adjacent regions. In order to visually distinguish one roi as more fluorescent than adjacent skin, it 
was found that the roi needed to be at least 120%. 
At 24 and 96 h following iv injection of Pc 3.11, the HT-29 tumor tissue was harvested 
from mice and flash frozen. The tissue was kept in 5 mL of acetone/methanol (5:1) at -20 °C 
overnight, then crushed repeatedly using a mortar, filtered and the organic solvents removed 
under reduced pressure. The residues were analyzed by MALDI-TOF and UV-Vis 
spectrophotometry. Frozen sections of tumor were cut to 10 µm thickness and mounted on glass 
slides.  Tissues were immediately imaged for both eGFP indicating regions of HT-29 tumor and 
near-IR indicating Pc fluorescence using Chroma 41017 (450-490 nm excitation, 500-550 nm 
emission) and Omega Optical 140-2 (570-645 nm excitation, 668-723 nm emission) filter sets 
respectively. 
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SYNTHESES, CHARACTERIZATION AND PHOTOPHYSICAL EVALUATION OF 
REGIOMERICALLY PURE PHTHALOCYANINES FOR CANCER IMAGING AND 
PHOTODYNAMIC THERAPY APPLICATIONS 
4.1. Background 
Pcs exhibit strong absorptions in the near-IR, a feature that has made them find multiple 
applications in biology, medicine and materials science. They have found use as colorant dyes, 
optical sensors, bioimaging agents, and as photosensitizers for the photodynamic therapy (PDT) 
of cancers and the inactivation of bacteria and viruses.
1-3
 Photofrin, a derivative of 
hematoporphyrin IX, has been used for nearly three decades in the PDT treatment of various 
cancers, including lung, skin, cervical and bladder.
4,5
 Nevertheless, its persistence in healthy 
tissues for long periods of time after systemic administration causes unwanted side-effects, such 
as patient photosensitivity for several weeks post-PDT. This is what has caused great interest in 
the search for new PDT drugs. In PDT, a photosensitizer is activated by light and produces 
singlet oxygen and other reactive oxygen species (ROS) in situ, as discussed in Chapter 1. The 
ROS produced destroy proximal cells via necrosis and/or apoptosis.
6,7
 Pcs are promising 
photosensitizers because they are photochemically stable and produce ROS upon light activation. 
Sulfonated Al(III)Pc or Photosense, and a Si(IV)Pc (Pc4) are in clinical trials for PDT.
8-10
  
Addition of peripheral water-solubilizing substituents and/or axial ligands minimizes 
aggregation and increases Pc solubility in aqueous media. Polyethylene glycol (PEG) may serve 
as a delivery vehicle
11-13
 and, in some cases, can be covalently bound to Pcs
14-16
 for improved 
delivery to target tissues. Pegylation of photosensitizers increases their water-solubility, serum 
life, tumor accumulation, and also reduces their uptake by the reticuloendothelial system.
17-20
 As 
a continuation of the investigation of Pcs as potential photosensitizers with enhanced biological 





regiomerially pure Pcs, containing at least a PEG group. It is anticipated that pegylation of the 
ZnPc macrocycle will increase solubility and biological efficacy. The Pcs described in this 
Chapter can serve as biomarkers or photosensitizers for PDT. They are also single isomers as 
opposed to those reported in earlier Chapters.   
4.2. Synthesis of A2B2- and A3B-type Pcs  
In Chapter 1, some of the protocols for the tetramerization of two or more phthalonitriles 
that have been reported in the past were described. Kobayashi and coworkers developed a 
method to synthesize A3B-type Pcs via ring expansion of a subphthalocyanine template.
21
 The 
polymeric-support synthesis of A3B-type Pcs was developed by Leznoff and coworkers in 1982, 
where a mono-functionalized diiminoisoindoline precursor bound to solid polymer support reacts 
with another precursor to form A3B-type Pcs.
22-24
 Tomoda method – by optimization of reactant 
ratios and reaction conditions – gives differently substituted Pcs, not including constitutional 
isomers.
21
 The use of one of the phthalonitriles in excess is one such modification that may favor 
the formation A3B-type Pcs.
25
 In some cases, half Pcs have been used in the preparation of A2B2-
type Pcs.
26
 Side-strapped Pcs have also been synthesized, with the aim of reducing the number of 
isomers obtained in case of A2B2-type Pcs. These bridged Pcs may be obtained via bis-
phthalonitriles. Suitable bis(3-phthalonitriles) can be synthesized from 2,2-dialkyl propane-1,3-
diols or chiral bis-naphthols, although it has been reported that many other bis(3-phthalonitriles) 
do not form side-strapped Pcs.
27
 A chiral side-strapped Pc with D2h symmetry has been 
synthesized from bis(4-phthalonitrile) containing flexible linker.
28
 Another example is the 
synthesis of 1,2-bis(3,4-dicyanophenoxymethyl)benzene, using 1,2-bis(hydroxymethyl)benzene 
and 4-nitrophthalonitrile.
29
 In our synthetic strategy, a carefully designed a protecting group (1,2-





the target di-pegylated bis-phthalonitrile. The bis-phthalonitrile facilitated the formation of A2B2-
type Pc. The other product formed during this reaction led to the formation of A3B-type Pc, 
following acidic deprotection of the precursor Pc. 
4.2.1. Synthesis of Phthalonitriles 
The synthesis of the regiomerically pure Pcs started with a reaction of 3-
nitrophthalonitrile and N-Boc-serinol. Mass spectrum and X-ray structure of the crude revealed 
that the reaction did not yield the desired product, tert-butyl-(1,3-bis(2,3-
dicyanophenoxy)propan-2-yl)carbamate 4.2 (Scheme 4.1). Instead, it formed a bis-phthalonitrile 
ether 4.3 (Figure 4.1). It was probably formed via nucleophilic attack of the nitro group by 
hydroxyl group, and then a nucleophilic attack by the 3-hydroxyphthalonitrile on another 3-
nitrophthalonitrile to form ether 4.3. 
 
Scheme 4.1. Synthetic strategy to tert-butyl-(1,3-bis(2,3-dicyanophenoxy)propan-2-yl)carbamate 
4.2. Conditions and reagents, a: N-Boc-serinol, K2CO3, DMF, 65 °C, 24 h. 
This led to new strategy where a mixture of 3-nitrophthalonitrile and 1,2-
bis(hydroxymethyl)benzene gave 3,3'-((1,2-phenylenebis(methylene))bis(oxy))diphthalonitrile, 
4.4, which was characterized by NMR and MS (HRMS-ESI). Dimerization of the bis-
phthalonitrile in the presence of Zn(II) acetate and a catalytic amount of DBN in DMAE resulted 





peak at 844.177 (M)
+
, calcd for C48H28N8O4Zn 844.153. The formation of the macrocycle could 
not be achieved in reasonable amounts by varying reaction conditions, such as temperature,  
concentration and reaction time. This indicated that the formation of this type of side-strapped Pc 
was difficult. Construction of a model of Pc 4.5 revealed that there was a lot of strain in the 
molecule. This explained why the product was obtained in trace amounts. 
 
Scheme 4.2. Synthetic strategy to 3,3'-[(1,2-phenylenebis(methylene))bis(oxy)]diphthalonitrile 
4.4 and bis-phthalocyanine 4.5. Conditions and reagents: (a) 1,2-benzenedimethanol, K2CO3, 






Figure 4.1. X-ray structures of phthalonitriles 4.3 and 4.7 from crystal structure determinations 
(N atoms are blue, O atoms red and H atoms white). 
The above strategy seemed promising but due to solubility issues and difficulties in the 
macrocyclization, a new approach was sought. To enhance solubility, a mixture of 3-
nitrophthalonitrile and 3-cyclohexene-1,1-dimethanol was reacted and after tedious purification 
of the crude, yellow crystals of mono-substituted adduct 4.7 were obtained (Scheme 4.3). When 
the conversion of the mono-substituted adduct to di-substituted product 4.6 was attempted, the 






Scheme 4.3. Synthetic strategy to 3,3'-[(cyclohex-3-ene-1,1-diylbis(methylene))bis(oxy)]-
diphthalonitrile 4.6. Conditions and reagents: 3-cyclohexene-1,1-dimethanol, K2CO3, DMF, 65 
°C, 24 h, 25%. 
In Chapter 1, a review of the published syntheses of bridged-Pcs, or side-strapped Pcs 
obtained from single phthalonitriles precursors, was presented. The synthesis of these Pcs is 
usually carried out under dilute conditions for the cyclotetramerization of bis-phthalonitriles. 
Suitable bis(3-phthalonitriles) are prepared from 2,2-dialkyl propane-1,3-diols or chiral bis-
naphthols, although not many bis(3-phthalonitriles) form side-strapped Pcs.
27
 This suggests that 
the choice of precursor phthalonitriles is important in the syntheses of A2B2-type Pcs. 
Therefore, in our synthesis of pegylated and regiomerically pure Pcs, a mixture of 
phthalonitrile 4.8, synthesized according to a literature procedure,
15
 and 1,2-
bis(bromomethyl)benzene reacted to give the target di-pegylated bis-phthalonitrile 4.9 in 84.3% 
yield (Scheme 4.4). The yield for this bis-phthalonitrile was higher compared with those 
obtained in prior attempts. Its purification was relatively easy. In addition, it had a better 
solubility in organic solvents, a feature that made it a suitable candidate for the synthesis of 
regiomerically pure Pcs. The PEG groups on either side of the bis-phthalonitrile molecule 
resulted in enhanced solubility of the Pcs described in this Chapter. This made it possible to use 





The 1,2-bis(bromomethyl)benzene used in this synthesis was designed to introduce a 1,2-
dimethylbenzene protecting group that was later removed under acidic conditions to give the 
desired product. The 
1




H NMR spectrum of phthalonitrile 4.9 at 400 MHz (* denotes solvent).  
4.2.2. Synthesis of Pcs 
The methodology developed in this Chapter was specifically meant to afford A3B- and 
A2B2-type regiomerically pure photosensitizers. Their synthetic route is shown in Scheme 4.4. 
The condensation of phthalonitrile 4.9 and unsubstituted phthalonitrile in refluxing DMAE, and 
in the presence of Zn(II) acetate and 1,5-diazabicyclo(4.3.0)non-5-ene (DBN) gave the protected 
Pcs 4.10 and 4.11 in 5 – 7% yields. Reaction of Pcs 4.10 and 4.11 with concentrated H2SO4 gave 
deprotected Pcs 4.12 and 4.13 respectively, in 95% and 40% yields.
29,30
 Pc 4.13 reacted with 





Scheme 4.4. Synthetic strategy to Pcs 4.12, 4.13 and 4.14. Conditions and reagents: (a) 1,2-
bis(bromomethyl)benzene, K2CO3, DMF, 65 °C, 24 h, 84.3% (b) Zn(OAc)2, DMAE, 140 °C, 5 
h, 5-7% (c) H2SO4, 0 °C. 15-30 min, 40-95% (d) 3,3’-(dimethylamino)propyl chloride 
hydrochloride, K2CO3, DMF, 65 °C, 6 h, 50%. 
Attempts to dimerize bis-phthalonitrile 4.9 into a Pc with four PEG groups failed. No 
evidence of the Pc was present in the MALDI-TOF spectra. This was in agreement with the 




confirmed that the strain in this type of Pcs does not favor their formation. Although Pc 4.5 was 
formed in traces, bis-phthalonitrile 4.9 failed to form a similar type of macrocycle. Instead, this 
reaction gave A2B2-type Pc 4.10 and clamshell-type Pc 4.11 in 5.1 and 7.2% yields respectively.  
 Initial attempts to deprotect Pcs 4.10 and 4.11 at room temperature using 
BCl3/pentamethylbenzene did not work.
31
 Metal-catalyst mediated deprotection of Pcs using 
Palladium on carbon and hydrogen gas in THF did not work either. The anticipated 
hydrogenolysis of the ‘benzylic ether’ did not occur. Instead, the palladium catalyst resulted in 
decomposition of Pc 4.10, while Pc 4.11 was all recovered. The use of hydrobromic acid (HBr) 
or acetic acid did not work either; it instead, removed Zn from the Pc core. Therefore, even the 
deprotection experiments using H2SO4 (strong acid), which gave us the desired products, had to 
be performed within a short duration to avoid the removal of the Zn metal.  
 
Scheme 4.5. Strategy for the deprotection of benzyl groups under mild conditions. 
It has been previously observed that a PEG group increases cellular uptake into human 
HEp2 cells, and decreased cytotoxicity of the Pc macrocycles.
32
 In this Chapter, a low molecular 
weight PEG (10-atom, triethylene glycol) on the Pc macrocycle as a solubilizing group was 
investigated; this PEG group has the advantage of being commercially available and is also 
relatively less flexible than the penta(ethylene glycol) previously reported. These Pcs have a 
mono- or di-hydroxyl group(s), which may be used in further functionalization of the 
macrocycles as illustrated in Scheme 4.4. Such functionalization of the Pcs is essential, 




4.3. Spectroscopic and Photophysical Characterization 
 N-Methylated Pcs are sensitive to heat and therefore, the solvents used during the 
synthesis and column chromatography of ZnPc 4.14 were removed at temperatures < 70 °C, 
to avoid loss of N-methyls. The Pc was then immediately characterized by NMR and MS. 
Although N-Demethylation in ZnPc 4.14 was not observed, MS analysis of previously 
synthesized N-Methylated Pcs had shown N-Demethylation of ZnPcs upon prolonged storage 
at room temperature.
33
 This observation may not be used to draw a conclusive observation, 
but may suggest that N-demethylation is limited to benzylic N-methyls.  
The Pcs were characterized by MS, NMR, UV-Vis and fluorescence spectroscopy; 
MALDI-TOF was used to confirm the NMR data in deuterated DMF or acetone solvents. The 
relative simplicity of the aromatic region of 
1
H-NMR spectra of ZnPcs 4.10, 4.11, and 4.14 
suggested the regiomeric purity of the Pcs, compared with the ZnPcs synthesized in Chapters 2 
and 3 (see Appendix C.1 and C.2 for 
13
C NMR). Various regioisomers (up to fifteen for the di-





H NMR spectra of Pcs 4.10 and 4.11 are shown in Figures 4.3 and 4.4, 
respectively. The 1,2-dimethylenebenzene protecting group had a peak at 6.42 (s, 4H, OCH2), 
and other multiplets within the aromatic region for the benzene ring. Removal of the protecting 
group under acidic conditions was confirmed by disappearence of these peaks from the 
1
H NMR 
spectrum of ZnPc 4.11. MS spectrum of the deprotected ZnPc also agreed with the NMR 
observations. In the 
1
H-NMR data of ZnPc 4.14 (Figure 4.5), the aromatic region remained 
relatively simple in spite of the two different substituents added to the macrocycle. The two N-
methyls in ZnPc 4.14, have a peak at 2.53 ppm while the O-methyl peak is at 3.25 ppm. All the 


















H NMR spectrum of ZnPc 4.14 at 400 MHz (* denotes solvent). 
The spectroscopic properties for Pcs 4.10, 4.11, 4.12, 4.13 and 4.14 are summarized in 
Table 4.1. All Pcs showed strong Q-band absorption bands between 687 – 697 nm in DMF, 
except for ZnPc 4.12, which absorbed at 718 nm. In Chapter 1, a reviewed of the UV-vis 
spectroscopic properties of ZnPcs with four substituents at the α-position revealed a 
bathochromic shift in their Q-bands of approximately 15 nm, and 20 nm in their Soret-bands 
compared with the mono-substituted Pcs was observed.
34
 This may explain the 10 nm difference 
in the Q-bands of ZnPc 4.10 and 4.11, since 4.10 has two more α-substituents compared with 
4.11. Removal of the protecting group from ZnPc 4.10 gives two hydroxyl (-OH) groups, which 
are strong donors and therefore, results in further red-shift of the Q-band of ZnPc 4.11 by about 
20 nm. The effect of –OH group is also seen in ZnPc 4.13, where the Q-band of the Pc is red-




Table 4.1. Spectral properties of ZnPcs 4.10, 4.11, 4.12, 4.13 and 4.14 at room temperature. a: 
excitation at 640 nm; b: calculated using ZnPc (Фf = 0.17)  as the standard in DMF. 
Pc Excitation
a
 (nm) Emission (nm) Stokes’ Shift фF
b
 
4.10 697 700 3 0.12 
  4.11 687 697 10 0.23 
4.12 718 722 4 0.10 
4.13 694 696 2 0.14 
4.14 690 693 3 0.21 
 
Figure 4.6 UV-Vis spectra for Pc 4.10, 4.11, 4.12, 4.13 and 4.14 in DMF: 2.0 µM (red), 4.0 




All the Pcs exhibit UV-vis absorption spectra that are typical of monomeric species 
(Figure 4.6).  The bis-phthalocyanine 4.11 shows substantial broadening of the Q-band centering 
at 687 nm and the Soret-band at 340 nm, which are characteristic of aggregation phenomena. 
The observation of both a blue shifted Q-band peak at 635 nm in addition to a red shifted 680–
750 nm shoulder points to mixed dimer-types Pcs.
35
 Since the shapes of the absorption spectra of 
ZnPc 4.11 remained unchanged by the concentration of the Pc, this is a sign of intramolecular 
assembly of the Pc molecules – probably an open clamshell type assembly of the molecules.  
The emissions observed ranged between 693 – 722 nm in DMF solvent. The Stoke’s 
Shifts were characteristics of ZnPcs, except for Pc 4.11, which had a 10 nm shift.  A similar shift 
was reported for bis-phthalocyanine by Yoshiyama et al. in chloroform solvent.
35
 The 




 The solubility of the ZnPcs 4.10, 4.11, 4.12, 4.13 and 4.14 in polar organic solvents 
such as DMSO, DMF and THF was investigated and all were found to be soluble in these 
solvents. The Pcs were also fairly soluble in common organic solvents, such as DCM and 
ethyl acetate. None of the Pcs could dissolve in water, even upon sonication, except Pc 4.11. 
However, all Pcs remained in aqueous solution when diluted from concentrated stocks in 
DMSO/cremophor EL into PBS (final DMSO concentration of 1%, cremophor 5%) at 10 µM 
concentrations. No aggregation of the Pcs was observed at up to 8.0 µM concentrations in 
DMF. At this concentration, all the ZnPcs show a Soret absorption band between 330 – 370 
nm, a strong Q band centered at ~ 684 nm and two vibrational bands at around 620 and 650 








Photosensitizing drugs associated with different types of delivery vehicles have received 
interest within the field of PDT of tumors.
38
 Pcs containing a PEG group on the macrocycle have 
been shown to increase the Pc tumor-cell targeting ability
32
 They also express increased water 
solubility and cell permeability. A series of Pcs with either a short spacer or a low molecular 
weight PEG-linker have also been reported recently.
15
 A low molecular PEG-linker was added to 
some of the Pcs to increase water solubility (by reducing the hydrophobicity originating from 
tert-butyl groups) and/or increase cellular uptake.
39
 
In our synthesis, the starting material – phthalonitrile 4.8 – was synthesized according to 
the literature procedure.
15
 The summary of the synthetic strategy is shown in Scheme 4.4. The di-
pegylated, bis-phthalonitrile 4.9 was used in macrocyclization reaction, with a 30 molar equiv. 
excess of phthalonitrile to give di-PEG-Pc 4.10 and bis-phthalocyanine 4.11, respectively. The 
PEG group(s) on the Pcs significantly increased their solubility in organic solvents, which made 
their purification and characterization relatively easy. The target mono- and di-pegylated 
macrocycles were mono-hydroxylated Pc 4.12 and di-hydroxylated 4.13 respectively, and were 





NMR spectra of our Pcs were relatively simple in the aromatic region compared to those 
synthesized in Chapters 2 and 3, an indication of regiomerically pure macrocycles. 
Synthesis of A3B-type and A2B2-type Pcs often gave us statistical mixtures of isomers in 
our syntheses in Chapters 2, 3 and 5. By eliminating the tert-butyl groups from the macrocycle, 
pure regiomeric isomers of the Pcs were synthesized. Such pure regiomeric Pcs, may result in 
reproducible photosensitizers as opposed to Photofrin, an oligomer of up to eight porphyrin 





Five regiomerically pure Pcs 4.10, 4.11, 4.12, 4.13 and 4.14 were synthesized in this 
study. They might find application as potential florescence imaging agents for cancers, or for 
PDT applications. Due to the hydrophobic nature of the Pc macrocycle, pegylation of the 
macrocycles significantly improved the solubility of the Pcs, making their purification possible. 
The spectroscopic data for the bis-phthalocyanine was significantly different from the other Pcs. 
It had a Stoke’s Shift of 10 nm, and it also had two strong Q-bands in the 600 – 700 nm region 
(characteristic of clamshell-type Pcs). 
4.6. Experimental Section 
General. All reagents and solvents were purchased from commercial suppliers and used 
directly without further purification. Analytical thin-layer chromatography (TLC) was carried 
out using plastic backed TLC plates 254 (precoated, 200 μm) from Sorbent Technologies. Silica 
gel 60 (230×400 mesh, Sorbent Technologies) was used for column chromatography. NMR 
spectra were recorded on Liquid AV-400 Bruker spectrometer (400 MHz for 
1
H, 100 MHz for 
13
C). The chemical shifts are reported in δ ppm using the following deuterated solvents as 
internal references: CD3COCD3 2.04 ppm (
1
H), 29.92 ppm (
13





C). MALDI-TOF mass spectra were recorded on a Bruker UltrafleXtreme (MALDI-
TOF/TOF) using 4-chloro-α-cyanocinnamic acid (CCA) as the matrix while high resolution ESI 
mass spectra were obtained on an Agilent Technologies 6210 Time-of-Flight LC/MS. 
Absorption spectra were measured on a UV-Vis NIR scanning spectrophotometer using 10 mm 
path length quartz cuvettes. Stock solutions (1.0 mM, 1.0 mL each) of each Pc in DMF solvent 
(HPLC grade) were prepared and dilutions achieved by spiking 20 – 80 µL of each stock 




Fluorolog® - HORIBA JOBINVYON, Model LFI-3751 spectrofluorimeter. The optical densities 
of the solutions used for emission studies ranged between 0.04 – 0.05 at excitation wavelengths. 
All measurements were taken within 4 h of solution preparation and carried out at (25 °C). 
4.6.1. Synthesis of Phthalonitriles 
3,3'-((1,2-phenylenebis(methylene))bis(oxy))diphthalonitrile 4.4. A mixture of 3-
nitrophthalonitrile (0.9 g, 5.2 mmol) and 1,2-benzenedimethanol (360.6 mg, 2.61 mmol) was 
dissolved in DMF (10 mL) and heated to 65 °C. Potassium carbonate, K2CO3 (2.07 g, 0.015 mol) 
were added into solution in four portions after every five minutes. The reaction mixture was 
stirred for 24 h under argon at the same temperature. It was left to cool to room temperature and 
poured into ice-cold water (200 mL). This was then filtered, washed with water, dried to obtain 
(0.722 g, 71.2%. The product was used without purification due to solubility issues. 
1
H NMR 
(DMF-d7, 400 MHz): δ 7.96-7.88 (m, 4H, Ar-H), 7.75-7.72 (m, 4H, Ar-H), 7.54-7.52 (m, 2H, 
Ar-H), 5.71 (s, 4H, CH2).  
3,3'-((cyclohex-3-ene-1,1-diylbis(methylene))bis(oxy))-diphthalonitrile 4.6. A mixture 
of 3-nitrophthalonitrile (0.935 g, 5.4 mmol) and 3-cyclohexene-1,1-dimethanol (371.2 mg, 2.61 
mmol) was dissolved in DMF (7.0 mL) and heated to 65 °C. Potassium carbonate, K2CO3 (2.07 
g, 0.015 mol) were added into solution in four portions after every five minutes. The reaction 
mixture was stirred for 24 h under argon at the same temperature. It was then left to cool to room 
temperature and poured into ice-cold water (200 mL). This was then filtered and washed with 
water. The crude was characterized by MS (MALDI-TOF) m/z 395.1494 [M+H]
+
, calcd for, 
C24H18N4O2, 395.1508. The tedious purification of the crude product using a silica column eluted 
with DCM/methanol (99:1 → 98:2) gave the first fraction as white solid on concentration. 




adduct 4.7. Mp = 120 - 121°C. Trying to form di-substituted product gave the bis-phthalonitrile 
ether 4.3 formed earlier. 
4.6.2. Synthesis of Pcs 
Side-strapped Pc 4.5. A mixture of phthalonitrile 4.4 (42.5 mg, 0.1 mmol) and zinc 
acetate (11.0 mg, 0.06 mmol) were mixed together in DMAE (5.0 mL). The solution was 
refluxed under the flow of argon, and two drops of DBN were added into the reaction solution. 
The reaction solution was further refluxed at 130 °C for 5 hours. After the reaction, the solvent 
was removed under vacuum. The residue was purified by tedious column chromatography with 
the elution of DCM/methanol (98:2) to give a green solid 0.93 mg, 2.2 %. The product was 
characterized by MS (MALDI-TOF) m/z peak at 844.177 (M)
+
, calcd for C48H28N8O4Zn 
844.153. 
Di-pegylated bis-phthalonitrile 4.9. A mixture of phthalonitrile 4.8
15
 (1.592 g, 5.2 
mmol) and 1,2-bis(bromomethyl)benzene (688.9 mg, 2.61 mmol) was dissolved in DMF (10 
mL) and heated to 67 °C. Potassium carbonate, K2CO3 (2.07 g, 0.015 mol) were added into 
solution in four portions after every five minutes. The reaction mixture was stirred for 4 h under 
argon at the same temperature. It was then left to cool to room temperature, poured into ice-cold 
water (100 mL) and filtered. The crude product was purified using alumina column eluted with 
DCM/methanol (95:5) to give a light-yellow solid on concentration (1.572 g, 84.3%). 
1
H NMR 
(Acetone-d6, 400 MHz): δ 7.71-7.61 (m, 6H, Ar-H), 7.48-7.45 (m, 2H, Ar-H), 5.57 (s, 4H, 
OCH2), 4.35 (t, J = 4.52, 4H, OCH2), 3.87 (t, J = 4.64, 4H, OCH2), 3.70-3.66 (m, 4H, OCH2), 
3.60-3.55 (m, 10H, OCH2), 3.45 (t, 4H, OCH2), 3.27 (s, 6H, OCH3).  
13
C NMR (Acetone-d6, 100 
MHz): δ 156.6, 155.7, 135.1, 130.1, 129.9, 121.3, 121.0, 114.3, 114.1, 105.34, 105.28 (Ar-H), 










, calcd for, C38H43N4O10, 715.2974, 
C38H43N4KO10, 737.2533. 
 Di-pegylated ZnPc 4.10. A mixture of phthalonitrile 4.9 (172.0 mg, 0.24 mmol), 
phthalonitrile (845.6 mg, 6.60 mmol), and zinc acetate (220.0 mg, 1.20 mmol) were mixed 
together in DMAE (13.0 mL). The solution was heated at 140 °C under the flow of argon, and 
one drop of DBN was added to the reaction solution. The reaction solution was further refluxed 
at 140 °C for 5 hours. After the reaction, the solvent was removed under vacuum. The residue 
was dissolved in acetone and filtered under gravity to give a green viscous residue on 
concentration. A silica column eluted by DCM/methanol (95:5) gave the Pcs as a green fraction. 
A second silica column eluted by DCM/methanol (95:5) gave fraction green fraction. A third 
silica column eluted by DCM/THF (3:1) gave Pc 4.10 as a green solid 12.7 mg, 5.1%. 
1
H NMR 
(DMF-d7, 400 MHz): δ 9.28-9.17 (m, 4H, Ar-H), 8.19-8.11 (m, 4H, Ar-H), 8.02-7.95 (m, 2H, 
Ar-H), 7.82-7.80 (m, 2H, Ar-H), 7.71-7.63 (m, 4H, Ar-H), 6.42 (s, 4H, OCH2), 4.95-4.48 (m, 
4H, OCH2), 4.46 (t, J = 3.92, 4H, OCH2), 4.10 (t, J = 4.64, 4H, OCH2), 3.83 (t, J = 3.88, 4H, 
OCH2), 3.65 (m, J = 4.64, 4H, OCH2), 3.54-3.42 (m, 4H, OCH2), 3.24 (s, 6H, OCH3).  
13
C NMR 
(DMF-d7, 100 MHz): δ 155.1, 154.6, 154.3, 154.1, 153.8, 152.6, 150.9, 140.0, 139.5, 135.4, 
134.7, 133.6, 133.0, 132.9, 130.4, 130.3, 130.0, 129.8, 129.1, 128.2, 126.2, 124.1, 124.0, 123.8, 
123.5, 123.4, 122.7, 121.5, 116.7 (Ar-C), 76.6, 72.8, 72.0 71.63, 71.57, 71.3, 71.2, 70.7, 70.4, 
70.2 (OCH2), 59.0 (OCH3). MS (MALDI-TOF) m/z 1034.302 [M]
+
 calcd for, C54H50N8O10Zn, 
1034.294. UV-vis (DMF): λmax (log ε) 340 (4.57), 629 (4.43), 697 (5.16) nm.  
 Deptrotected di-pegylated ZnPc 4.12. A mixture of Pc 4.10 (22.5 mg, 21.7 mmol) was 
dissolved in H2SO4 (5.0 mL) at 0°C. The reaction mixture was stirred for 15 minutes at 0°C and 







To the mixture, 2N NaHCO3 (90.0 mL) was added and the product extracted from the organic 
layer using DCM/methanol (9:1, 50.0 mL × 3) and washed with water (5 mL × 2). Organics were 
removed under reduced pressure and the residue purified by column chromatography using 
mixed solvents, DCM/methanol (98:2→ 95:5 → 9:1) to give deprotected di-pegylated bis-
phthalocyanine 4.12 as a green solid (19.2 mg, 95.0 %). 
1
H NMR (DMF-d7, 400 MHz): δ 9.29 (s, 
4H, Ar-H), 8.17 (m, 4H, Ar-H), 7.75-7.51 (m, 4H, Ar-H), 5.06 (br, 4H, OCH2), 4.53-36 (br, 4H, 
OCH2), 4.09 (t, J = 4.72, 4H, OCH2), 3.66 (t, J = 4.52, 4H, OCH2), 3.51-3.43 (m, 4H, OCH2), 
3.26 (s, 6H, OCH3).  
13
C NMR (DMF-d7, 100 MHz): δ 155.0, 154.2, 153.7, 151.5, 150.6, 149.8, 
139.7, 139.4, 136.3, 130.0, 129.9, 124.0, 123.6, 123.2, 122.8, 119.8, 118.2 (Ar-C), 72.9, 72.8, 
72.0 71.6, 71.33, 71.29, 70.7, (OCH2), 59.1, 59.0 (OCH3). MS (MALDI-TOF) m/z peak at 
932.294 (M)
+
, calcd for C46H44N8O10Zn 932.247.  UV-vis (DMF): λmax (log ε) 341 (4.86), 648 
(4.63), 718 (5.23) nm. 
 Di-pegylated bis-phthalocyanine 4.11. This Pc was isolated during the first column 
using DCM/methanol (95:5) as a greenish solid (28.2 mg, 7.2%). 
1
H NMR (DMF-d7): δ 9.11-
9.02 (m, 7H, Ar-H), 8.53-8.41 (m, 7H, Ar-H), 8.30-8.23 (m, 4H, Ar-H), 8.17-8.08 (m, 4H, Ar-
H), 7.93-7.90 (m, 2H, Ar-H), 7.82-7.77 (m, 4H, Ar-H), 7.46-7.44 (m, 2H, Ar-H), 7.01 (s, 4H, 
OCH2), 6.87-6.84 (m, 2H, Ar-H), 4.65-4.55 (m, 8H, OCH2), 4.13-4.11 (m, 4H, OCH2), 3.89-3.86 
(m, 4H, OCH2), 3.73-3.70 (m, 4H, OCH2), 3.55-3.52 (m, 4H, OCH2), 3.30 (s, 6H, OCH3).  
13
C 
NMR (DMF-d7, 100 MHz): δ 154.1, 153.5, 152.9, 152.4, 152.3, 151.8, 151.1, 150.6, 150.4, 
140.4, 139.6, 139.4, 139.2, 139.0, 137.8, 130.2, 130.0, 129.2, 129.1, 129.4, 129.0, 128.2, 126.7, 
126.3, 123.6, 123.34, 123.26, 123.0, 122.7, 119.2, 118.7, 117.4, 114.4 (Ar-C), 73.5, 72.9, 72.1, 









, calcd for C86H66N16O10Zn2 1614.3717.  UV-vis (DMF): λmax (log ε) 336 (4.93), 
638 (5.01), 687 (4.98) nm.  
 A mixture of ZcPc 4.11 (22.5 mg, 13.9 mmol) was dissolved in H2SO4 (5.0 mL) at 0°C. 
The reaction mixture was stirred for 30 minutes at 0°C and then poured into ice (50.0 mg), in a 
separating funnel containing DCM/methanol (9:1, 50.0 mL). To the mixture, ~ 2N NaHCO3 
(90.0 mL) added to attain a neutral pH. The product was extracted from the organic layer using 
DCM/methanol (9:1, 50.0 mL × 3) and washed with water (5 mL × 2). Organics were removed 
under reduced pressure and the residue purified using silica column chromatography with eluting 
solvent system of DCM/ethyl acetate (1:2) to give a greenish solid (10.1 mg, 41.0 %). 
1
H NMR 
(DMF-d7): δ 9.32 - 9.02 (m, 6H, Ar-H), 8.29-8.12 (m, 6H, Ar-H), 7.82-7.42 (m, 2H, Ar-H), 6.99 
(br, 1H, OH), 5.11-4.97 (m, 2H, OCH2), 4.45-4.42 (m, 2H, OCH2), 4.12 (t, J = 4.76, 2H, OCH2), 
3.68 (t, J = 3.52, 2H, OCH2), 3.48 (t, J = 4.68, 2H, OCH2), 3.30-3.27 (s, 3H, OCH3). 
13
C NMR 
(DMF-d7, 100 MHz): δ 154.4, 153.9, 152.9, 150.7, 139.3, 138.0, 130.3, 130.2, 129.4, 126.7, 
123.8, 123.5, 123.4, 123.2, 123.0, 119.7, 117.7 (Ar-C), 72.9, 72.1, 71.7, 71.4 (OCH2), 59.1 
(OCH3). MS (MALDI-TOF) m/z peak at 755.225 (M+H)
+
, calcd for C39H31N8O5Zn 755.1709.  
UV-vis (DMF): λmax (log ε) 342 (4.71), 628 (4.49), 694 (5.19) nm. 
 3-(Dimethylamino)propyl substituted ZnPc 4.14. A procedure reported in literature 
was used, with little modification, to furnish the desired product.
40,41
  A mixture of Pc 4.13 (18.1 
mg, 0.024 mmol) and 3-(Dimethylamino)propyl chloride hydrochloride (4.7 mg, 0.030 mmol) 
were mixed together in DMF (5.0 mL), the solution heated at 65 °C under argon, and K2CO3 
(50.0 mg, 3.6 mmol) added to the reaction solution. The reaction solution was heated at the same 
temperature for 6h. The solvent was removed under reduced pressure and the residue dissolved 







(20 mL) and dried to obtain a blue solid. The solid was purified by silica column 
chromatography using DCM/methanol (9:1) to give a blue-green solid (10.0 mg, 49.8 %). 
1
H 
NMR (DMF-d7): δ 9.52-9.45 (m, 6H, Ar-H), 8.27-8.19 (m, 6H, Ar-H), 7.71 (dd, J = 8.54, 2H, 
OCH2), 5.03 (t, J = 5.16, 2H, OCH2), 4.82 (t, J = 5.80, 2H, OCH2), 4.49 (t, J = 4.68, 2H, OCH2), 
4.11 (t, J = 4.76, 2H, OCH2), 3.84 (t, J = 5.08, 2H, OCH2), 3.67-3.65 (m, 2H, OCH2), 3.47 (t, J 
= 4.96, 2H, OCH2), 3.34-3.28 (m, 2H, OCH2), 3.25 (s, 3H, OCH3), 2.66-2.60 (m, 2H, OCH2), 
2.53 (s, 6H, N(CH3)2). 
13
C NMR (DMF-d7): δ 154.9, 154.8, 154.7, 154.5, 154.2, 152.3, 151.6, 
140.3, 140.0, 130.1, 130.0, 129.3, 128.7, 123.8, 123.4, 123.4, 123.3, 117.9, 116.2 (Ar-C), 72.8, 
72.0, 71.6, 71.3, 68.9 (OCH2), 59.0 (OCH3), 57.8 (N-CH2), 45.9 (N(CH3)2), 28.9 (CH2).  MS 
(MALDI-TOF) m/z peak at 840.341 (M+H)
+
, calcd for C44H42N9O5Zn 840.2600. UV-vis 
(DMF): λmax (log ε) 341 (4.51), 624 (4.28), 690 (5.00) nm. 
2.6.3. Phthalonitrile Molecular Structures  
 Crystal structure analyses of phthalonitriles 4.3 and 4.7 were based on data collected at 
T=90K on a Bruker Kappa Apex-II CCD diffractometer with a CuKα radiation (compound 4.3) 
and a Bruker Kappa Apex-II DUO diffractometer with a MoKα radiation (compounds 4.7). The 
crystals were obtained by slow evaporation of mixed solvents DCM/acetone 5:1. The crystal 
structure analyses of these phthalonitriles  confirm the formation of the side product or 
intermediate. Crystal data: 4.3, C16H6N4O, Mr = 270.25, triclinic space group P-1, a = 7.9348 
(10) Å, b = 12.0783 (14) Å, c = 13.8674 (17) Å, α = 74.402 (7)°, β = 88.148 (8)°, γ = 78.258 
(8)°, V = 1252.9 (3) Å
3
, Z = 4, Dx = 1.433 Mg m
−3
 , max = 67.9°, R = 0.081 for 4363 data and 
380 refined parameters; 4.7, C16H16N2O2, Mr = 268.31, triclinic space group P-1, a = 6.7586 (4) 
Å, b = 8.0397 (4) Å, c = 12.7269 (7) Å, V = 684.71 (6) Å
3
, Z = 2, Dx = 1.301 Mg m
−3
 , max = 







4.7. Spectroscopic Studies  
All absorption spectra were measured on UV-VIS NIR Scanning Spectrometer UV-
3101PC SHIMADZU (Cell positioned) equipped with a CPS-260 lamp. Stock solutions (1000 
µM, 1.0 mL) of all Pcs were prepared in DMF (HPLC grade) and the dilutions achieved by 
spiking 20 – 80 µL of the corresponding stock solution into DMF to a 10.0 mL final volume. 
Emission spectra were recorded on a Fluorolog
®
-HORIBA JOBINVYON (Model LFI-3751) 
spectrofluorimeter. The optical densities of the solutions used for emission studies were kept 
between 0.04 – 0.05 (AU) at the excitation wavelengths for all the ZnPcs. All the measurements 
were recorded within 3 h of preparation at 25 °C, using a 10 mm path length spectrophotometric 
cell. The fluorescence quantum yields (Фf) were determined using a secondary standard 
method.
42
 Unsubstituted ZnPc (Фf = 0.17) was used as a reference and the values of fluorescence 
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SYNTHESES AND BIOLOGICAL EVALUATION OF PEGYLATED AND CATIONIC 
ZINC(II)-PHTHALOCYANINES AND MONOCLONAL ANTI-CARCINOEMBRYONIC 




Pcs are promising second-generation photosensitizers with intense absorptions at 
wavelengths (λmax) > 670 nm. They also have capacity to penetrate cellular membranes and can 
produce ROS upon light activation. Some Pcs, such as Photosense, and a Si(IV)Pc, Pc4, have 
been evaluated in clinical trials for PDT.
1-3
 These Pcs and other potential Pc-based 
photosensitizers have tangential water-solubilizing substituents and/or axial ligands that can 
minimize their aggregation or increase solubility the Pcs in aqueous media. The enhancing of 
these features results in improved photodynamic activity of the photosensitizers. Polyethylene 
glycol (PEG) groups have been investigated either as delivery vehicles,
4-6
 or as covalently 
attached substituents
7-9
 for enhanced delivery to target tissues. Their covalent attachment to 
photosensitizers is known to enhance water-solubility, serum life and tumor accumulation of 
photosensitizers, but reduces their uptake by the reticuloendothelial system.
10-15
  
Cationic photosensitizers are attractive for PDT applications
16-23
 and the 
photoinactivation of virus and bacteria,
24-26
 due to their stronger interaction with the negatively 
charged cell membranes. They also target biomolecules (e.g. DNA and RNA) within the cell 
nucleus, which may result in effective photodamage and overall enhanced photodynamic 
efficacy. In Chapter 2, di-cationic α-substituted ZnPcs were synthesized and found to be the most 
phototoxic within a series of Pcs containing positively-charged trimethylaminophenoxy groups, 
                                                

 Part of this chapter was published in Journal of Theranostics: Ongarora, B. G.; Hu, X.; 
Verberne-Sutton, D.; Garno, J. C.; Vicente, M. G. J. Theranostics 2012, 2 (9), 850-870.
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in addition to being the most promising photosensitizers for PDT. In this Chapter, the syntheses 
of a new series of di-cationic Pcs containing a PEG group or a diglycolic spacer between the 
ZnPc and the positively charged quaternary ammonium groups is described. The synthesis of 
pegylated ZnPcs, which were conjugated with monoclonal antiCEA for application in the 
diagnosis of cancer is also described. 
5.2. Results and Discussion 
5.2.1. Syntheses of Cationic ZnPcs 
The synthetic strategy to di-cationic ZnPcs 5.4, 5.6, 5.9, 5.11, 5.15, 5.17, 5.20, 5.22, 5.27 
and 5.32 is shown in Schemes 5.1 – 5.4, starting from 3- or 4-nitrophthalonitrile (5.23 and 5.28). 
The ZnPcs 5.1, 5.2, 5.12 and 5.13 were prepared according to procedures prescribed in Chapters 
2 and 3. The nitrophthalonitriles reacted with p-N-Boc-aminophenol in DMF at 80 ºC under 
basic conditions to give the corresponding p-(N-Boc-aminophenoxy)phthalonitriles. The 
phthalonitrile was then heated at 140 ºC in DMAE and in the presence of zinc(II) acetate, 3 
equiv. 4-tert-butylphthalonitrile and a catalytic amount of DBN, giving the Boc-protected α- or 
β-substituted A3B-type ZnPcs in 15-20% yields. Deprotection of the Boc groups was achieved 
using TFA. Reaction with diglycolic anhydride gave the α- and β- substituted ZnPcs 5.1  and 
5.12 respectively, which were conjugated with commercially available tert-butyl-12-amino-
4,7,10-trioxadodecanoate, using HOBt, EDCI and TEA in DMF to produce pegylated ZnPcs 5.2  
and 5.13 upon deprotection usning TFA.
28
 Reaction of ZnPcs 5.1 and 5.2 with 1,4-bis(N-Boc)-
triazaheptane using similar coupling reagents, followed by acidic Boc-deprotection gave ZnPcs 
5.5 and 5.3, respectively, in 69-73% yields. Trimethylation of the amino groups was achieved 
using excess methyl iodide and DIPA in DMF as described in Chapter 2, giving the respective 







L-aspartic acid in DMF gave ZnPc 5.7, followed by deprotection with TFA.
29
 In this reaction, 
TEA was used as a base, while HATU and HOBt served as coupling reagents.  
 
 Scheme 5.1. Synthesis of dicationic α-substituted ZnPcs 5.4, 5.6, 5.9 and 5.11. Reaction 
conditions: (i) tert-butyl-12-amino-4,7,10-trioxadodecanoate, TEA, HOBt, EDCI, DMF (82%); 
(ii) TFA, DCM. 0 
o
C, 3 h (89%); (iii) 1,4-bis(N-Boc)-triazaheptane, TEA, HOBt, EDCI, DMF 
(77%); (iv) CH3I, DIPA, DMF (59-68%); (v) L-aspartic acid di(tert-butyl) ester, TEA, HATU, 
DMF (89%); (vi) N-Boc-2,2′-(ethylenedioxy)diethylamine, TEA, HOBt, EDCI, DMF (52%); 
(vii) N-Boc-ethylenediamine, TEA, HOBt, EDCI, DMF (58%). 
The dicarboxylate terminated ZnPc 5.7 was coupled to N-Boc-2,2′-







a similar protocol as that described for ZnPc 5.3 above, giving ZnPcs 5.8 and 5.10 respectively 
after deprotection. The ZnPcs 5.8 and 5.10 were quaternized following the procedure described 
above, to afford di-cationic ZnPcs 5.9 and 5.11 in 68 and 59% yields, respectively (Scheme 5.1). 
 
Scheme 5.2. Synthesis of dicationic β-substituted ZnPcs 5.15, 5.17, 5.20 and 5.22. Reaction 
conditions: (i) tert-butyl-12-amino-4,7,10-trioxadodecanoate, TEA, HOBt, EDCI, DMF (77%); 
(ii) TFA, DCM. 0 
o
C, 3 h (83-91%); (iii) 1,4-bis(N-Boc)-triazaheptane, TEA, HOBt, EDCI, 
DMF (80-89%); (iv) CH3I, DIPA, DMF (58-67%); (v) L-aspartic acid di(tert-butyl) ester, TEA, 
HATU, DMF (89%); (vi) N-Boc-2,2′-(ethylenedioxy)diethylamine, TEA, HOBt, EDCI, DMF 







Reaction of ZnPcs 5.12 and 5.13 with 1,4-bis(N-Boc)-triazaheptane following a similar 
protocol as that described for ZnPc 5.7 above, gave ZnPcs 5.16 and 5.14 in 72 and 79% yields 
respectively, after N-Boc-deprotection by TFA. Quaternization of the amino groups using excess 
methyl iodide and diisopropylamine (DIPA) in DMF gave the corresponding di-cationic ZnPcs 
5.17 and 5.15 in 58 and 64% yields, respectively. The pronged ZnPcs 5.18 was synthesized via 
reaction of 5.12 with di-tert-butyl ester protected L-aspartic acid in DMF, using TEA, HATU 
and HOBt, followed by N-Boc-deprotection using TFA. Coupling ZnPc 5.18 to N-Boc-2,2′-
(ethylenedioxy)diethylamine or N-Boc-ethylenediamine as described above, gave ZnPcs 5.19 
and 5.21 in 47 and 56% yields, respectively. Reacting the Pcs with methyl iodide, gave the di-
cationic ZnPcs 5.20 and 5.22 in 64 and 67% yields respectively (Scheme 5.2). 
 
Scheme 5.3. Synthesis of pegylated α-substituted ZnPc 5.27. Reaction conditions: (i) tert-butyl-
20-hydroxy-3,6,9,12,15,18-hexaoxaicosan-1-oate, K2CO3, THF, 65 
o
C, 6 h (78%); (ii) 4-tert-
butylphthalonitrile, Zn(OAc)2, DMAE, 145 
o
C, 5 h (17%); (iii) TFA, DCM, 0 
o
C, 3 h (91-94 %); 
(iv) 1,4-bis(N-Boc)-triazaheptane, TEA, HOBt, EDCI, DMF (64%); (v) CH3I, DIPA, DMF, r.t., 
2 days (67%). 
Pegylated phthalonitrile 5.24 was obtained by reacting tert-butyl 20-hydroxy-
3,6,9,12,15,18-hexaoxaicosan-1-oate,
30
 with 3-nitrophthalonitrile in THF at 65 ºC, in the 
presence of K2CO3 (Scheme 5.3). Phthalonitrile 5.24 was then tetramerized with excess 4-tert-
butylphthalonitrile in the presence of zinc(II) acetate and 2-3 drops of DBN in DMAE, followed 







Pegylated ZnPc 5.25 was conjugated with 1,4-bis(N-Boc)-triazaheptane using TEA, HOBt and 
EDCI, followed by N-Boc-deprotection to give ZnPc 5.26 in 58% yields. Reaction of ZnPc 5.26 
with methyl iodide using the procedure described above gave the corresponding di-cationic ZnPc 
5.27 in 67% yield.  
Using a similar methodology, phthalonitrile 5.29 was obtained by reacting tert-butyl 20-
hydroxy-3,6,9,12,15,18-hexaoxaicosan-1-oate with 4-nitrophthalonitrile in THF at 65 ºC, in the 
presence of K2CO3 (Scheme 5.4). Phthalonitrile 5.29 was tetramerized as described for ZnPc 
5.25 above to give the corresponding A3B-type ZnPc 5.30 in about 15% yield. Conjugation of 
the pegylated ZnPc 5.30 with 1,4-bis(N-Boc)-triazaheptane using TEA, HOBt and EDCI, 
followed by TFA cleavage of N-Boc gave ZnPc 5.31 in 61% yields. Reaction of ZnPc 5.31 with 
methyl iodide as described above gave di-cationic ZnPc 5.32 in 63% yield.  
 
Scheme 5.4. Synthesis of pegylated β-substituted ZnPc 5.32. Reaction conditions: (i) tert-butyl-
20-hydroxy-3,6,9,12,15,18-hexaoxaicosan-1-oate, K2CO3, THF, 65 
o
C, 6 h (78%); (ii) 4-tert-
butylphthalonitrile, Zn(OAc)2, DMAE, 145 
o
C, 5 h (16%); (iii) TFA, DCM, 0 
o
C, 3 h (93-94 %); 
(iv) 1,4-bis(N-Boc)-triazaheptane, TEA, HOBt, EDCI, DMF (61%); (v) CH3I, DIPA, DMF, r.t., 
2 days (63%). 
 All the synthesized di-cationic ZnPcs 5.4, 5.6, 5.9, 5.11, 5.15, 5.17, 5.20, 5.22, 5.27 
and 5.32 were soluble in polar organic solvents, such as DMF, THF and methanol. None of 







Nevertheless, upon dilution from concentrated Pc stocks in DMF or DMSO into PBS (final 
DMF or DMSO concentration of 1%) at 10 µM concentrations, the Pcs remained in aqueous 
solution. Cationic ZnPcs may undergo N-demethylation upon prolonged storage at room 
temperature, as observed for this type of Pcs in Chapter 2.  The spectroscopic properties of 
the ZnPcs in DMF are summarized in Table 5.1 and shown in Figure 5.1.  
 
i)                                                                       ii) 
Figure 5.1. (i) Absorption and (ii) fluorescence spectra for Pc 5.4 (red), 5.6 (black), 5.9 
(grey), 5.11 (light green), 5.15 (green), 5.17 (brown), 5.20 (purple), 5.22 (orange), 5.27 
(pink), 5.32 (blue) at 8.0 and 0.5-0.8 µM concentrations, respectively, in DMF. 
 For concentrations < 10 µM, the ZnPcs did not aggregate in DMF. They all exhibited 
strong Q absorptions and emissions in the near-IR between 679 – 686 nm in the same 
solvent, with small Stokes’ shifts between 2 – 4 nm, as has been observed for this type of 
macrocycle.
31-33
 The all had a Soret absorption between 330 – 360 nm.  A strong Q-band 
between 677 – 683 nm and a vibrational band at around 620 nm, that strictly followed the 
Lambert-Beer law was also observed in for each Pc. There was no colloidal solution 







aggregates were not formed at this concentration for this ZnPcs.
32
 The expected fluorescence 
quantum yields ca. 0.09 – 0.23 for ZnPcs in DMF were observed.
31-33
 
Table 5.1. Spectroscopic Properties of Pcs in DMF at 25 °C.  













5.3 680 684 4 5.52 0.23 
5.4 679 683 4 5.32 0.15 
5.5 680 684 4 5.19 0.19 
5.6 679 682 3 5.23 0.21 
5.7 679 682 3 5.17 0.13 
5.8 680 683 3 5.20 0.14 
5.9 680 683 3 5.01 0.14 
5.10 680 683 3 5.23 0.13 
5.11 679 682 3 5.19 0.09 
5.14 677 680 3 5.28 0.15 
5.15 677 680 3 5.30 0.14 
5.16 677 679 2 5.19 0.20 
5.17 676 679 3 5.31 0.15 
5.18 677 680 3 5.28 0.10 
5.19 677 681 4 5.27 0.11 
5.20 677 680 3 5.01 0.11 
5.21 677 680 3 5.19 0.12 
5.22 677 680 3 4.99 0.11 
5.25 681 684 3 5.34 0.19 
5.26 683 686 3 5.31 0.21 
5.27 682 685 3 5.28 0.18 
5.30 676 680 4 5.14 0.19 
5.31 678 681 3 5.35 0.18 
5.32 677 680 3 5.26 0.17 
a
 Excitation at 640 nm. 
b
 Calculated using ZnPc (Фf = 0.17) as the standard in DMF.  
5.2.2. Biological Evaluation of Cationic ZnPcs 
 The time-dependent cellular uptake, cytotoxicity and intracellular localization of the 







used in the evaluation of cytotoxicity viability assay, as reported previously in literature,
20,29,34
 at 
concentrations up to 400 µM for all the cationic ZnPcs. Low toxicity in the dark (IC50 > 180 
µM), especially for the branched dicationic Pcs 5.9, 5.11, 5.20 and 5.22 was observed, which 
exhibited remarkably low dark toxicity (IC50 > 400 µM). This could be due to their low uptake 
into cells as seen in Figure 5.2. Cationic ZnPcs 5.6, 5.27 and 5.32 may not suitable candidates for 
imaging due to their relatively high dark toxicity at higher concentrations, although ZnPc 5.27 
may be used for PDT; it has higher dark- to photoxicity IC50 ratio. Due to its low dark toxicity 
and higher phototoxicity, cationinc ZnPc 5.11 may find application as a PDT agent. These results 
also indicate that Pcs 5.20 and 5.22 may be useful as bioimaging dyes due to the low 
phototoxicity observed. Table 5.2 summarizes the IC50 results obtained for the cationic ZnPcs.  
 
Figure 5.2. Dark toxicity of Pc 5.4 (red), 5.6 (black), 5.9 (grey), 5.11 (light green), 5.13 (purple), 
5.15 (green), 5.17 (brown square), 5.20 (light-blue), 5.22 (orange), 5.27 (pink), 5.32 (blue) at 10 







Table 5.2. Cytotoxicity and localization sites for ZnPcs in HEp2 cells. 




Ratio Major sites of localization 
5.4 351.7 10.7 32.9 ER 
5.6 179.9 14.8 12.2 Golgi 
5.9 >400.0 28.8 >13.9 Lysosomes 
5.11 >400.0 12.7 >31.5 Lysosomes 
5.13 397.3 >100.0 >4.0 Mitochondria 
5.15 280.0 >100.0 >2.8 Mitochondria, Golgi 
5.17 346.3 >100 >3.5 Mitochondria, Lysosomes 
5.20 >400.0 >100.0 >4.0 Lysosomes 
5.22 >400.0 >100.0 >4.0 Mitochondria 
5.27 220.1 8.7 25.3 Mitochondria, ER 
5.32 249.7 47.0 5.3 ER 
The uptake of each Pc into HEp2 cells with time was investigated at a concentration of 10 
µM of over 24 h (Figure 5.3a). In Chapter 2, it was observed that the cytotoxicity of cationic Pcs 
depends on the position of the substituent on the macrocycle periphery. The α-substituted 
compounds were found be more toxic than their β-substituted counterparts. All β-substituted 
ZnPcs were not toxic even at 100 µM concentrations upon irradiation with low light dose (~1.5 
J/cm
2
); only ZnPc 5.22 was relatively phototoxic (IC50 = 47 µM). The α-substituted ZnPcs 5.4, 
5.6, 5.9, 5.11 and 5.27 were the most phototoxic, with calculated IC50 values of 10.7, 14.8, 28.8, 
12.7 and 8.7 µM, respectively (see dose-response curves, Figure 5.3b). Of the cationic Pcs 
synthesized in this Chapter, 5.4, 5.11 and 5.27 are the most promising for PDT applications due 
to their high ratio (>25) of dark toxicity and high phototoxicity. As noted in Chapter 1, a good 
PDT drug should have low dark toxicity to phototoxicity ratio. The results in Table 5.2 show that 
the dark toxicity IC50 value should be large enough compared to the phototoxicity IC50, for a 












Figure 5.3. (a) Time-dependent uptake at 10 μM, and (b) Phototoxicity of ZnPcs 5.4 (red), 5.6 
(black), 5.9 (grey), 5.11 (light green), 5.13 (purple), 5.15 (green), 5.17 (brown), 5.20 (light blue), 
5.22 (orange), 5.27 (pink), 5.32 (blue) in HEp2 cells. 
It was remarkable to note that both of the most phototoxic ZnPcs (5.4 and 5.27) had a 
PEG group. The two cationic charges were only separated by an ethylene group and the two 





favors intracellular localization in the ER,
28
 whereas the positive charges may favor their 
localization at the plasma membrane, or subcellularly within mitochondria and lysosomes.
34-37
  
The β-substituted ZcPcs 5.15 and 5.17 accumulated within HEp2 cells to a great extent 
than the other Pcs. The fastest of all ZnPcs in terms of cellular uptake was Pc 5.17, although the 
uptake slowed down to a plateau approximately 8 h post exposure. The PEG group in ZnPc 5.15 
probably resulted in continued accumulation within cells up to 24 h post exposure. The di-
cationic Pcs (5.15 and 5.17) containing the two cationic charges in close proximity on the same 
chain, exhibited increased uptake unlike the neutral Pc-PEG 5.13, or the cationic Pcs 5.9, 5.11, 
5.20 and 5.22, which were branched.  
With exception of 5.20, which was found mainly in the lysosomes (Table 5.2), all the 
other cationic ZnPcs localized within multiple subcellular sites. Other ZnPcs (5.4, 5.6, 5.11 and 
5.32) were localized at the plasma membrane. The most phototoxic compounds (5.4, 5.11 and 
5.27) were all localized within the ER. The ER is an important organelle that is responsible for 
the regulation of protein synthesis and stress responses, which in turn induces cell apoptosis in 
PDT.
38,39
 The results in this Chapter show that the subcellular localization of the ZnPcs, and not 
the extent of cellular uptake, or their charge distribution about the macrocycle determines their 
photodynamic activity. This could be due to their different interactions with the subcellular units. 
The fluorescence microscopy experiments were carried out, 6 h post exposure of HEp2 cells 
(Figures 5.4 – 5.8). The following organelle specific fluorescent tracers for co-localization 
experiments were used: ER Tracker Blue/White (ER), MitoTracker Green (mitochondria), 
BODIPY Ceramide (Golgi) and LysoSensor Green (lysosomes). The results indicate that the α-
substituted ZnPcs were more toxic than the corresponding β-substituted ZnPcs in the dark. Upon 
exposure of the ZnPcs to approximately 1.5 J/cm
2






a)                                                                             b) 
Figure 5.4. Subcellular localization of: (a) ZnPc 5.4 in HEp2 cells at 10 µM for 6 h. (A) Phase 
contrast, (B) Overlay of 5.4 fluorescence and phase contrast, (C) ER Tracker Blue/White 
fluorescence, (E) MitoTracker green fluorescence, (G) BODIPY Ceramide fluorescence, (I) 
LysoSensor green fluorescence, and (D, F, H, J) overlays of organelle tracers with 5.4 
fluorescence. (b) Pc 5.6 in HEp2 cells at 10 µM for 6 h. (A) Phase contrast, (B) Overlay of 5.6 
fluorescence and phase contrast, (C) ER Tracker Blue/White fluorescence, (E) MitoTrack green 
fluorescence, (G) BoDIPY Ceramide, (I) LysoSensor green fluorescence, and (D, F, H, J) 






a)                                                                             b) 
Figure 5.5. Subcellular localization of: (a) Pc 5.9 in HEp2 cells at 10 µM for 6 h. (A) Phase 
contrast, (B) Overlay of 5.9 fluorescence and phase contrast, (C) ER Tracker Blue/White 
fluorescence, (E) MitoTrack green fluorescence, (G) BoDIPY Ceramide, (I) LysoSensor green 
fluorescence, and (D, F, H, J) overlays of organelle tracers with 5.9 fluorescence. (b) ZnPc 5.11 
in HEp2 cells at 10 µM for 6 h. (A) Phase contrast, (B) Overlay of 5.11 fluorescence and phase 
contrast, (C) ER Tracker Blue/White fluorescence, (E) MitoTracker green fluorescence, (G) 
BODIPY Ceramide, fluorescence (I) LysoSensor green fluorescence, and (D, F, H, J) overlays of 






a)                                                                           b) 
Figure 5.6. Subcellular localization of: (a) Pc 5.15 in HEp2 cells at 10 µM for 6 h. (A) Phase 
contrast, (B) Overlay of 5.15 fluorescence and phase contrast, (C) ER Tracker Blue/White 
fluorescence, (E) MitoTrack green fluorescence, (G) BoDIPY Ceramide, (I) LysoSensor green 
fluorescence, and (D, F, H, J) overlays of organelle tracers with 5.15 fluorescence. (b) Pc 5.17 in 
HEp2 cells at 10 µM for 6 h. (A) Phase contrast, (B) Overlay of 5.17 fluorescence and phase 
contrast, (C) ER Tracker Blue/White fluorescence, (E) MitoTrack green fluorescence, (G) 
BoDIPY Ceramide, (I) LysoSensor green fluorescence, and (D, F, H, J) overlays of organelle 







a)                                                                              b) 
Figure 5.7. Subcellular localization of: (a) Pc 5.20 in HEp2 cells at 10 µM for 6 h. (A) Phase 
contrast, (B) Overlay of 5.20 fluorescence and phase contrast, (C) ER Tracker Blue/White 
fluorescence, (E) MitoTrack green fluorescence, (G) BoDIPY Ceramide, (I) LysoSensor green 
fluorescence, and (D, F, H, J) overlays of organelle tracers with 5.20 fluorescence. (b) Pc 5.22 in 
HEp2 cells at 10 µM for 6 h. (A) Phase contrast, (B) Overlay of 5.22 fluorescence and phase 
contrast, (C) ER Tracker Blue/White fluorescence, (E) MitoTrack green fluorescence, (G) 
BoDIPY Ceramide, (I) LysoSensor green fluorescence, and (D, F, H, J) overlays of organelle 






a)                                                                              b) 
Figure 5.8. Subcellular localization of: (a) ZnPc 5.27 in HEp2 cells at 10 µM for 6 h. (A) Phase 
contrast, (B) Overlay of 5.27 fluorescence and phase contrast, (C) ER Tracker Blue/White 
fluorescence, (E) MitoTracker green fluorescence, (G) BODIPY Ceramide fluorescence, (I) 
LysoSensor green fluorescence, and (D, F, H, J) overlays of organelle tracers with 5.27 
fluorescence. (b) Pc 5.32 in HEp2 cells at 10 µM for 6 h. (A) Phase contrast, (B) Overlay of 5.32 
fluorescence and phase contrast, (C) ER Tracker Blue/White fluorescence, (E) MitoTrack green 
fluorescence, (G) BoDIPY Ceramide, (I) LysoSensor green fluorescence, and (D, F, H, J) 





5.2.3. Pc-Monoclonal Anti-Carcinoembryonic Antigen (AntiCEA) Conjugates 
Monoclonal antibodies (mAbs) are antibodies that are made by identical immune cells 
that are all clones of a unique parent cell, and they have affinity for a specific substance.
40
 The 
mAbs are artificially produced via a technique of cell fusion followed by selection; body cells 
are obtained from a single cell in a culture medium. Monoclonal antibody therapy is the use of 
mAbs to target specific cells or proteins.
41,42
 Several antibodies have been approved for the 
treatment of cancer, either as unconjugated antibodies or for delivery of drugs to cancer cells. 
Some of the monoclonal antibodies that have been approved by FDA for the treatment of various 
types of cancer are show in Table 5.3.
40
 
Table 5.3. Some of the antibodies approved by DFA for cancer treatment.  
Monoclonal antibody Target Cancer 
Alemtuzumab (Campath)  Chronic lymphocytic leukemia  
Bevacizumab (Avastin)  Breast cancer, colon cancer, lung cancer  
Cetuximab (Erbitux)  Colon cancer, head and neck cancers  
Gemtuzumab (Mylotarg)  Acute myelogenous leukemia  
Ibritumomab (Zevalin)  Non-Hodgkin's lymphoma  
Panitumumab (Vectibix)  Colon cancer  
Rituximab (Rituxan)  Non-Hodgkin's lymphoma  
Tositumomab (Bexxar)  Non-Hodgkin's lymphoma  
Many factors dictate the success of targeted therapeutics: affinity and specificity of the 
ligand used, the density of the target molecule on the cell surface, localization of the drug within 
the target tissue, and the rate at which the drug molecules enter the appropriate cell 
compartments.
43





 are among the EGFR-targeting biomolecules, which have recently been 





molecules are particularly attractive due to their availability, low immunogenicity, ease of 
conjugation to various molecules, and reported superior EGFR-targeting ability. Monoclonal 
antibodies have also been used in targeted therapeutics.
46-49
 Despite their large molecular weight 
and relatively higher cost, monoclonal antibodies have attracted interest in targeted therapeutics 
due to their unique specificity. 
In this section, several ZnPcs were synthesized and conjugated to human 
carcinoembryonic antigen (antiCEA). The conjugates were then investigated in mice bearing 
colon tumors derived from HT-29 cell lines, as imaging agents. The CEA is most abundantly 
expressed extracellular marker associated with human colorectal cancer or the precursor aberrant 
crypti foci, and is used as serum marker of CRC in clinical medicine.
50,51
 The CEA antigen is 
also non-internalizing and as a result was not expected to cause phototoxicity. The CEA is a 
large protein and therefore, cannot be internalized – it has a molecular mass of about 150 kD. 
The non-internalization of the CEA is important since the conjugate will be bound to the tumor 
surface, resulting in enhanced fluorescence. The ZnPc derivatives conjugated to monoclonal 
antiCEA investigated in here, are pegylated and/or cationic; this enhanced their water-solubility. 
Solubility in water is a key factor since all the conjugation reactions were carried out at pH 7.4 in 
PBS solution. Positively charged photosensitizers may also interact with negatively charged cell 
membranes and the targeted surfaces.
16-23
  
In Chapter 2, ZnPcs with tert-butyl groups, which minimized aggregation, were 
synthesized.  These groups introduced hydrophobicity to the macrocycles and thus reduced their 
solubility in aqueous media. The removal of the tert-butyl groups from the Pc macrocycles 
synthesized in this section resulted in enhanced solubility in aqueous medium. The synthesized 





groups that were used in the conjugation reactions. Introduction of the PEG groups enhanced the 
solubility of the ZnPcs and also served as spacers between the ZnPcs and the CEA.   
5.2.4. Syntheses of Pcs for Conjugation to the AntiCEA  
Water-soluble pegylated ZnPcs and a hexa-cationic ZnPc were synthesized for 
conjugation to the mAb. Water-solubility is critical since the mAb is stable in basic aqueous 
medium and thus conjugation was carried out in PBS. Conjugation of mAb to cationic 
porphyrins has been reported before.
52
 The conjugation was achieved in 0.5 M bicarbonate 
buffer (pH = 9.2). The conjugations were performed using 20, 40 and 60 equivalents of the 
porphyrins to obtain an average degree of loading (DOL) of 2. DOL is the number of 




The synthesis of the ZnPcs started with 3-nitrophthalonitrile or 4-nitrophthalonitrile, 
which reacted with either aminophenol or a diol in DMF solvent under heat to give various 
phthalonitriles. In Scheme 5.6, 2,3-dicyanohydroquinone was the starting reagent and served as 
the alcohol in the reaction. The synthetic strategies to these starting materials are shown in 
Schemes 5.5 – 5.7.  
Phthalonitrile 5.34 was obtained via reaction of 1,4-dioxane-2,6-dione with 5.33 in 92.1% 
yield. Reacting  tert-butyl-1,2-amino-4,7,10-trioxadodecanoate with 5.34 using coupling reagents 
DIEA, HOBt and TBTU, gave 5.35 in  92.2% yield. The crystal structures of phthalonitriles 
5.33, 5.35 and 5.36 are shown in Figure 5.9. The molecular structure of phthalonitrile 5.35 was 
grown in a mixed solvent systen of acetone/methanol (9:1) over a period of one month. The 
conditions favored the formation of the ester analog of the target phthalonitrile, as seen from X-













Figure 5.9. Molecular structures of phthalonitriles (a) 5.33, (b) 5.35 and (c) 5.36 from crystal 
structure determinations (N atoms are blue, O atoms red, S atoms orange and H atoms 
green). Ellipsoids are drawn at the 50% probability level.  
 Synthesis of ZnPc 5.40 was achieved according to a procedure previously reported in 
Chapter 2.
 
Phthalonitrile 5.35 was obtained by reacting phthalonitrile 5.34 with tert-butyl-
1,2-amino-4,7,10-trioxadodecanoate using DIEA, HOBt and TBTU in DMF at 25 °C.  
Phthalonitrile 5.35 was reacted with 3 equiv. phthalonitrile 5.36 at 140 ºC for 5 h in DMAE 
and in the presence of zinc(II) acetate, and a catalytic amount of DBN. The ZnPc 5.37 was 
obtained in 10.1% yield. Reacting ZnPc 5.37 with iodomethane in DMF, gave 5.38 in 98.0% 








Scheme 5.5. Synthesis of Pc-antiCEA conjugate 5.40. Conditions: (i) 1, 4-dioxane-2, 6-dione, 
DMF, r.t., (92.1%). (ii) tert-butyl-1,2-amino-4,7,10-trioxadodecanoate, DIEA, HOBt, TBTU, 
DMF, 48 h, r.t., (92.2%). (iii) phthalonitrile 5.36, zinc acetate, DBN, DMAE, 5 h, (10.1%) (iv) 
iodomethane, DMF, 2 days, r.t., (98%). (v) TFA, dichloromethane, 4 h, (quantitative). (vi) 
DIEA, HOBt, TBTU, monoclonal antibody, DMSO/NaHCO3. 
 Mono-pegylated phthalonitrile 5.42 was synthesized according to the literature 
procedure,
9
 and used in macrocyclization reaction with phthalonitrile to give mono-PEG-Pc 5.43 
(Scheme 5.6). Phthalonitrile 5.42 was mixed with 30 equiv. phthalonitrile in DMAE solvent, and 
heated at 140 ºC for 5 h in the presence of zinc(II) acetate and a catalytic amount of DBN. 
Purification of the crude product via column chromatography gave ZnPc 5.43 in 9.8% yield. 
Reacting ZnPc 5.43 with tert-butyl 3-(2-(2-(2-iodoethoxy)ethoxy)ethoxy)propanoate gave ZnPc 








Scheme 5.6. Synthesis of Pc-antiCEA conjugate 5.45. Conditions: (i) 1-iodo-2-(2-(2-
methoxyethoxy)-ethoxy)ethane, K2CO3, DMF, 65 °C, 24 h (42%). (ii) phthalonitrile, zinc 
acetate, DBN, DMAE, 5 h (9.8%). (iii) tert-butyl 3-(2-(2-(2-iodoethoxy)ethoxy)ethoxy)-
propanoate, K2CO3, DMF, 65 °C, 24 h (76.7%). (iv) TFA, dichloromethane, 4 h, (97.7%). (v) 
DIEA, HOBt, TBTU, monoclonal antibody, DMSO/NaHCO3. 
5.2.5. Conjugation of Pcs to AntiCEA 
Monopegylated ZnPc 5.46 was prepared according to the procedure described earlier in 
Chapter 3. Coupling ZnPcs 5.39, 5.44 and 5.46 with monoclonal antibody, antiCEA, using 
DIEA, HOBt and TBTU, in DMSO/NaHCO3 gave Pc-conjugates 5.40, 5.45 and 5.47 
respectively, which were purified using microspin columns. The mAb was reconstituted at 2 
mg/mL in 0.1 M NaHCO3 solution. Then ZnPcs 5.39, 5.44 and 5.46 (1 mg each) were dissolved 
in DMSO (50 µL) and DIPA (0.078 mg, 0.006 mmol) added. The mixture was stirred for 1 h, 
after which HOBt (0.34 mg, 0.002 mmol) and TBTU (0.59 mg, 0.002 mmol) were added and the 
reaction solutions stirred for 2 h. The reconstituted monoclonal antibody solution (500 µL) was 
added into each activated Pc solution and the solutions were kept with frequent shaking at room 







The crude of each antibody-Pc conjugate solution was purified by spin column 
chromatography (50 µL for each spin column to load, 3000 rpm, 1 min, 24 C). The resulting 
solutions were combined for each Pc, to afford the blue conjugate solution (600 - 700 µL).  
The PEG group on the ZnPcs significantly enhanced their solubility in organic solvents, 
which made their purification and characterization relatively easy. The solubility of ZnPc 5.46 in 
aqueous medium was relatively lower than that of ZnPc 5.44, which made conjugation reaction 
relatively less successful compared with Pc-conjugate 5.47. ZnPc 5.44 was soluble in aqueous 
medium, which made conjugation reaction a success (see Table 5.5). Of all the Pc-antiCEA 
conjugates, 5.47 was the one with the lowest UV-vis absorption, resulting in lower DOL. This 
can be associated to the tert-butyl groups on the macrocycle (which make it more hydrophobic) 
and it also has a single PEG compared with ZnPc 5.44, which has two PEG groups. Reduced 
solubility of the ZnPc in aqueous medium will affect conjugation reaction. The ZnPc precipitate 
will not label the mAb. Thus, the observed result was expected. 
 
Scheme 5.7. Synthesis of Pc-antiCEA conjugate 5.47. Conditions: (i) DIEA, HOBt, TBTU, 
monoclonal antibody, DMSO/NaHCO3. 
 All the ZnPcs 5.37, 5.38, 5.39, 5.43, 5.44, 5.45 and 5.46 were soluble in polar organic 
solvents, such as DMF, THF and methanol, while the cationic Pc 5.39 was water-soluble. 
Cationic Pc 5.39 remained aggregated in DMF, even upon sonication. Nonetheless, all Pcs 







solvents into 0.1 M NaHCO3 (final DMF or DMSO concentration of 1%) for 10 µM 
concentrations.  
The spectroscopic properties of the ZnPcs 5.38, 5.39, 5.43, 5.44 and 5.46 in DMF are 
summarized in Table 5.4. All ZnPcs showed strong Q absorptions and emissions in the near-IR 
between 679 – 686 nm in DMF, with small Stokes’ shifts between 2 – 4 nm, as is characteristic 
of this type of macrocycle.
31-33
 All the ZnPcs show a Soret absorption between 330 – 360 nm, a 
strong Q band between 678 – 696 nm and a vibrational band at around 620 nm, that strictly 
follow the Lambert-Beer law. The ZnPcs had fluorescence quantum yields in the range 0.10 – 
0.29 in DMF, as expected for this type of compounds.
32,33
 


















5.38 696 699 3 5.04 0.29 
5.39 696 698 2 4.94 0.21 
5.43 694 696 2 5.17 0.14 
5.44 688 691 3 5.18 0.22 
5.46 678 682 4 5.35 0.10 
a
 Excitation at 640 nm. 
b
 Calculated using ZnPc (Фf = 0.17) as the standard in DMF.  
Table 5.5. Estimated payloads (ZnPc per unit antiCEA) for various conjugates. 
ZnPc CCEA=[A280nm - (0.5 × 
AZnPc)]/εCEA 
CZnPc = AZnPc/εZnPc CZnPc/ CCEA 
5.40 2.560 × 10
-7
 1.918 × 10
-6
 7 
5.45 2.970 × 10
-7
 2.816 × 10
-6
 9 
5.47 1.454 × 10
-6
 2.199 × 10
-6
 2 
The concentrations for the above conjugates were obtained using samples which had been 
diluted five times. Therefore, the actual Pc concentrations are 3.8 × 10
-5
, 5.6 × 10
-5
 and 4.2 × 10
-5
 
M for Pc-antiCEA conjugates 5.40, 5.45 and 5.47 respectively. ZnPc 5.44 (5.0 × 10
-5







used as the control. The ZnPc/CEA ratio was determined by the measurements of absorbance at 
280 nm to estimate the concentration of antibody and absorbance at 353 nm, 337 nm and 338 nm 
to estimate the concentration of Pc 5.39, 5.44 and 5.46 respectively. The molar antibody and 
ZnPc concentrations were calculated by the formula CCEA=[A280nm - (0.5 × AZnPc)]/εCEA, CZnPc = 
AZnPc/εZnPc according to the literature;
47,52,54



















). The extinction coefficients of the 
ZnPcs were determined by dissolving the non-conjugated ZnPcs in 0.1 M NaHCO3 containing 
0.1% DMSO. 
5.2.6. Preliminary Animal Studies 
 The ZnPc conjugate 5.45 with Pc concentrations of 5.6 × 10
-5
 M for Pc-antiCEA 
conjugate, and ZnPc 5.44 (5.0 × 10
-5
 M) as a control, were used in the study. Both the conjugate 
and the unconjugated ZnPc were both visible in the tumor at 1 h and diffused slightly by 6 h 
(Figure 5.10 and 5.11 respectively). There was appreciable regional tissue retention of the Pc-
CEA conjugate 5.45 in the tumor at 24 h, while Pc alone showed dissipation. At 96 h post 
injection, the dyes were not detectable, contrary to the observations made earlier in Chapter 3, 
where Pc-EFGR-L1 conjugate 3.11 was used during in vivo studies. Of all the Pcs prepared, 5.45 
was chosen for preliminary studies in mice due to the low DOL of ZnPc 5.47 and the apparently 
lower fluorescence intensity of ZnPc 5.40. 
After injection of Pc-antiCEA conjugate 5.45 and Pc 5.44 into a non-tumor bearing 
mouse, both dyes were retained for a few hours, but diffused away within 24 hours (Figure 5.12). 
This result suggests that the antiCEA in Pc-antiCEA conjugate 5.45 enhances the targeting 
specificity after intratumoral injection. The result is in agreement with our previous observations 








Figure 5.10. Fluorescent images (exc 630 nm/em 700 nm) of nude mice bearing subcutaneous 
tumor implants of HT-29 cancer cells taken at various times following intratumoral 
administration of Pc-antiCEA conjugate 5.45.  
 
Figure 5.11. Fluorescent images (exc 630 nm/em 700 nm) of nude mice bearing subcutaneous 
tumor implants of HT-29 cancer cells taken at various times following intratumoral 








Figure 5.12. Fluorescent images (exc 630 nm/em 700 nm) of nude mice bearing no tumor 
implants of cancer cells, taken at various times following intratumoral administration of Pc-
antiCEA conjugate 5.45 and Pc 5.44 in mice.  
5.3. Conclusions 
Ten dicationic ZnPcs were investigated in human carcinoma HEp2 cells for their 
biological properties for possible in vivo applications. The ZnPcs were A3B-type, synthesized via 
statistical condensation of two different phthalonitriles. The Pcs with the cationic charge non-
peripherally substituted on the ring were found to be more phototoxic (> 5-fold) than their 
peripherally substituted counterparts. ZnPc 5.27 was more phototoxic (IC50 = 8.7 µM at 1.5 
J/cm
2
) than 5.4 (IC50 = 10.7 µM), although their localization in the ER and favorable interaction 
with important biological targets made them the most phototoxic among the series. In addition, a 
PEG group on the macrocycle and/or the positive charges in close proximity are likely to boost 
phototoxicity. Markedly, the β-substituted ZcPcs 5.15 and 5.17 accumulated the most within 





substitution and close proximity of charges) and the subcellular localization of the positively 
charged ZnPcs, and not the degree of their cellular uptake, which determine their photodynamic 
activity for the synthesized ZnPcs. 
The antiCEA conjugate investigations have also shown that Pc-antiCEA conjugates can 
be used for near-IR fluorescence imaging of cancers over-expressing CEA, such as CRC. Due to 
the hydrophobic nature of the Pc macrocycle, two low molecular PEG linkers were required for 
adequate aqueous solubility and receptor targeting ability. Pc-antiCEA conjugate 5.45 had 
equivalent or superior tumor uptake and retention compared to uncoupled Pc 5.44 after 
intratumoral injection. Both dyes diffused regionally after injection and then dissipated within 24 
h in non-tumor mice. 
5.4. Methods and Materials 
5.4.1. Syntheses 
The reagents and solvents were all obtained from suppliers and used without additional 
purification. Antibody, mAb to Carcinoembryonic Ag Monoclonal Antibody to Human 
Carcinoembryonic Antigen (CEA), was obtained from Meridian Life Science Inc. (catalog # 
H45655M, 5.71 mg/mL, OD 280 nm). MicroSpin
TM
 G-25 Columns were bought from 
Amersham Biosciences. Purification of conjugates was performed on an AccuSpin Micro 17 
Centrifuge (Fisher Scientific) at 25 °C. Silica chromatographic gel 60 (230×400 mesh, Sorbent 
Technologies), Sephadex G-100 and LH-20 (Amersham Biosciences) were used for purification 
of the ZnPcs. Thin-layer chromatography (TLC) for analytical purposes was carried out using 
polyester backed TLC plates 254 (precoated, 200 μm) from Sorbent Technologies. The NMR 
spectroscopy was performed using an AV-400 LIQUID Bruker spectrometer (400 MHz for 
1
H, 
100 MHz for 
13





solvents as internal orientation: DMF-d7 8.03 ppm (
1
H), 163.15 ppm (
13
C); CD3COCD3 2.04 
ppm (
1
H), 29.92 ppm (
13
C); THF-d8 3.58 ppm (
1
H), 67.57 ppm (
13





C); DMSO-d6 2.50 ppm (
1
H), 39.51 ppm (
13
C). MALDI-TOF mass spectra were 
performedd on a Bruker UltrafleXtreme (MALDI-TOF/TOF) with 4-chloro-α-cyanocinnamic 
acid as the matrix. The high resolution ESI mass spectra were recorded using Agilent 
Technologies 6210 TOF LC/MS spectrometer. The UV-vis spectra were measured on a UV-vis 
NIR scanning spectrophotometer; a 10 mm path length quartz cuvette was used. The stock 
solutions (1.0 mM, 1.0 mL each) of all the ZnPcs in HPLC grade DMF solvent were diluted by 
spiking 20 – 80 µL of each stock solution into DMF (10 mL) and their absorbances recorded. 
Emissions were recorded on a Fluorolog® - HORIBA JOBINVYON, Model LFI-3751 
spectrofluorimeter. The optical densities were kept within 0.04 – 0.05 at excitation wavelengths 
for the solutions used in emission studies to minimize re-absorption by the photosensitizers. The 
experiments were performed within 4 h after solution preparation between 23-25 °C. The ZnPcs 
5.1, 5.2, 5.12 and 5.13 were synthesized as described previously in Chapters 2 and 3. 
 ZnPc 5.3. To a mixture of ZnPc 5.2 (20.0 mg, 0.017 mmol) in DMF (0.4 mL) were added 
in the sequence: Et3N (3.3 mg, 0.032 mmol), HOBt (4.7 mg, 0.035 mmol), 1,4-bis-Boc-
triazaheptane (7 mg, 0.023 mmol), and EDCI (4.0 mg, 0.026 mmol). The mixture was stirred at 
25 °C for 4 days, diluted with ethyl acetate (40 mL) and washed with water (2 × 20 mL). The 
organic phase was dried over anhydrous Na2SO4 and the solvent removed under reduced 
pressure. The crude product was purified by column chromatography using DCM/methanol for 
elution, to afford a blue solid (20.2 mg, 81.8%). 
1
H NMR (DMSO-d6): δ 9.33-9.03 (m, 6H, Ar-
H), 8.30-8.07 (m, 5H, Ar-H), 7.84-7.44 (m, 5H, Ar-H), 7.20 (br, 1H, N-H), 6.79 (br, 1H, N-H), 





2H, CH2NH), 3.00 (br, 2H, CH2NH), 2.31-2.20 (m, 2H, CH2CO), 1.80–1.76 (m, 27H, C(CH3)3), 
1.37-1.34 (m, 18H, -OC(CH3)3). 
13
CNMR (DMSO-d6): δ 171.0, 170.1, 168.9, 167.4, 167.3 
(C=O), 155.6, 155.3, 154.7, 152.9, 152.6, 151.5, 150.8, 150.4, 150.2, 140.2, 138.1, 137.9, 137.6, 
135.8, 135.2, 133.1, 132.4, 130.6, 128.3, 127.4, 127.0, 122.5, 122.0, 121.8, 121.5, 118.9, 118.6, 
117.7, 117.4, 115.8 (Ar-C), 78.5, 77.5 (-OC(CH3)3), 70.6, 70.5, 70.4, 69.6, 69.5, 68.8, 66.7 
(OCH2), 46.7, 46.2, 38.2, 36.1, 35.7, 35.6 (N-CH2), 31.8 (Ar-C(CH3)3), 28.2, 28.0 (O-C(CH3)3). 
MS (MALDI-TOF) m/z 1455.650 [M]
+
, calcd for C77H93N13O12Zn 1455.636. The blue solid 
(20.2 mg, 0.014 mmol) was dissolved in a 1:1 mixture of DCM/trifluoroacetic acid (TFA) (6 
mL) and stirred at 0 C for 3 h. Solvent was removed and the residue treated with 2N NaOH (10 
mL) to afford the title ZnPc as a blue solid (15.5 mg, 89.0 %). 
1
H NMR (DMF-d7): δ 9.59-9.07 
(m, 6H, Ar-H), 8.41-8.32 (m, 4H, Ar-H), 8.12-8.06 (m, 1H, Ar-H), 7.92-7.85 (m, 2H, Ar-H), 
7.60-7.53 (m, 2H, Ar-H), 6.96 (br, 1H, N-H), 4.23-4.10 (m, 4H, CH2O), 3.57-3.28 (m, 20H, 
CH2O), 2.13-2.03 (m, 2H, CH2CO), 1.79-1.75 (m, 27H, C(CH3)3). 
13
CNMR (DMF-d7): δ 171.2, 
171.1, 170.4, 168.8, 168.7, 157.3, 156.8, 155.9, 155.7, 155.5, 155.4, 155.0, 154.8, 154.6, 154.3, 
154.2, 153.9, 153.7, 152.9, 152.7, 152.3, 152.1, 142.6, 140.1, 139.8, 137.7, 137.4, 134.7, 134.3, 
131.7, 131.5, 130.6, 128.50, 128.3, 124.0, 123.6, 123.4, 123.2, 122.6, 122.4, 120.7, 120.1, 120.0, 
119.8, 119.6, 119.0118.3, 117.6, 117.1 (Ar-C), 72.4, 72.13, 72.08,  71.1, 71.0, 70.9, 70.24, 70.20, 
68.3, 68.0 (O-C(CH3)3), 48.9, 48.7, 39.6, 39.3, 38.7, 37.5, 37.3, 36.8 (N-CH2), 32.7, 32.6 (m, 
27H, C(CH3)3). MS (MALDI-TOF) m/z 1255.633 [M]
+
, calcd for C67H77N13O8Zn 1255.531. UV-
vis (DMF): λmax (log ε) 350 (5.00), 612 (4.77), 680 (5.52) nm. 
ZnPc 5.4. ZnPc 5.3 (20.0 mg, 0.015 mmol), DIPA (0.015 mL, 0.107 mmol) and CH3I 
(0.2 mL) were dissolved in dry DMF (0.5 mL), and the final solution stirred at 25 °C for 2 days. 





G-100 using DCM/methanol to afford a blue solid (17.2 mg, 68.3%). 
1
H NMR (DMF-d7): δ 
9.57-9.06 (m, 7H, Ar-H), 8.38-8.18 (m, 5H, Ar-H), 7.94-7.84 (m, 3H, Ar-H), 7.61-7.54 (m, 2H, 
Ar-H), 4.29-4.13 (m, 8H, CH2O), 3.62-3.44 (m, 18H, CH2O/N-CH2/N-CH3), 3.28 (s, 9H, N-
CH3), 2.47-2.30 (m, 2H, COCH2), 1.78 (s, 27H, C(CH3)3). 
13
C NMR (DMF-d7): δ 172.6, 170.5, 
168.8, 168.7 (C=O), 157.1, 156.4, 155.8, 155.5, 155.3, 154.5, 154.2, 154.1, 153.9, 153.8, 153.5, 
152.8, 152.7, 152.3, 142.7, 140.3, 140.2, 139.9, 137.8, 137.5, 134.9, 134.4, 131.4, 130.5, 129.7, 
128.3, 128.1, 123.5, 123.3, 123.2, 123.1, 122.7, 122.5, 121.9, 120.4, 120.0, 119.8, 119.7, 118.9, 
117.5 (Ar-C), 72.2, 72.0, 71.1, 71.0, 67.9 (CH2O), 64.6, 64.4, 58.6, 57.1, 54.3, 52.4 (N-CH3), 










UV–Vis (DMF): λmax (log ε) 348 (4.81), 611 (4.55), 679 (5.32) nm. 
  ZnPc 5.5. A procedure related to that described for ZnPc 5.3 was used: ZnPc 5.1 (40.0 
mg, 0.04 mmol), DMF (0.5 mL), Et3N (5.2 mg, 0.051 mmol), HOBt (7.5 mg, 0.055 mmol), 1,4-
bis-Boc-triazaheptane (15.5 mg, 0.051 mmol) and EDCI (9.8 mg, 0.051 mmol). The protected 
ZnPc was achieved as a blue solid (38.6 mg, 77.0%). 
1
H N MR (DMF-d7): δ 9.60-9.03 (m, 6H, 
Ar-H), 8.40-8.20 (m, 5H, Ar-H), 7.96-7.79 (m, 3H, Ar-H), 7.61–7.50 (m, 2H, Ar-H), 6.73 (br, 
1H, N-H), 4.26–4.12 (m, 4H, CH2O), 3.38–3.26 (m, 6H, CH2NH), 3.20–3.16 (m, 2H, CH2NH), 
1.82–1.78 (m, 27H, C(CH3)3), 1.42–1.32 (m, 18H, -OC(CH3)3). 
13
C NMR (DMF-d7): δ 170.4, 
168.6 (C=O), 157.1, 156.8, 156.5, 156.2, 155.5, 155.4, 155.3, 155.2, 155.0, 154.6, 154.4, 154.3, 
154.2, 154.1, 153.5, 152.5, 152.1, 142.3, 140.0, 139.9, 139.6, 137.6, 137.5, 137.2, 135.0, 134.5, 
131.7, 130.1, 129.4, 128.6, 128.4, 123.6, 123.5, 122.7, 122.5, 122.0, 120.4, 120.1, 120.0, 119.8, 
119.7, 119.0, 118.9, 117.5 (Ar-C), 79.9, 78.7 (-OC(CH3)3), 72.3, 72.0 (OCH2), 48.4, 48.2, 47.6, 





TOF) m/z 1053.438 [M-2Boc+H]
+
, calcd for C58H61N12O4Zn 1053.423. The blue solid (51.6 mg, 
0.044 mmol) was dissolved in 1:1 DCM/TFA (6 mL) and stirred at 0 C for 3 h. The solvent was 
evaporated and the residue treated with 2N NaOH (10 mL) to obtain a blue-greenish solid (38.2 
mg, 89.2 %). 
1
H NMR (DMF-d7): δ 9.62-9.12 (m, 7H, Ar-H), 8.63-8.31 (m, 5H, Ar-H), 7.99–
7.88 (m, 3H, Ar-H), 7.65–7.58 (m, 2H, Ar-H), 4.29–4.17 (m, 4H, CH2O), 4.01 (br, 4H, NH2), 
3.63–3.55 (m, 6H, CH2NH), 3.38–3.35 (m, 2H, CH2NH), 1.81 (s, 27H, C(CH3)3). 
13
C NMR 
(DMF-d7): δ  171.4, 168.6 ,168.5 (C=O), 161.2, 160.9, 160.6, 160.2, 157.1, 156.4, 155.9, 155.8, 
155.6, 155.5, 154.9, 154.8, 154.7, 154.6,154.0, 153.8, 153.7, 153.6, 153.3, 152.7, 152.3,  142.8, 
140.5, 140.3, 140.0, 138.0, 137.9, 137.6, 134.8, 134.3, 131.2, 130.5, 129.9, 128.1, 127.9, 123.4, 
123.2, 122.9, 122.7, 122.5, 121.9, 120.3, 120.0, 119.8, 119.7, 119.6, 118.7, 117.4, 116.8 (Ar-C), 
72.1, 71.8 (OCH2), 48.4, 46.0, 37.3, 36.7 (N-CH2), 32.7, 32.5 (Ar-C(CH3)3).  MS (MALDI-TOF) 
m/z 1053.433 [M+H]
+
, calcd for C58H61N12O4Zn 1053.423. UV-vis (DMF): λmax (log ε) 350 
(4.66), 612 (4.42), 680 (5.19) nm. 
ZnPc 5.6. A procedure related to that described for ZnPc 5.4 was used: ZnPc 5.5 (20.0 
mg, 0.021 mmol), DIPA (0.015 mL, 0.107 mmol), CH3I (0.2 mL) and dry THF (0.5 mL). The 
product was attained as a pale-green solid (14.7 mg, 53.3%). 
1
H NMR (DMF-d7): δ 9.56-9.06 
(m, 6H, Ar-H), 8.36-8.24 (m, 4H, Ar-H), 7.96-7.80 (m, 4H, Ar-H), 7.58-7.51 (m, 2H, Ar-H), 
4.34-4.13 (m, 8H, CH2O/N-CH2), 3.80-3.67 (m, 4H, N-CH2), 3.62-3.47 (m, 6H, N-CH3), 3.41-
3.27 (m, 9H, N-CH3), 1.79-1.71 (m, 27H, C(CH3)3). 
13
C NMR (DMF-d7): δ 171.3, 168.7, 168.6, 
168.4, 157.2, 156.7, 155.9, 155.8, 155.7, 155.6, 155.5, 155.43, 155.36, 155.1, 155.0, 154.9, 
154.8, 154.7, 154.6, 154.5, 154.1, 154.0, 153.8, 153.7, 153.6, 153.5, 153.2, 152.7, 152.63, 
152.55, 152.33, 152.27, 152.2, 142.8, 140.4, 140.3, 140.0, 137.9, 137.6, 134.7, 134.3, 133.4, 





120.0, 119.9, 119.8, 119.7, 119.6, 119.5, 118.6, 117.3 (Ar-C), 72.0, 71.9, 71.8, 71.4 (CH2O), 
66.9, 66.6, 64.9, 64.5, 58.6, 58.5, 57.1, 54.3, 52.40, 52.35 (N-CH3), 36.8, 36.7 (N-CH2) 32.7, 
32.6 (C(CH3)3). MS (MALDI-TOF) m/z 1238.544 [M-I-CH3+2H]
+
, calcd for C62H71IN12O4Zn 
1238.406. UV–Vis (DMF): λmax (log ε) 357 (4.72), 611 (4.46), 679 (5.23) nm 
ZnPc 5.7. A procedure related to that described for ZnPc 5.3 was used: ZnPc 5.1 (50.0 
mg, 0.05 mmol), DMF (0.8 mL), Et3N (6.2 mg, 0.061 mmol), HOBt (9.3 mg, 0.069 mmol), 
aspartic acid di-tert-butyl ester hydrochloride (18 mg, 0.064 mmol) and EDCI (12.3 mg, 0.064 
mmol). The crude was purified on a  silica column chromatography eluted by DCM/methanol 
(98/2), to give the di-ester ZnPc as a blue solid (0.052 g, 87.1%). 
1
H NMR (DMF-d7): δ 10.09, 
10.05 (s, 1H, N-H), 9.63-9.28 (m, 6H, Ar-H), 9.19-9.01 (m, 1H, Ar-H), 8.47-8.20 (m, 5H, Ar-H), 
7.97-7.79 (m, 3H, N-H), 7.62-7.47 (m, 2H, N-H), 4.55-4.45 (m, 1H, N-H), 4.28-4.19 (m, 4H, 
CH2O), 2.96-2.67 (m, 3H, CH2), 1.81–1.77 (m, 27H, C(CH3)3), 1.45-1.36 (m, 18H, -OC(CH3)3). 
13
C NMR (DMF-d7): δ 170.9, 170.7, 170.4, 170.0, 168.7 (C=O), 156.8, 156.2, 155.6, 155.4, 
154.5, 154.3, 154.1, 153.6, 152.5, 152.2, 142.3, 140.0,139.9, 139.6, 1137.5, 137.5, 137.2, 135.2, 
134.6, 131.8, 130.2, 129.5, 128.8, 128.5, 123.7, 123.5, 123.3, 122.5, 122.3, 120.4, 120.1, 119.9, 
119.7, 119.0, 117.6 (Ar-C), 82.4, 81.7 (-OC(CH3)3), 72.3, 71.9 (OCH2), 50.4, 38.4, 36.8 (N-
CH2), 32.7, 32.6 (Ar-C(CH3)3), 28.4, 28.3 (O-C(CH3)3). MS (MALDI-TOF) m/z 1083.625 [M-
2C4H9+H]
+
, calcd for C58H55N10O8Zn 1083.350. The solid (0.052 g, 0.044 mmol) was dissolved 
in 1:1 DCM/TFA (8 mL) and stirred for 4 h at 0°C. The tert-butyl group was removed as 
described for ZnPc 5.5 to give the product as a blue solid (34.3 mg, 82.3 %). (MALDI-TOF) m/z 
1195.180 [M+Na]
+
, calcd for C58H54N10NaO8Zn 1105.332. UV-vis (DMF): λmax (log ε) 349 





ZnPc 5.8. A procedure related to that described for ZnPc 5.3 was used: ZnPc 5.7 (18.4 
mg, 0.017 mmol), DMF (0.5 mL), Et3N (6.2 mg, 0.061 mmol), HOBt (5.7 mg, 0.042 mmol), N-
Boc-2,2′-(ethylenedioxy)diethylamine (9.4 mg, 0.038 mmol) and EDCI (6.5 mg, 0.042 mmol). 
The crude was purified on a silica column eluted by DCM/methanol (95:5) to obtain a blue solid 
(13.6 mg, 51.9 %). 
1
H NMR (DMF-d7): δ 9.59-9.08 (m, 6H, Ar-H), 8.50-8.27 (m, 5H, Ar-H), 
7.99-7.74 (m, 5H, Ar-H), 7.61-7.53 (m, 2H, Ar-H), 6.65 (br, 1H, Ar-H), 4.77–4.71 (m, 1H, 
NHCH(CH2)CO), 4.28–4.16 (m, 4H, CH2O), 3.48–3.36 (m, 14H, CH2O), 3.31–3.16 (m, 8H, 
CH2O), 2.75–2.67 (m, 2H, CHCH2CO), 1.81–1.76 (m, 27H, C(CH3)3), 1.37 (s, 18H, OC(CH3)3). 
13
C NMR (DMF-d7): δ 171.90, 171.86, 171.35, 171.28, 170.3, 168.7, 168.6 (C=O), 157.1, 155.4, 
155.3, 154.5, 153.6, 152.6, 142.4, 140.0, 137.6, 135.1, 134.6, 132.5, 131.8, 129.9, 128.7, 123.4, 
122.6, 122.4, 120.1, 119.0, 117.6 (Ar-C), 78.7 (OC(CH3)3), 72.1, 71.9, 71.0, 70.95, 70.7, 70.4, 
70.3 (CH2O), 51.1 (NHCH(CH2)CO), 41.2, 40.1, 38.4, 36.8 (CH2), 32.7, 32.6 (C(CH3)3), 28.9 
(OC(CH3)3). MS (MALDI-TOF) m/z 1542.669 [M]
+
, calcd for C80H98N14O14Zn 1542.668. The 
solid ZnPc (13.1 mg, 8.5 mmol) was dissolved in DCM/TFA (1:1) and stirred at 0°C for 3 h. The 
solvent was evaporated and the residue treated with 2N NaOH (10 mL) to obtain a blue solid 
(10.5 mg, 92.3%). 
1
H NMR (DMF-d7): δ 9.60-9.10 (m, 7H, Ar-H), 8.60-8.29 (m, 5H, Ar-H), 
7.95-7.87 (m, 2H, Ar-H), 7.56–7.51 (m, 2H, Ar-H), 4.56 (br,  1H, NH), 4.21 (d, 9.48 Hz, 2H, 
CH2O), 4.16 (d, 8.92 Hz, 2H, CH2O), 3.75–3.35 (m, 10H, CH2O), 3.16–2.95 (m, 9H, CH2O), 
2.90–2.80 (m, 3H, CH2O), 2.90–2.80 (m, 3H, CH2O), 2.62-2.47 (m, 2H, CH2), 2.19 (br, 2H, 
NH2), 1.80–1.74 (m, 27H, C(CH3)3). 
13
C NMR (DMF-d7): δ 171.8, 171.3, 171.2, 170.2, 168.6, 
168.5, 157.7, 157.4, 155.9, 155.6, 155.5, 155.0, 154.3, 154.2, 154.1, 154.0, 153.7, 152.4, 151.7, 
142.4, 140.1, 139.8, 137.7, 137.3, 134.4, 134.1, 131.7, 130.8, 128.5, 123.7, 123.4, 123.1, 122.5, 





51.2 (NHCH(CH2)CO), 40.9, 39.9, 39.8, 38.1, 36.8 (CH2), 32.7, 32.6 (C(CH3)3). MS (MALDI-
TOF) m/z 1343.610 [M+H]
+
, calcd for C70H83N14O10Zn 1343.571. UV-vis (DMF): λmax (log ε) 
349 (4.70), 612 (4.45), 680 (5.20) nm. 
ZnPc 5.9. A procedure related to that described for ZnPc 5.4 was used: ZnPc 5.8 (20.0 
mg, 0.015 mmol), DIPA (0.015 mL, 0.107 mmol), CH3I (0.2 mL) and dry DMF (0.5 mL). The 
product was attained as a blue solid (17.2 mg, 68.3%). 
1
H NMR (DMF-d7): δ 9.57-9.33 (m, 5H, 
Ar-H), 9.20-9.05 (m, 1H, Ar-H), 8.52-8.28 (m, 4H, Ar-H), 7.95-7.84 (m, 4H, Ar-H), 7.61-7.52 
(m, 2H, Ar-H), 4.31-4.11 (m, 4H, OCH2), 3.93 (br, 2H, NH), 3.71-3.40 (m, 27H, OCH2/N-CH3), 
3.33-3.29 (m, 10H, N-CH3), 1.80-1.76 (m, 27H, C(CH3)3). MS (MALDI-TOF) m/z 1427.749 [M-
2I-H]
+
, calcd for C76H95N14O10Zn
+
 1427.665. UV–Vis (DMF): λmax (log ε) 348 (4.48), 612 
(4.23), 680 (5.01) nm. 
ZnPc 5.10. A procedure related to that described for ZnPc 5.3 was used: ZnPc 5.7 (18.4 
mg, 0.017 mmol), DMF (0.5 mL), Et3N (6.2 mg, 0.061 mmol), HOBt (5.7 mg, 0.042 mmol), N-
Boc-ethylenediamine (6.1 mg, 0.038 mmol) and EDCI (6.5 mg, 0.042 mmol). The mixture was 
stirred for 4 days at 25 °C. The solvent was evaporated and the residue treated with 2N NaOH 
(10 mL) to obtain a blue solid (13.4 mg, 57.8 %). 
1
H NMR (DMF-d7): δ 9.59-9.21 (m, 6H, Ar-
H), 8.45-8.23 (m, 4H, Ar-H), 8.12-7.82 (m, 3H, Ar-H), 7.62–7.52 (m, 2H, Ar-H), 6.73-6.66 (m, 
2H, Ar-H), 4.75-4.71 (m, 1H, NH), 4.28–4.18 (m, 4H, CH2O), 3.29–3.11 (m, 8H, CH2NH), 2.70-
2.65 (m, 2H, CH2CO), 1.81–1.77 (m, 27H, C(CH3)3), 1.41–1.34 (m, 18H, C(CH3)3). 
13
C NMR 
(DMF-d7): δ 172.1, 172.0, 171.5, 171.4, 170.3, 168.7, 168.6, 157.2, 157.1, 155.6, 155.4, 155.2, 
154.4, 154.1, 153.7, 153.6, 152.6, 152.3, 142.3, 139.9, 139.7, 137.6, 137.2, 135.1, 134.6, 131.8, 
130.1, 129.4, 128.6, 128.5, 123.5, 122.6, 122.4, 122.0, 120.1, 119.7, 119.1, 119.0, 117.7 (Ar-C), 












, calcd for C62H66N14O6Zn 1166.4581, 
C62H66NaN14O6Zn 1189.4479, C62H66KN14O6Zn 1206.4218 respectively. The ZnPc (13.1 mg, 
0.0096 mmol) was dissolved in a mixture of DCM/TFA (1:1) at 0 °C for 3h. The solvent was 
evaporated and the residue treated with 2N NaOH (10 mL) to obtain a blue solid (10.1 mg, 
90.1%). 
1
H NMR (THF-d8): δ 9.58-9.08 (m, 7H, Ar-H), 8.39-8.07 (m, 4H, Ar-H), 7.82-6.86 (m, 
5H, Ar-H), 4.15-3.76 (m, 4H, CH2O), 3.57–3.20 (m, 8H, CH2NH), 2.28-2.13 (m, 2H, CH2CO), 
1.80–1.72 (m, 27H, C(CH3)3). 
13
C NMR (DMF-d7): δ 171.2, 171.0, 169.6, 168.2, 157.7, 155.8, 
155.7, 155.0, 154.4, 153.9, 153.5, 151.6, 142..4, 140.1,139.8, 139.5, 137.7, 137.2, 133.4, 131.9, 
130.4, 128.5, 128.3, 123.9, 123.4, 122.2, 121.9, 120.8, 120.4, 119.9, 119.8, 117.1, 116.6 (Ar-C), 
71.7, 71.6 (CH2NH), 50.7 (NHCH(CH2)CO), 40.7, 40.2, 36.8, 36.7 (CH2), 32.8, 32.7, 32.6 
(C(CH3)3). MS (MALDI-TOF) m/z 1166.503 [M-2Boc]
+
, calcd for C62H66N14O6Zn 1166.4581. 
UV-vis (DMF): λmax (log ε) 349 (4.72), 613 (4.48), 680 (5.23) nm. 
ZnPc 5.11. A procedure related to that described for ZnPc 5.4 was used: ZnPc 5.10 (20.0 
mg, 0.017 mmol), DIPA (0.015 mL, 0.107 mmol), CH3I (0.2 mL) and dry THF (0.5 mL). After 
purification, the title ZnPc was obtained (15.2 mg, 58.9%). 
1
H NMR (DMF-d7): δ 9.56-8.80 (m, 
10H, Ar-H), 8.38-8.24 (m, 4H, Ar-H), 7.96-7.85 (m, 3H, Ar-H), 7.62-7.54 (m, 2H, Ar-H), 7.16 
(d, 8.6Hz, 1H, Ar-H), 6.90 (d, 8.2Hz, 1H, Ar-H), 4.22-4.09 (m, 4H, OCH2), 3.38-3.29 (m, 8H, N-
CH2), 3.11-3.02 (m, 18H, N-CH3), 1.92-1.73 (m, 27H, C(CH3)3). 
13
C NMR (d-DMF): δ 172.8, 
172.7, 171.7, 170.8, 168.9, 168.8 (C=O), 157.9, 155.9, 155.7, 155.4, 154.9, 153.9, 153.8, 153.6, 
144.2, 142.9, 140.4, 140.1, 138.0, 137.7, 134.7, 134.2, 128.7, 128.1, 123.4, 123.2, 122.8, 122.7, 





(N-CH3), 32.7, 32.6 (C(CH3)3). MS (MALDI-TOF) m/z 1209.761 [M-3CH3-2I]
+
, calcd for 
C65H73N14O6Zn
+
 1209.513. UV–Vis (DMF): λmax (log ε) 348 (4.65), 612 (4.42), 679 (5.19) nm. 
ZnPc 5.14. A procedure related to that described for ZnPc 5.3 was used: ZnPc 5.13 (20.0 
mg, 0.017 mmol), DMF (0.4 mL), Et3N (3.2 mg, 0.032 mmol), HOBt (4.7 mg, 0.035 mmol), 1,4-
bis-Boc-triazaheptane (7 mg, 0.023 mmol) and EDCI (4.0 mg, 0.026 mmol). The crude was 
purified as described above to obtain a blue solid (19.7 mg, 79.6%). 
1
H NMR (DMF-d7): δ 9.32-
8.67 (m, 8H, Ar-H), 8.35-8.30 (m, 4H, Ar-H), 8.15-8.04 (m, 2H, Ar-H), 7.94-7.82 (m, 2H, Ar-
H), 7.64-7.59 (m, 2H, Ar-H), 6.90 (br, 1H, N-H), 4.39 (d, J = 13.6, 2H, CH2O), 4.30 (d, J = 9.76, 
2H, CH2O), 3.73-3.68 (m, 4H, CH2O), 3.62-3.56 (m, 14H, CH2O), 3.51-3.47 (m, 2H, CH2NH), 
3.35-3.19 (m, 8H, CH2NH), 2.47-2.42 (m, 2H, CH2CO), 1.86–1.82 (m, 27H, C(CH3)3), 1.45-1.36 
(m, 18H, -OC(CH3)3). 
13
C NMR (DMF-d7): δ 172.4, 171.5, 170.6, 169.2, 169.1 (C=O), 161.0, 
160.4, 157.1, 156.3, 154.4, 153.9, 139.1, 138.9, 136.7, 136.3, 133.7, 128.7, 125.3, 123.5, 122.8, 
122.0, 121.5, 121.1, 120.8, 120.3, 115.0, 112.8, 111.6 (Ar-C), 79.9, 78.7 (O-C(CH3)3), 72.4, 
72.20, 72.16, 71.3, 71.2, 71.12, 71.06, 70.4, 68.2, 67.9 (OCH2), 48.6, 48.3, 46.1 39.7, 38.9, 37.6, 









; calcd for C72H85N13O10Zn 1355.583, C67H77N13O8Zn 
1255.531. The blue solid (19.0 mg, 0.013 mmol) was dissolved in 1:1 DCM/TFA (6 mL) and 
stirred at 0 C for 3 h. The crude product was treated as described for ZnPc 5.3 above to give a 
blue solid (14.9 mg, 90.7 %). 
1
H NMR (DMF-d7): δ 9.56-8.89 (m, 8H, Ar-H), 8.39-8.31 (m, 4H, 
Ar-H), 8.08-7.92 (m, 2H, Ar-H), 7.55-7.51 (m, 2H, Ar-H) 4.36 (d, J = 6.88, 2H, CH2O), 4.26 (d, 
J = 6.64, 2H, CH2O), 3.56-3.25 (m, 24H, CH2O), 2.38-2.22 (m, 2H, CH2CO), 1.80-1.76 (m, 27H, 
C(CH3)3). 
13
CNMR (DMF-d7): δ 171.3, 170.6, 169.2, 169.1, 160.6, 160.3, 155.2, 155.1, 154.8, 





122.8, 121.3, 120.7, 119.8, 115.0, 112.6, 111.5, 111.0 (Ar-C), 72.4, 72.2, 71.2, 71.1, 70.9, 70.3, 
68.1 (O-C(CH3)3), 48.9, 48.1, 39.7, 39.3, 37.5, 37.3  (N-CH2), 32.6 (m, 27H, C(CH3)3).  MS 
(MALDI-TOF) m/z 1255.555 [M]
+
, calcd for C67H77N13O8Zn 1255.531. UV-VIS (DMF): λmax 
(log ε) 351 (4.81), 612 (4.53), 677 (5.28) nm. 
  ZnPc 5.15. A procedure related to that described for ZnPc 5.4 was used: ZnPc 5.14 (20.0 
mg, 0.015 mmol), DIPA (0.015 mL, 0.107 mmol), CH3I (0.2 mL) and dry DMF (0.5 mL). The 
title ZnPc was attained as a blue solid (16.2 mg, 64.3%). 
1
H NMR (DMF-d7): δ 9.57-9.26 (m, 
7H, Ar-H), 8.38-8.18 (m, 5H, Ar-H), 7.94-7.84 (m, 2H, Ar-H), 7.61-7.48 (m, 2H, Ar-H), 4.35-
4.23 (m, 8H, CH2O), 3.81-3.48 (m, 18H, CH2O/N-CH2/N-CH3), 3.46 (s, 9H, N-CH3), 2.47-2.30 
(m, 2H, COCH2), 1.85-1.76 (m, 27H, C(CH3)3). 
13
C NMR (DMF-d7): δ 173.0, 172.6, 172.4, 
170.6, 169.2, 169.1 (C=O), 160.6, 160.2, 155.1, 154.9, 154.6, 154.0, 153.9, 153.2, 141.4, 140.0, 
139.9, 137.6, 137.4, 136.5, 136.2, 134.9, 134.6, 129.5, 128.7, 128.4, 125.0, 123.3, 122.8, 121.3, 
121.1, 120.7, 119.8, 115.0, 112.6, 111.5 (Ar-C), 72.4, 72.2, 71.2, 71.1, 70.3, 68.0 (CH2O), 64.6, 
64.4, 58.6, 57.2, 55.9, 54.4, 52.5, 49.9, 48.0 (N-CH3), 43.2, 39.7, 37.5, 36.8 (N-CH2) 32.6 
(C(CH3)3). MS (MALDI-TOF) m/z 1493.710 [M-I+K]
+
, calcd for C72H89IKN13O8Zn
+
 1493.493. 
UV–Vis (DMF): λmax (log ε) 351 (4.84), 610 (4.54), 677 (5.30) nm. 
  ZnPc 5.16. A procedure related to that described for ZnPc 5.5 was used: ZnPc 5.12 (40.0 
mg, 0.04 mmol), DMF (0.5 mL), Et3N (5.2 mg, 0.051 mmol), HOBt (7.5 mg, 0.055 mmol), 1,4-
bis-Boc-triazaheptane (15.5 mg, 0.051 mmol), and EDCI (9.8 mg, 0.051 mmol). The product 
was obtained as a blue solid (44.4 mg, 88.6%). 
1
H NMR (DMF-d7): δ 9.42-9.24 (m, 6H, Ar-H), 
8.78 (br, 1H, NH), 8.40-8.20 (m, 4H, Ar-H), 8.10-8.04 (m, 2H, Ar-H), 7.89-7.79 (m, 1H, Ar-H), 
7.64–7.59 (m, 2H, Ar-H), 6.82-6.76 (m, 1H, N-H), 4.38 (d, J = 6.92 MHz, 2H, CH2O), 4.29 (d, J 





1.87–1.83 (m, 27H, C(CH3)3), 1.48 (s, 9H, -OC(CH3)3), 1.41 (s, 18H, -OC(CH3)3). 
13
CNMR 
(DMF-d7): δ 170.6, 169.1 (C=O), 160.6, 160.5, 160.2, 160.1, 157.2, 156.6, 156.4, 154.8, 154.72, 
154.65, 154.5, 154.3, 154.2, 154.1, 154.0, 153.9, 153.4, 152.8, 141.1, 139.8, 139.6, 137.4, 137.3, 
137.2, 136.5, 136.2, 134.5, 134.3, 132.6, 129.8, 128.4, 128.3, 126.2, 125.0, 123.4, 123.3, 122.9, 
122.0, 121.3, 121.1, 120.8, 120.7, 119.9, 119.7, 112.7, 111.5 (Ar-C), 80.0, 78.8 (-OC(CH3)3), 
72.4, 72.1 (OCH2), 48.5, 48.3, 47.7, 40.1, 39.9, 38.7, 38.5, 36.8 (N-CH2), 32.7 (Ar-C(CH3)3), 
29.0, 28.9 (O-C(CH3)3). MS (MALDI-TOF) m/z 1052.447 [M-2Boc]
+
, calcd for C58H60N12O4Zn 
1052.415. The blue solid (44.4 mg, 0.035 mmol) was dissolved in DCM/TFA (1:1) and stirred at 
0 C for 3 h. The solvent was evaporated and the remaing solid treated with 2N NaOH (10 mL) 
to afford a blue-greenish solid (33.5 mg, 89.9 %). 
1
H NMR (DMF-d7): δ 9.55-9.24 (m, 7H, Ar-
H), 8.97-8.89 (m, 1H, Ar-H), 8.40-8.11 (m, 4H, Ar-H), 8.07 – 8.00 (m, 1H, Ar-H), 7.92 – 7.90 
(m, 1H, Ar-H), 7.65–7.50 (m, 2H, Ar-H), 4.37 (d, J = 6.88 MHz, 2H, CH2O), 4.26 (d, J = 4.24 
MHz, 2H, CH2O), 3.47 (br, 2H, CH2NH), 3.03–2.91 (m, 2H, CH2NH), 1.82-1.79 (m, 27H, 
C(CH3)3). 
13
C NMR (DMF-d7): δ  171.4, 169.2 ,169.1 (C=O), 160.6, 160.5, 160.2, 159.7, 155.2, 
155.1, 154.8, 154.7, 154.3, 154.1, 154.0, 153.4,153.2, 141.4, 140.0, 139.8, 137.7, 137.5, 134.9, 
134.7, 128.3, 128.2, 125.0, 123.3, 123.2, 122.8, 121.2, 121.1,120.7, 119.9, 119.8, 119.3, 116.4, 
112.7, 111.5 (Ar-C), 72.3, 72.1, 72.0 (OCH2), 49.1, 48.7, 47.5, 47.0, 39.5, 38.7, 36.7 (N-CH2), 
32.6 (Ar-C(CH3)3).  MS (MALDI-TOF) m/z 1052.411 [M]
+
, calcd for C58H60N12O4Zn 1052.415. 
UV-vis (DMF): λmax (log ε) 351 (4.73), 609 (4.43), 676 (5.19) nm. 
ZnPc 5.17. A procedure related to that described for ZnPc 5.4 was used: ZnPc 5.16 (20.0 
mg, 0.021 mmol), DIPA (0.015 mL, 0.107 mmol), CH3I (0.2 mL) and dry THF (0.5 mL). The 
title ZnPc was obtained as a blue-green solid (16.1 mg, 58.3%). 
1
H NMR (DMF-d7): δ 9.56-9.19 





7.58-7.45 (m, 4H, Ar-H), 4.41-4.27 (m, 8H, CH2O/N-CH2), 3.92-3.82 (m, 4H, N-CH2), 3.53 (s, 
6H, N-CH3), 3.49 (s, 9H, N-CH3), 1.86-1.72 (m, 27H, C(CH3)3). 
13
C NMR (DMF-d7): δ 171.4, 
169.0, 168.6, 168.9, 160.5, 160.4, 160.1, 160.0, 155.9, 155.5, 155.3, 155.2, 155.1, 154.9, 154.8, 
154.3, 154.0, 153.9, 153.8, 141.6, 140.2, 140.0, 137.8, 137.7, 137.6, 136.3, 136.0, 135.2, 135.0, 
128.3, 128.12, 128.07, 125.1, 123.24, 123.15, 123.0, 122.8, 122.7, 121.3, 121.1, 120.6, 119.9, 
119.8, 119.7, 112.8, 111.7 (Ar-C), 72.1, 71.9 (CH2O), 64.5, 58.7, 57.3, 54.5, 52.5 (N-CH3), 36.7 
(N-CH2) 32.6 (C(CH3)3). MS (MALDI-TOF) m/z 1252.575 [M-I+2H]
+
, calcd for 
C63H73IN12O4Zn 1252.421. UV–Vis (DMF): λmax (log ε) 351 (4.83), 610 (4.55), 676 (5.31) nm. 
 ZnPc 5.18. A procedure related to that described for ZnPc 5.3 was used: ZnPc 5.12 (50.0 
mg, 0.05 mmol), DMF (0.8 mL), Et3N (6.2 mg, 0.061 mmol), HOBt (9.3 mg, 0.069 mmol), 
aspartic acid di-tert-butyl ester hydrochloride (18 mg, 0.064 mmol) and EDCI (12.3 mg, 0.064 
mmol). The protected ZnPc was obtained as a blue solid (0.056 g, 89.0%). 
1
H NMR (Acetone-
d6): δ 9.86-9.68 (m, 1H, N-H), 9.37-8.57 (m, 6H, Ar-H), 8.38-7.96 (m, 6H, Ar-H), 7.92-7.56 (m, 
4H, Ar-H), 4.74 (br, 1H, N-H), 4.25 (s, 4H, CH2O), 2.82 (s, 1H, CH), 2.66 (s, 2H, CH), 1.94–
1.87 (m, 27H, C(CH3)3), 1.45 (s, 18H, -OC(CH3)3). 
13
C NMR (Acetone-d6): δ 170.6, 170.4, 
169.99, 169.95, 168.3, 168.23, 168.17 (C=O), 160.0, 159.9, 159.8, 159.4, 159.3, 159.2, 155.3, 
155.1, 154.6, 154.4, 153.2, 1153.1, 153.03, 152.97, 139.4, 139.1, 139.0, 136.8, 135.9, 135.8, 
135.4, 127.7, 124.3, 122.8, 122.4, 121.8, 121.1, 121.0, 120.5, 120.4, 119.5, 112.8, 112.6, 111.5 
(Ar-C), 82.4, 81.7 (-OC(CH3)3), 72.4, 71.9 (OCH2), 50.1, 50.0, 38.4, 36.6 (N-CH2), 32.6 (Ar-







, calcd for C66H70N10O8Zn 1194.467, C62H62N10O8Zn 1138.404, 
C58H55N10O8Zn 1083.350. The solid (0.056 g, 0.047 mmol) was dissolved in DCM/TFA (1:1) 





(10 mL) to obtaiin a blue solid (42.1 mg, 83.0 %).
 





, calcd for C58H54N10O8Zn 1082.34, C58H54N10NaO8Zn 1105.7. UV-vis 
(DMF): λmax (log ε) 351 (4.83), 610 (4.51), 677 (5.28) nm. 
ZnPc 5.19. A procedure related to that described for ZnPc 5.3 was used: ZnPc 5.18 (18.4 
mg, 0.017 mmol), DMF (0.5 mL), Et3N (6.2 mg, 0.061 mmol), HOBt (5.7 mg, 0.042 mmol), N-
Boc-2,2′-(ethylenedioxy)diethylamine (9.4 mg, 0.038 mmol) and EDCI (6.5 mg, 0.042 mmol). 
The product was obtained as a blue solid (13.3 mg, 50.8 %). 
1
H NMR (DMF-d7): δ 9.52-9.15 (m, 
6H, Ar-H), 8.81-8.54 (m, 2H, Ar-H), 8.42-8.34 (m, 3H, Ar-H), 8.17-8.05 (m, 4H, Ar-H), 7.97-
7.88 (m, 1H, Ar-H), 7.65–7.59 (m, 2H, Ar-H), 6.70 (br, 2H, Ar-H), 4.87 – 4.85 (m, 1H, N-H), 
4.42 (d, 8.0 Hz, 2H, CH2O), 4.33 (d, 5.96 Hz, 2H, CH2O), 3.58–3.46 (m, 16H, CH2O), 3.42–3.37 
(m, 4H, CH2NH), 3.25–3.19 (m, 4H, CH2NH), 2.83–2.78 (m, 2H, CH2CO), 1.86–1.83 (m, 27H, 
C(CH3)3), 1.40–1.36 (m, 18H, OC(CH3)3). 
13
C NMR (DMF-d7): δ 172.0, 171.4, 170.42, 170,40, 
169.1, 169.0, 160.6, 160.5, 160.2, 160.1, 157.1, 154,73, 154.67, 154.4, 154.2, 154.0, 153.9, 
153.4, 152.9, 141.2, 139.8, 139.6, 137.5, 137.3, 136.,5, 136.2, 134.6, 128.4, 125.1, 123.35, 
123.25, 122.83, 122.79, 122.0, 121.3, 121.2, 121,1, 120.73, 120.67, 119.9, 1119.8, 112.8, 111.6  
(Ar-C), 78.8 (OC(CH3)3), 72.2, 72.0, 71.1, 70.04, 70.01, 71.0, 70.8, 70.5, 70.4 (CH2O), 51.2 
(NHCH(CH2)CO), 42.5, 41.2, 40.2, 38.5 (CH2), 32.6 (C(CH3)3), 28.9 (OC(CH3)3). MS (MALDI-
TOF) m/z 1544.802 [M]
+
, calcd for C80H98N14O14Zn 1544.669. The ZnPc (13.1 mg, 8.5 mmol) 
was dissolved in DCM/TFA (1:1) and stirred at 0°C for 3 h. The solvent was evaporated and the 
solid treated with 2N NaOH (10 mL) to give the title product (10.2 mg, 89.7%). 
1
H NMR (DMF-
d7): δ 9.54-9.23 (m, 7H, Ar-H), 9.00-8.77 (m, 1H, Ar-H), 8.39-8.29 (m, 3H, Ar-H), 8.09-7.94 (m, 
3H, Ar-H), 7.47 – 7.42 (m, 2H, Ar-H), 4.66 (br, 1H, NH), 4.33 (d, 7.36 Hz, 2H, CH2O), 4.33 (d, 





CH2NH), 2.98-2.91 (m, 2H, CH2NH), 2.87-2.80 (m, 2H, CH2NH),  2.72-2.58 (m, 2H, CH2CO), 
2.34 (br, 2H, NH2), 2.13 (br, 2H, NH2), 1.80–1.73 (m, 27H, C(CH3)3). 
13
C NMR (DMF-d7): δ 
171.9, 171.5, 170.2, 170.17, 168.95, 168.87, 160.5, 160.0, 155.5, 155.4, 155.2, 155.1, 155.0, 
154.8, 154.4, 154.1, 153.9, 153.3, 141.5, 140.0, 139.9, 137.7, 136.2, 135.2, 134.9, 132.5, 129.9, 
128.5, 125.2, 123.3, 122.8, 122.7, 122.3, 122.0, 120.8, 120.1, 119.8, 113.3, 112.1 (Ar-C), 72.1, 
72.0, 71.4, 71.1, 70.7, 70.52, 70.46, 70.3, 70.2, 70.1 (N-CH), 51.2 (NHCH(CH2)CO), 40.6, 40.2, 







 calcd for C70H83N14O10Zn 1343.5708, C70H82NaN14O10Zn 
1365.5528, C70H82KN14O10Zn 1381.5267. UV-vis (DMF): λmax (log ε) 352 (4.77), 611 (4.50), 
677 (5.27) nm. 
ZnPc 5.20. A procedure related to that described for ZnPc 5.4 was used: ZnPc 5.19 (20.0 
mg, 0.015 mmol), DIPA (0.015 mL, 0.107 mmol), CH3I (0.2 mL) and dry DMF (0.5 mL). The 
ZnPc was a blue solid (16.2 mg, 64.3%). 
1
H NMR (DMF-d7): δ 9.56-9.27 (m, 7H, Ar-H), 9.06-
8.83 (m, 2H, Ar-H), 8.36-8.26 (m, 4H, Ar-H), 8.13-8.06 (m, 2H, Ar-H), 7.92-7.81 (m, 1H, Ar-
H), 7.52-7.44 (m, 2H, Ar-H), 4.38 (d, 8.0Hz, 2H), 4.28 (d, 6.0Hz, 2H), 3.94-3.90 (m, 5H, NH), 
3.73-3.49 (m, 24H, OCH2), 3.34-3.23 (m, 18H, N-CH3), 1.78-1.64 (m, 27H, C(CH3)3). 
13
C NMR 
(DMF-d7): δ 172.2, 171.5, 170.5, 169.2 (C=O), 159.9, 159.1, 155.6, 155.1, 153.8, 141.8, 140.4, 
140.2, 137.9, 136.3, 135.9, 135.2, 128.1, 124.9, 123.1, 122.9, 122.8, 121.0, 120.4, 119.7, 112.7, 
111.6 (Ar-C), 72.2, 72.0, 71.0, 70.9, 70.8, 70.7, 70.4 (OCH2), 66.2, 65.65, 65.60 (NHCH2), 54.4 
(N-CH3), 32.6 (C(CH3)3). MS (MALDI-TOF) m/z 1413.828 [M-2I-CH3]
+
, calcd for 
C75H93N14O10Zn
+
 1413.649. UV–Vis (DMF): λmax (log ε) 350 (4.51), 610 (4.26), 677 (5.01) nm. 
ZnPc 5.21. A procedure related to that described for ZnPc 5.3 was used: ZnPc 5.18 (18.4 





Boc-ethylenediamine (6.1 mg, 0.038 mmol) and EDCI (6.5 mg, 0.042 mmol). After stirring for 
for 4 days at 25 °C followed by purification, the ZnPc was obtained as a blue solid (14.3 mg, 
61.6 %). 
1
H NMR (DMF-d7): δ 9.52-9.14 (m, 6H, Ar-H), 8.80-8.33 (m, 4H, Ar-H), 8.20-8.10 (m, 
3H, Ar-H), 7.65-7.61 (m, 2H, Ar-H), 6.79-6.76 (m, 2H, Ar-H) 4.83 (br, 1H, NH), 4.43 (d, 8.24 
Hz, 2H, CH2O), (d, 5.76 Hz, 2H, CH2O), 3.39–3.25 (m, 4H, CH2NH), 3.24–3.16 (m, 4H, 
CH2NH), 2.82-2.77 (m, 2H, CH2CO), 1.95-1.84 (m, 27H, C(CH3)3), 1.41 (s, 18H, C(CH3)3). 
13
C 
NMR (DMF-d7): δ 172.1, 171.6, 170.4, 169.1, 169.0, 160.6, 160.5, 160.2, 160.1, 157.3, 157.2, 
154.7, 154.4, 154.2, 154.0, 153.9, 152.9, 141.2, 139.8, 137.5, 137.3, 136.2, 134.5, 128.4, 128.23 
125.0, 123.2, 122.83, 122.79, 122.0, 121.3, 121.1, 120.7, 119.9, 119.7, 112.7, 111.6 (Ar-C), 
78.91, 78.87 (OC(CH3)3), 72.3, 72.0 (CH2O), 51.3 (NHCH(CH2)CO), 41.1, 40.6, 40.5, 38.8, 36.8 







, calcd for C62H66N14O6Zn 1166.4581, 
C62H66N14NaO6Zn 1189.4479, C62H66KN14O6Zn 1206.4218 respectively.  The ZnPc (14.3 mg, 
0.0105 mmol) was dissolved in DCM/TFA (1:1) at 0 °C for 3h. The solvent was evaporatedand 
the residue treated with 2N NaOH (10 mL) to obtaiin the title compound (11.1 mg, 91.2%). 
1
H 
NMR (THF-d8): δ 9.80-9.36 (m, 8H, Ar-H), 9.01-8.8.97 (m, 1H, Ar-H), 8.43-8.37 (m, 3H, Ar-
H), 8.00–7.81 (m, 3H, Ar-H), 7.51 – 7.42 (m, 2H, Ar-H), 4.20-3.70 (m, 4H, CH2O), 3.47–3.10 
(m, 8H, CH2NH), 2.08-1.93 (m, 2H, CH2CO), 1.75–1.65 (m, 27H, C(CH3)3). 
13
C NMR (DMF-
d7): δ 171.8, 171.0, 170.4, 169.8, 168.8, 161.0, 160.4, 155.4, 154.9, 154.1, 141.6, 140.0, 137.6, 
136.4, 135.9, 134.9, 134.6, 128.4, 125.2, 123.3, 122.7, 121.6, 121.1, 120.7, 119.8, 112.7, 111.3 
(Ar-C), 72.0, 71.5 (CH2NH), 50.8 (NHCH(CH2)CO), 41.0, 40.1, 36.7 (CH2), 32.6, 32.3 
(C(CH3)3). MS (MALDI-TOF) m/z 1166.534 [M-2Boc+2H]
+
, calcd for C62H66N14O6Zn 





ZnPc 5.22. A procedure related to that described for ZnPc 5.4 was used: ZnPc 5.21 (20.0 
mg, 0.017 mmol), DIPA (0.015 mL, 0.107 mmol), CH3I (0.2 mL) and dry DMF (0.5 mL). After 
work-up, the title compound was achieved as a blue solid (17.4 mg, 67.4%). 
1
H NMR (DMF-d7): 
δ 9.56-9.27 (m, 7H, Ar-H), 9.04-8.92 (m, 1H, Ar-H), 8.65-8.50 (m, 3H, Ar-H), 8.39-8.31 (m, 3H, 
Ar-H), 7.92-7.90 (m, 1H, Ar-H), 7.54-7.47 (m, 2H, Ar-H), 4.47-4.31 (m, 4H, OCH2), 381-3.70 
(m, 8H, CH2), 3.38-3.35 (m, 18H, N-CH3), 1.79-1.74 (m, 27H, C(CH3)3). 
13
C NMR (Acetone-
d6): δ 172.6, 171.8, 170.9, 169.2, 155.5, 154.8, 154.0, 153.5,  153.0, 141.8, 140.3, 140.2, 137.7, 
136.4, 136.0, 129.6, 128.8, 128.3, 126.2, 125.0, 123.2, 122.8, 121.1, 120.5, 119.6, 115.0, 112.8, 
111.7 (Ar-C), 72.2, 72.1, 65.6 (N-CH2), 54.0 (N-CH3), 32.6 (C(CH3)3). MS (MALDI-TOF) m/z 
1194.434 [M-4CH3-2I]
+
, calcd for C64H70N14O6Zn
+
 1194.489. UV–Vis (DMF): λmax (log ε) 350 
(4.55), 610 (4.25), 677 (4.99) nm. 
  Phthalonitrile 5.24. To a mixture of 3-nitrophthalonitrile 5.23 (2.0 g, 11.5 mmol) and 
tert-butyl 20-hydroxy-3,6,9,12,15,18-hexaoxaicosan-1-oate (4.99 g, 12.6 mmol) in THF (15 
mL), K2CO3, (5.26 g, 40 mmol) was added in six portions every 5 min. The solution was heated 
at 65 C for 6 h.  The solids were removed and the product purified via silica chromatography. A 
mixed solvent system of DCM/methanol (199:1 → 98:2) was used for elution. The product was 
obtained as a brown-yellow oil (4.70 g, 78.3%). 
1
H NMR (d-CDCl3, 400 MHz): δ 7.64 (d, J =  
8.1 Hz, 1H, Ar-H), 7.31 (d, J =  8.2 Hz, 1H, Ar-H), 4.27 (t, J = 4.4, 2H, OCH2), 3.96 (s, 2H, 
OCH2), 3.87 (t, 2H, J = 4.5, OCH2),  3.70-3.58 (m, 20H, OCH2), 1.41 (s, 9H, C(CH3)3). 
13
C 
NMR (CDCl3): δ 169.65 (CH2C(O)OtBu), 161.41, 134.71, 125.34, 117.55, 113.09, 104.91 (Ar-
C), 116.77,  115.41, (CN), 81.49 (C(CH3), 71.11, 70.67, 70.54, 69.72, 69.21, 68.98 (OCH2), 
28.09 (C(CH3)3). MS (MALDI-TOF) m/z 545.2232 [M+H+Na]
+
, calcd for, C18H36NaO9, 
519.2257; m/z 545.2466 [M+H]
+





  ZnPc 5.25. A combination of 4-tert-butylphthalonitrile (1.32 g, 7.16 mmol), 
phthalonitrile 5.24 (475.0 mg, 1.42 mmol) and zinc(II) acetate (500 mg, 2.73 mmol) was stirred 
in DMAE (35 mL). The solution was heated under the flow of argon and two drops of DBN were 
added. The reaction solution was heated for 5 h. The solvent was evaporated and the residue 
purified on a silica column eluted by DCM/methanol (97:3). Another silica column eluted by 
chloroform, and then chloroform/methanol (99:1 → 98:2) gave a blue solid (273.6 mg, 16.9%). 
1
H NMR (DMF-d7): δ 9.63-8.92 (m, 6H, Ar-H), 8.47-8.05 (m, 3H, Ar-H), 7.85-7.62 (m, 3H, Ar-
H), 4.95-4.88 (m, 2H, CH2O), 4.49-4.39 (m, 2H, CH2O), 4.16-4.00 (m, 3H, CH2O), 3.88-3.44 
(m, 19H, CH2O), 1.88–1.82 (m, 27H, C(CH3)3), 1.45, 1.38, 1.36 (s, 9H, -OC(CH3)3). 
13
CNMR 
(DMF-d7): δ 170.73, 170.66 (C=O), 158.1, 157.8, 157.4, 157.3, 157.2, 154.9, 154.8, 154.7, 
154.5, 154.3, 154.1, 153.8, 153.7, 141.9, 141.8, 140.1, 139.9, 139.8, 137.9, 137.5, 137.2, 136.7, 
137.2, 134.0, 131.6, 131.30, 131.26, 130.5, 128.9, 128.4, 126.9, 126.7, 126.4, 123.6, 123.4, 
123.3, 122.9, 120.2, 120.1, 119.8, 119.7, 118.7, 117.0, 116.3, 114.8, 114.7, 114.6, 104.6 (Ar-C), 
81.73, 81.68 (-OC(CH3)3), 72.1, 71.9, 71.7, 71.5, 71.44, 71.36, 71.3, 71.2, 70.9, 70.4, 70.0, 69.9, 
69.62, 69.56, 68.9 (OCH2), 52.1, 45.9, 36.8 (N-CH2), 32.8, 32.7 (Ar-C(CH3)3), 28.6 (O-
C(CH3)3). MS (MALDI-TOF) m/z 1139.675 [M+H]
+
, calcd for C62H75N8O9Zn 1138.495. The 
protected ZnPc (273.6 mg, 0.240 mmol) was dissolved in DCM/TFA (1:1) and the solution was 
stirred at 0 C for 3 h. The solvent was removed and the resulting residue treated with 2 N NaOH 
(15 mL). The product was extracted using 5:1, DCM/methanol (20 mL × 4) and the organic 
phase washed with water (20 mL × 2) and dried over anhydrous sodium sulfate. The solvent was 
removed under reduced pressure to afford the title ZnPc as a blue solid (243.7 mg, 93.7 %). 
1
HNMR (DMF-d7): δ 9.59-9.11 (m, 6H, Ar-H), 8.40-8.34 (m, 3H, Ar-H), 8.19-7.70 (m, 3H, Ar-





(m, 16H, CH2O), 1.83–1.78 (m, 27H, C(CH3)3). 
13
CNMR (DMF-d7): δ 170.6 (C=O), 157.5, 
157.1, 156.8, 155.9, 155.3, 155.0, 154.5, 153.8, 153.6, 142.5, 140.5, 140.2, 140.0, 138.3, 137.9, 
137.6, 136.2, 132.5, 131.4, 130.4, 128.9, 128.5, 128.1, 127.2, 127.0, 123.9, 123.6, 123.1, 122.8, 
120.7, 120.0, 119.8, 119.7, 119.5, 116.5, 116.1, 113.9 (Ar-C), 72.5, 72.0, 71.7, 71.5, 71.3, 71.2, 
71.0, 70.5, 70.2, 69.7, 69.6, 68.9, 68.6 (OCH2), 52.1, 46.2, 36.8, 36.7 (N-CH2), 32.7, 32.6 (Ar-
C(CH3)3). MS (MALDI-TOF) m/z 1083.444 [M+H]
+
, calcd for C58H67N8O9Zn 1083.432. UV-vis 
(DMF): λmax (log ε) 345 (4.77), 613 (4.57), 681 (5.34) nm. 
 ZnPc 5.26. A procedure related to that described for ZnPc 5.3 was used: ZnPc 5.25 (20.0 mg, 
0.018 mmol), DMF (0.4 mL), Et3N (3.3 mg, 0.032 mmol), HOBt (4.7 mg, 0.035 mmol), 1,4-bis-
Boc-triazaheptane (7.0 mg, 0.023 mmol) and EDCI (4.0 mg, 0.026 mmol). After work-up and 
purification the ZnPc was achieved as a blue solid (16.1 mg, 63.6%). 
1
H NMR (DMF-d7): δ 9.54-
9.20 (m, 5H, Ar-H), 9.06-8.84 (m, 1H, Ar-H), 8.47-8.35 (m, 3H, Ar-H), 7.82-7.76 (m, 2H, Ar-
H), 6.76-6.70 (m, 1H, Ar-H), 4.96-4.92 (m, 2H, COCH2O), 4.58-4.44 (m, 2H, CH2O), 4.19-4.10 
(m, 1H, CH2O), 4.07-3.09 (m, 1H, CH2O), 3.88-3.72 (m, 5H, CH2O), 3.60-3.43 (m, 17H, CH2O), 
3.34-3.28 (m, 6H, CH2NH), 3.20-3.18 (m, 2H, CH2NH), 1.86-1.82 (m, 27H, C(CH3)3), 1.46-1.39 
(m, 18H, -OC(CH3)3). 
13
C NMR (DMF-d7): δ 170.7, 175.1, 156.4, 154.8, 154.0, 139.8, 137.5, 
131.8, 128.5, 123.4, 119.8, 116.4, 114.9, 114.7 (Ar-C), 79.9, 78.7 (O-C(CH3)3), 72.0, 71.71, 
71.66, 71.5, 71.4, 71.3, 71.2, 71.0, 70.4, 69.9 (CH2O), 48.4, 48.2, 44.3 40.1, 39.9, 38.4, 36.8 (N-







; calcd for C72H93N11O12Zn 1367.630, C62H78KN11O8Zn 1207.496. The 
blue solid (16.1 mg, 0.0118 mmol) was dissolved in a 1:1 mixture of DCM/TFA (6 mL) and 
stirred at 0 C for 3 h. The solvent was evaporated and the residue treated with 2N NaOH (10 
mL) to give a blue solid (12.5 mg, 91.0 %). 
1





8.52-8.31 (m, 3H, Ar-H), 8.13-8.03 (m, 1H, Ar-H), 7.83-7.70 (m, 1H, Ar-H), 5.02-4.83 (m, 2H, 
COCH2O), 4.59-4.35 (m, 2H, CH2O), 4.19-4.00 (m, 2H, CH2O), 3.92-3.00 (m, 22H, CH2O), 1.79 
(s, 27H, C(CH3)3). 
13
C NMR (DMF-d7): δ 171.2, 170.9, 170.3, 157.3, 155.0, 154.4, 154.1, 154.0, 
142.2, 140.3, 140.1, 138.0, 137.7, 131.6, 129.0, 128.3, 126.9, 123.6, 123.3, 119.8, 116.5, 115.0, 
114.7 (Ar-C), 71.9, 71.6, 71.4, 71.3, 71.2, 71.1, 70.8, 70.6, 70.1, 69.6 (CH2O), 49.1, 48.0, 47.5, 
47.0, 46.6, 46.3, 45.9, 45.8, 44.6, 44.3, 39.6, 38.8, 36.8 (N-CH2), 32.6 (Ar-C(CH3)3). MS 
(MALDI-TOF) m/z 1167.520 [M]
+
, calcd for C62H77N11O8Zn 1167.525. UV-vis (DMF): λmax 
(log ε) 346 (4.77), 615 (4.55), 683 (5.31) nm. 
ZnPc 5.27. A procedure related to that described for ZnPc 5.4 was used: ZnPc 5.26 (20.0 
mg, 0.017 mmol), DIPA (0.015 mL, 0.107 mmol), CH3I (0.2 mL) and dry DMF (0.5 mL). The 
title compound was obtained as a blue solid (17.4 mg, 67.4%). 
1
H NMR (DMF-d7): δ 9.57-9.34 
(m, 6H, Ar-H), 9.13-8.99 (m, 1H, Ar-H), 8.38-8.18 (m, 3H, Ar-H), 8.20-8.09 (m, 1H, Ar-H), 
7.88-7.72 (m, 1H, Ar-H), 5.03-4.94 (m, 2H, COCH2), 4.65-4.36 (m, 2H, CH2O),4.15-3.51 (m, 
28H, CH2O/N-CH2/N-CH3), 3.43 (s, 9H, N-CH3), 1.83-1.79 (m, 27H, C(CH3)3). 
13
C NMR 
(DMF-d7): δ 171.7, 170.5 (C=O), 157.5, 157.4, 155.1, 155.0, 154.8, 154.5, 154.1, 154.0, 142.3, 
142.2, 142.1, 140.4, 140.0, 138.0, 137.7, 131.7, 128.4, 126.9, 123.6, 123.3, 119.9, 119.8, 116.5, 
115.0, 114.8 (Ar-C), 72.1, 72.0, 71.8, 71.7, 71.4, 71.2, 71.0, 70.7, 70.5, 70.2 (CH2O), 64.5, 54.5, 
53.5, 52.5, 52.2, 51.4, 48.2 (N-CH3), 43.3, 43.2, 36.8 (N-CH2) 32.7, 32.6 (C(CH3)3). MS 
(MALDI-TOF) m/z 1404.705 [M-I+2H+K]
+
; calcd for C67H90IKN11O8Zn
+
 1404.495. UV–Vis 
(DMF): λmax (log ε) 347 (4.75), 615 (4.51), 682 (5.28) nm. 
 Phthalonitrile 5.29. A procedure related to that described for ZnPc 5.24 was used: 4-
nitrophthalonitrile 5.28 (2.0 g, 11.5 mmol), tert-butyl 20-hydroxy-3,6,9,12,15,18-hexaoxaicosan-





was purified on a silica column eluted by DCM/methanol (98:2), to give brown oil (4.87 g, 
81.2%). 
1
H NMR (d-CDCl3, 400 MHz): δ 7.64 (d, J =  8.8 Hz, 1H, Ar-H), 7.24 (s, 1H, Ar-H), 
7.18 (d, J =  8.8 Hz, 1H, Ar-H), 4.15 (t, J = 3.5, 2H, OCH2), 3.91 (s, 2H, OCH2), 3.79 (t, 2H, J = 
3.7, OCH2),  3.60-3.50 (m, 20H, OCH2), 1.36 (s, 9H, C(CH3)3). 
13
C NMR (CDCl3): δ 169.48 
(CH2C(O)O
t
Bu), 161.95, 135.13, 119.81, 119.56, 117.01, 106.97 (Ar-C), 115.64, 115.20,  (CN), 
81.30 (C(CH3), 70.71, 70.50, 70.37, 70.29, 70.05 (OCH2), 28.12 (C(CH3)3). MS (MALDI-TOF) 
m/z 545.2473 [M+H+Na]
+
, calcd for, C26H37N2NaO9, 545.2475. 
ZnPc 5.30. A mixture of 4-tert-butylphthalonitrile (385 mg, 2.09 mmol), phthalonitrile 
5.29 (273.4 mg, 0.69 mmol) and zinc(II) acetate (254.7 mg, 1.4 mmol) were stirred in DMAE 
(35 mL). The solution was heated under a flow of argon in the presence of DBN. The reaction 
was treated as ZnPc 5.25 to give blue solid (121.6 mg, 15.5%). 
1
HNMR (DMF-d7): δ 9.59-8.92 
(m, 7H, Ar-H), 8.47-8.35 (m, 3H, Ar-H), 7.88-7.78 (m, 2H, Ar-H), 4.74-4.58 (m, 2H, CH2O), 
4.19-4.00 (m, 4H, CH2O), 3.87-3.57 (m, 18H, CH2O), 1.83–1.75 (m, 27H, C(CH3)3), 1.42- 1.38 
(s, 9H, -OC(CH3)3). 
13
CNMR (DMF-d7): δ 170.7 (C=O), 158.4, 158.1, 155.0, 154.9, 154.8, 
154.6, 154.4, 154.2, 154.0, 142.8, 141.8, 140.0, 137.6, 133.5, 132.9, 132.5, 132.2, 131.7, 131.3, 
130.4, 128.9, 128.4, 124.8, 123.9, 123.33, 123.25, 122.9, 120.8, 120.2, 119.9, 119.2, 118.9, 
109.4, 107.4, 104.2 (Ar-C), 81.7 (-OC(CH3)3), 71.74, 71.69, 71.5, 71.4, 71.33, 71.30, 70.8, 70.2, 
69.8, 69.61, 69.57, 69.0 (OCH2), 52.1, 47.4, 45.5, 36.8 (N-CH2), 32.6 (Ar-C(CH3)3), 28.5 (O-




, calcd for 
C62H74N8O9Zn 1138.487, C58H66N8O9Zn 1082.424. The solid (113.0 mg, 0.119 mmol) was 
dissolved in DCM/TFA (1:1) and stirred at 0 C for 3 hours. The solvent was evaporated and the 
solid treated with 2N NaOH (10 mL) to obtain a blue solid (94.7 mg, 93.7 %) was obtained. 
1





H), 4.56-4.46 (m, 2H, CH2O), 3.90-3.04 (m, 24H, CH2O), 1.83–1.78 (m, 27H, C(CH3)3). 
13
CNMR (DMF-d7): δ 171.8 (C=O), 159.6, 158.2, 157.9, 157.1, 155.2, 155.0, 154.9, 154.6, 
154.1, 154.0, 153.8, 153.6, 142.2, 141.9, 140.2, 141.1, 140.0, 137.8, 137.6, 134.4, 133.4, 133.0, 
132.5, 131.6, 131.4 130.8, 130.4, 128.9, 128.4, 128.3, 128.1, 128.0, 126.3, 124.7, 124.6, 123.9, 
123.2, 122.8, 120.7, 120.0, 119.9, 119.8, 119.1, 115.0, 107.5, 107.4, 107.2 (Ar-C), 71.7, 71.6, 
71.5, 71.4, 71.3, 71.2, 71.0, 70.7, 70.5, 70.1, 69.8, 69.5, 68.9 (OCH2), 52.1, 47.4, 46.1, 40.9, 
36.8, 36.5 (N-CH2), 32.6 (Ar-C(CH3)3). MS (MALDI-TOF) m/z 1083.428 [M+H]
+
, calcd for 
C58H67N8O9Zn 1083.432. UV-vis (DMF): λmax (log ε) 351 (4.65), 609 (4.38), 676 (5.14) nm.  
ZnPc 5.31. A procedure related to that described for ZnPc 5.3 was used: ZnPc 5.30 (20.0 
mg, 0.018 mmol), DMF (0.4 mL), Et3N (3.2 mg, 0.032 mmol), HOBt (4.7 mg, 0.035 mmol), 1,4-
bis-Boc-triazaheptane (7.0 mg, 0.023 mmol), and EDCI (4.0 mg, 0.026 mmol). The ZnPc was 
obtained as a blue solid (17.1 mg, 65.6%). 
1
H NMR (DMF-d7): δ 9.58-9.52 (m, 3H, Ar-H), 9.46-
9.22 (m, 4H, Ar-H), 8.96-8.88 (m, 1H, Ar-H), 8.45-8.38 (m, 3H, Ar-H), 7.82-7.76 (m, 2H, Ar-
H), 6.76-6.70 (m, 1H, Ar-H), 4.73-4.70 (m, 2H, COCH2O), 4.49-4.44 (m, 2H, CH2O), 3.89-3.82 
(m, 4H, CH2O), 3.77-3.72 (m, 2H, CH2O), 3.69-3.58 (m, 14H, CH2O), 3.35-3.28 (m, 6H, 
CH2NH), 3.20-3.18 (m, 2H, CH2NH), 1.82-1.80 (m, 27H, C(CH3)3), 1.45-1.36 (m, 18H, -
OC(CH3)3). 
13
CNMR (DMF-d7): δ 170.7, 162.2, 157.1, 156.5, 154.9, 154.8, 154.7, 154.3, 154.2, 
141.7, 139.9, 137.5, 133.4, 132.8, 132.1, 131.4, 130.4, 128.4, 123.4, 120.8, 119.9, 119.8, 119.2, 
115.0, 113.3, 107.4, 107.2 (Ar-C), 79.9, 78.7 (O-C(CH3)3), 71.74, 71.68, 71.51, 71.48, 71.41, 
71.37, 71.34, 71.30, 71.1, 70.8, 69.6 (OCH2), 48.4, 48.2, 48.0, 47.6, 47.4, 46.1 40.9, 40.1, 39.9, 





, calcd for C67H85N11O10Zn 1267.577. The solid (17.1 mg, 0.013 mmol) was 





residue treated with 2N NaOH (10 mL) to give a blue solid (13.5 mg, 92.8 %). 
1
H NMR (DMF-
d7): δ 9.60-9.25 (m, 7H, Ar-H), 9.15-8.91 (m, 1H, Ar-H), 8.52-8.31 (m, 3H, Ar-H), 7.89-7.73 (m, 
1H, Ar-H), 4.74-4.63 (m, 2H, COCH2O), 4.19-4.05 (m, 3H, CH2O), 3.92-3.45 (m, 29H, CH2O), 
3.29-3.10 (m, 6H, CH2NH) 1.80 (s, 27H, C(CH3)3). 
13
C NMR (DMF-d7): δ 171.6, 162.1, 160.2, 
159.7, 155.0, 154.6, 154.4, 154.1, 153.9, 141.9, 140.1, 137.7, 133.1, 128.2, 124.7, 123.3, 119.8, 
119.1, 107.2 (Ar-C), 71.72, 71.67, 71.6, 71.4, 71.3, 71.2, 71.0, 70.7, 69.6 (OCH2), 49.0, 46.5, 
38.4, 37.4, 36.7 (N-CH2), 32.6 (Ar-C(CH3)3). MS (MALDI-TOF) m/z 1167.531 [M]
+
, calcd for 
C62H77N11O8Zn 1167.525. UV-vis (DMF): λmax (log ε) 352 (4.90), 611 (4.61), 678 (5.35) nm. 
ZnPc 5.32. A procedure related to that described for ZnPc 5.4 was used: ZnPc 5.31 (20.0 
mg, 0.017 mmol), DIPA (0.015 mL, 0.107 mmol), CH3I (0.2 mL) and dry DMF (0.5 mL). A blue 
solid was obtained (16.2 mg, 62.8%). 
1
H NMR (DMF-d7): δ 9.57-9.34 (m, 7H, Ar-H), 9.03-8.99 
(m, 1H, Ar-H), 8.38-8.18 (m, 4H, Ar-H), 7.84-7.82 (m, 1H, N-H), 4.80-4.70 (m, 2H, COCH2), 
4.35 (br, 2H, CH2O),4.15-3.51 (m, 28H, CH2O/N-CH2/N-CH3), 3.37 (s, 9H, N-CH3), 1.85-1.79 
(m, 27H, C(CH3)3). 
13
C NMR (DMF-d7): δ 171.7 (C=O), 162.0, 155.0, 154.5, 154.3, 153.9, 
151.2, 142.1, 140.2, 137.7, 133.2, 128.3, 128.1, 124.6, 123.2, 119.7, 119.0, 107.5, 107.3, 107.1 
(Ar-C), 71.8, 71.7, 71.4, 71.3, 71.2, 71.1, 71.0, 70.7, 69.6 (CH2O), 64.3, 58.6, 57.2, 55.9, 54.3, 










UV–Vis (DMF): λmax (log ε) 351 (4.81), 610 (4.50), 677 (5.26) nm. 
5.4.2. Syntheses of Pcs and Their AntiCEA Bioconjugates 
tert-Butyl-12-iodo-4,7,10-trioxadodecanoate. A slurry of p-TsCl (0.38 g, 2.0 mmol) and 
pyridine (0.35 mL) was mechanically stirred in a three-neck, N2 flushed flask. The temperature 





trioxadodecanoate (0.5 g, 1.8 mmol) was slowly added from an addition funnel. After the 
addition was complete, the mixture was stirred for 15 minutes. The mixture was poured into ice-
cold water (10 mL) and washed with DCM (10 mL). The organic layer was washed with ice-cold 
6N HCl (3 × 5 mL) and reduced to minimum under reduced pressure. The tosylate obtained was 
used without further purification.
32
 To a solution of the above tosylate (700.0 mg, 1.62 mmol) in 
dry acetone (10 mL) was added NaI (300.0 mg, 2.0 mmol) and the reaction heated (65 °C) for 20 
h. On cooling to room temperature, the reaction mixture was filtered under vacuum and washed 
with acetone. The filtrate was concentrated and the residue dissolved in 20.0 mL of DCM. The 
solution was successively washed with 1N sodium thiosulfate solution and brine, and dried over 
anhydrous sodium sulfate. The solvent was removed under vacuum and the product obtained as a 
light yellow oil (623.8 mg, 99.2 %).
9
 
Phthalonitrile 5.33. A mixture of 4-nitrophthalonitrile (1 g, 5.8 mmol) and 4-
aminophenol (0.7 g, 6.4 mmol) was dissolved in DMF (15 mL) and heated to 63°C. Potassium 
carbonate, K2CO3 (2.63 g, 20 mmol) was added into solution in six portions after every five 
minutes. The reaction mixture was stirred 4 h under argon at the same temperature. It was left to 
cool to room temperature and poured into ice-cold water (500 mL). This was then filtered and 
the crude product (brown) purified using a silica column eluted with DCM/methanol (98:2). The 
solvent was removed to give a yellow solid (1.0 g, 73.3%), mp 130 - 131°C.  
1
H NMR (d-
CD2Cl2, 400 MHz): δ 7.70 (d, J =  8.6 Hz, 1H, Ar-H), 7.23 (t, J = 8.8 Hz, 2H, Ar-H), 6.87 (d, J =  
7.8 Hz, 2H, Ar-H), 6.73 (d, J = 7.8, 2H, H-Ar), 3.86 (br, 2H, NH2). 
13
C NMR (d-CDCl3, 100 
MHz): δ 162.89, 145.32, 144.96, 135.36, 121.71, 120.98, 120.82, 117.31, 116.16, 115.84, 
115.40, 107.96 (Ar-C, CN). MS (MALDI-TOF) m/z 236.0813 [M+H]
+






Phthalonitrile 5.34. A mixture of Pn 5.33 (0.5 g, 2.13 mmol) and 1,4-dioxane-2,6-dione 
(0.275 g, 2.37 mmol) was dissolved in DMF (1.5 mL) and stirred overnight at 25 °C. Then water 
(5.0 mL) was added to the solution to precipitate the product. The solid was centrifuged and 
washed with water and hexane. The solid was dried under vacuum for 2 days to afford the pure 
yellow solid (688.7 mg, 92.1%), mp 176 – 177 °C). 
1
H NMR (CD3COCD3, 400 MHz): δ 9.68 
(br, 1H, NH), 8.01 (d, J = 8.76 Hz, 1H, Ar-H), 7.86 (d, J = 9.00 Hz, 2H, Ar-H), 7.60 (d, J = 2.52 
Hz, 1H, Ar-H), 7.42 (dd, J = 2.60 Hz, 1H, Ar-H), 7.20 (d, J = 9.00 Hz, 2H, Ar-H), 4.37 (s, 2H, 
CH2O), 4.27 (s, 2H, CH2O).  
13
C NMR (CD3COCD3, 100 MHz): δ 172.4, 168.8 (CO), 163.0, 
150.6, 137.3, 136.9, 122.8, 122.5, 122.3, 122.0, 118.3, 109.5 (Ar-H), 116.5, 116.1 (CN), 72.5, 
69.7 (CH2O). MS (MALDI-TOF) m/z 352.0800 [M+H]
+
, calcd for, C18H14N3O5, 352.0933. 
Phthalonitrile 5.35. Phthalonitrile 5.34 (0.25 g, 0.712 mmol) was dissolved in DMF (8 
mL). Et3N (90 mg, 0.912 mmol, 122.4 µL, 1 h), HOBt (102.4 mg, 0.757 mmol, 2 h) and tert-
butyl-12-amino-4,7,10-trioxadodecanoate (240.3 mg, 0.868 mmol) were added to the reaction 
solution and the solution was stirred for 20 min. EDCI (117.9 mg, 0.757 mmol) was added to the 
reaction solution in one portion. The reaction solution was stirred for 3 days at 25 °C. The 
reaction solution was diluted using ethyl acetate (20 mL) and the organic solution washed 
subsequently with water (30 mL × 2). The organic layer was dried over anhydrous sodium 
sulfate. The solvent was evaporated and the crude was purified by silica column eluted by 
DCM/chloroform (4:1), and then DCM/methanol (98:2) to afford yellowish oil (400.6 mg, 
92.2%).  
1
H NMR (CD3COCD3, 400 MHz): δ 10.10 (br, 1H, NH), 8.02 (d, J = 8.76 Hz, 1H, Ar-
H), 7.88 (d, J = 8.96 Hz, 2H, Ar-H), 7.59 (d, J = 2.52 Hz, 1H, Ar-H), 7.44 – 7.40 (m, 1H, Ar-H), 
7.19 (d, J = 8.96 Hz, 2H, Ar-H), 4.21 (d, J = 3.24, 2H, CH2O), 3.65 (t, J = 6.36, 2H, CH2O), 3.57 







C NMR (CD3COCD3, 100 MHz): δ 171.3, 170.3, 168.7 (C=O), 163.0, 150.6, 137.6, 
136.9, 128.2, 125.4, 122.8, 122.5, 122.4, 122.0, 120.1, 118.3, 110.3, 109.5 (Ar-H), 116.5, 116.1 
(CN), 80.5 (CO), 72.6, 72.2, 71.1, 71.0, 70.2, 67.6 (CH2O), 39.6, 37.0 (CH2), 28.3 (C(CH3)3). 
MS (MALDI-TOF) m/z 633.2551 [M+Na]
+
, calcd for C31H38N4NaO9 610.2536. 
ZnPc 5.37. A mixture of 5.36 (1002.39 mg, 3.0 mmol), phthalonitrile 5.35 (610.26 mg, 
1.0 mmol) and zinc acetate (254.7 mg, 1.4 mmol) were mixed together in DMAE (10.0 mL). The 
solution was heated under the flow of argon, and two drops of DBN were added to the reaction 
solution. The reaction solution was further heateed at 135 °C for 5 hours. After the reaction, the 
solvent was removed under vacuum. The residue was purified by column chromatography 
(neutral alumina, 10 cm, loaded by chloroform) with the elution of mixed solvents of 
chloroform/DCM (95:5). A second column (sephadex G-100) eluted by DCM gave the title 
compound as a green solid, dried at 85 °C under vacuum overnight (50.8 mg, 10.1%). 
1
H NMR 
(d-DMF, 400 MHz): δ 9.25 – 8.83 (m, 9H, Ar-H), 8.25 – 8.22 (m, 1H, Ar-H), 7.89 – 7.54 (m, 
3H, Ar-H), 4.34 (s, 2H, OCH2), 4.26 (s, 2H, OCH2), 3.65 – 3.57 (m, 12H, OCH2), 3.40 – 3.37 
(m, 4H, OCH2), 3.03 – 2.99 (m, 12H, SCH2), 2.69 – 2.65 (m, 2H, CH2), 2.56 – 2.45 (m, 36H, 
NCH2), 2.33 – 2.29 (m, 12H, NCH2), 1.43 – 1.41 (m, 9H, Boc- C(CH3)3). MS (MALDI-TOF) 
m/z peak at 1621.551 (M-tBu+H)
+
, calcd for C75H96N16O9S6Zn 1621.519.  UV-vis (DMF): λmax 
(log ε) 371 (4.70), 631 (4.38), 701 (5.09) nm.  
ZnPc 5.38 (40 mg, 0.0239 mmol) was then dissolved and stirred in DCM (1 mL) and 
CH3I (2 mL) at 25 °C for 48 h. The solvent was removed under reduced pressure. The residue 
was washed with hexanes several times. The residue was purified on C18 column (40-75 µm) 
eluted by methanol/water (40:60 → 100:0) to give a green solid (20.3 mg, 33.7%). 
1
H NMR 





4H, Ar-H), 7.55 – 7.51 (m, 2H, Ar-H), 4.39 – 4.20 (m, 24H, OCH2/NCH3), 4.26 (s, 4H, OCH2), 
3.68 – 3.57 (m, 68H, OCH2/NCH3), 2.48 – 2.45 (m, 2H, CH2), 1.46 – 1.41 (m, 9H, Boc- 
C(CH3)3). UV-vis (DMF): λmax (log ε) 376 (4.68), 625 (4.31), 696 (5.04) nm. 
ZnPc 5.39. The Pc 5.38 was dissolved in a mixture of DCM/TFA (3 mL/3 mL) and the 
solution was stirred at 0 C for 4 h. After the reaction, the solvent was removed using nitrogen 
gas. The resulting residue was dissolved in acetone, cold ethyl ether added to precipitate the 
product and then centrifuged to afford green solid in quantitative yield. 
1
H NMR (DMSO-d6, 400 
MHz): δ 9.51 – 9.35 (m, 6H, Ar-H), 8.37 – 8.32 (m, 1H, Ar-H), 8.10 – 7.96 (m, 4H, Ar-H), 7.54 
– 7.51 (m, 2H, Ar-H), 4.39 – 4.25 (m, 24H, OCH2/NCH3), 3.81 (s, 4H, OCH2), 3.72 – 3.57 (m, 
68H, OCH2/NCH3), 2.55 – 2.52 (m, 2H, CH2). UV-vis (DMF): λmax (log ε) 378 (4.58), 625 
(4.22), 696 (4.94) nm. 
 ZnPc 5.40. The monoclonal antibody was reconstituted at 2 mg/mL in 0.1 M NaHCO3 
solution. Pc 5.39 (1 mg, 0.0005 mmol) was dissolved in DMSO (50 µL). DIEA (0.078 mg, 0.006 
mmol), HOBt (0.34 mg, 0.002 mmol) and TBTU (0.59 mg, 0.002 mmol) were added to the 
DMSO solvent and the reaction solution was stirred for 2 min. The reconstituted monoclonal 
antibody solution (500 µL) was added into the activated phthalocyanine solution and the 
combined solution was kept with shaking frequently at 25 °C for 1 hour. Then the solution was 
kept at 4 C overnight. The crude antibody-Pc conjugate solution was purified by spin column 
chromatography (50 µL for each spin column to load, 750 rcf, 1 min, 24 C). The resulting 
solution was combined together to afford the blue conjugate solution (600 µL). 
 ZnPc 5.43. A mixture of phthalonitrile 5.42 (75.0 mg, 0.24 mmol), phthalonitrile (885.0 
mg, 6.60 mmol), and zinc acetate (348.6 mg, 1.9 mmol) were mixed together in DMAE (10.0 





added to the reaction solution. The reaction solution was further heated at 140 °C for 5 hours. 
After the reaction, the solvent was removed under vacuum. The residue was filtered under 
gravity and purified by silica column chromatography with the elution of DCM/THF (3:1). The 
product was eluted by acetone and concentrated to give a blue-green solid. Another silica column 
eluted by DCM/ethyl acetate (1:2) gave the product as a green solid (17.8 mg, 9.8%). 
1
H NMR 
(DMF-d7): δ 9.32 - 9.02 (m, 6H, Ar-H), 8.29-8.12 (m, 6H, Ar-H), 7.82-7.42 (m, 2H, Ar-H), 6.99 
(br, 1H, OH), 5.11-4.97 (m, 2H, OCH2), 4.45-4.42 (m, 2H, OCH2), 4.12 (t, J = 4.76, 2H, OCH2), 
3.68 (t, J = 3.52, 2H, OCH2), 3.48 (t, J = 4.68, 2H, OCH2), 3.30-3.27 (s, 3H, OCH3). 
13
C NMR 
(DMF-d7, 100 MHz): δ 154.4, 153.9, 152.9, 150.7, 139.3, 138.0, 130.3, 130.2, 129.4, 126.7, 
123.8, 123.5, 123.4, 123.2, 123.0, 119.7, 117.7 (Ar-C), 72.9, 72.1, 71.7, 71.4 (OCH2), 59.1 
(OCH3). MS (MALDI-TOF) m/z peak at 755.225 (M+H)
+
, calcd for C39H31N8O5Zn 755.171.  
UV-vis (DMF): λmax (log ε) 342 (4.71), 628 (4.49), 694 (5.19) nm.
 
 ZnPc 5.44. A mixture of Pc 5.43 (9.0 mg, 0.012 mmol) and tert-Butyl-12-iodo-4,7,10-
trioxadodecanoate (6.6 mg, 0.017 mmol) were mixed together in DMF (5.0 mL). The solution 
was heated at 70 °C, and K2CO3 (25.0 mg, 1.8 mmol) was added to the reaction solution. The 
reaction solution was heated for 5-6 hours. After the reaction, the solvent was removed under 
reduced pressure. The residue was dissolved in ethyl acetate (10 mL), washed with water (10 
mL) and dried to obtain a blue solid. The solid was purified by column chromatography with the 
elution of DCM/methanol (95:5) to give a blue solid (9.2 mg, 76.7 %).
 1
H NMR (DMF-d7): δ 
9.40-9.35 (m, 6H, Ar-H), 8.26-8.20 (m, 6H, Ar-H), 7.62 (s, 2H, Ar-H), 4.94 (t, J = 4.52, 4H, 
OCH2), 4.46 (t, J = 4.56, 4H, OCH2), 4.10 (t, J = 4.28, 4H, OCH2), 3.84-3.81 (m, 4H, OCH2), 
3.67-3.62 (m, 6H, OCH2), 3.58-3.54 (m, 4H, OCH2), 3.24 (s, 3H, OCH3), 2.42 (t, J = 6.24, 2H, 









151.55, 151.8, 139.9, 139.6, 130.3, 130.2, 128.7, 128.4, 123.9, 123.4, 117.3 (Ar-C),  80.8 (C=O), 
72.8, 72.0, 71.6, 71.4, 71.3, 71.2, 70.8, 67.7 (OCH2), 59.0 (OCH3), 37.2 (CH2), 28.5 (C(CH3)3). 






, calcd for 
C52H55N8O10Zn 1014.325, C48H47N8O10Zn 959.271. The above product (9.2 mg, 9.1 mmol) was 
subjected to DCM/TFA (1:1, 5 mL) treatment for 4 h to remove the tert-butyl protecting group. 
After the reaction, the solvent was removed under reduced pressure (at 65 °C). The residue was 
dissolved in DCM (1.0 mL), treated with cold diethyl ether (10 mL) and centrifuged to obtain a 
blue solid. The solid was dried under vacuum for two days to give a blue solid (8.5 mg, 97.7 %).
 
1
H NMR (DMF-d7): δ 9.39 (s, 6H, Ar-H), 8.23(s, 6H, Ar-H), 7.62 (s, 2H, Ar-H), 4.96 (br, 4H, 
OCH2), 4.47 (s, 4H, OCH2), 4.10 (t, J = 4.72, 4H, OCH2), 3.85-3.81 (m, 4H, OCH2), 3.76-3.62 
(m, 6H, OCH2), 3.60-3.56 (m, 2H, OCH2), 3.47-3.44 (m, 2H, OCH2), 3.24 (s, 3H, OCH3), 2.54 
(t, J = 6.28, 2H, CH2). 
13
C NMR (DMF-d7): δ 173.7 (C=O), 154.4, 139.8, 139.6, 130.2, 123.8, 
123.5, 117.2 (Ar-C),  83.5 (C=O), 73.5, 72.8, 71.92, 71.89, 71.63, 71.61, 71.5, 71.4, 71.3, 71.2, 





; calcd for C48H47N8O10Zn 959.271, C48H47N8NaO10Zn 981.253. 
UV-vis (DMF): λmax (log ε) 335 (4.57), 619 (4.42), 688 (5.18) nm.  
ZnPc 5.45. The monoclonal antibody was reconstituted at 2 mg/mL in 0.1 M NaHCO3 
solution. Pc 5.44 (1 mg, 0.001 mmol) was dissolved in DMSO (50 µL). DIEA (0.078 mg, 0.006 
mmol. 1.1 µL), HOBt (0.34 mg, 0.002 mmol) and TBTU (0.59 mg, 0.002 mmol) were added to 
the DMSO solvent. The reaction solution was stirred for 2 h and added the monoclonal antiCEA 
as described for conjugate 5.40 above. The crude antibody-Pc conjugate solution was purified by 
spin column chromatography (50 µL for each spin column to load, 750 rcf (3000 rpm), 1 min, 24 





ZnPc 5.47. The monoclonal antibody was reconstituted at 2 mg/mL in 0.1 M NaHCO3 
solution. Pc 5.46 (1 mg, 0.001 mmol) was dissolved in DMSO (50 µL). DIEA (0.078 mg, 0.006 
mmol. 1.1 µL), HOBt (0.34 mg, 0.002 mmol) and TBTU (0.59 mg, 0.002 mmol) were added to 
the DMSO solvent. The reaction solution was stirred for 2 h and added the monoclonal antiCEA 
as described for conjugate 5.40 above. The crude antibody-Pc conjugate solution was purified by 
spin column chromatography (50 µL for each spin column to load, 750 rcf (8000 rpm), 1 min, 24 
C). The resulting solution was combined to afford the blue conjugate solution (700 µL). 
5.4.3. Cell Studies  
 The human carcinoma HEp2 cells used in this study were kept in a 50:50 mixture of 
DMEM:AMEM (Invitrogen) complemented with 5% FBS (Invitrogen), Primocin antibiotic 
(Invitrogen) and 5% CO2 at 37 
o
C. To sustain subconfluent stocks, the cells had to be subcultured 




 passage.  
 Time-Dependent Cellular Uptake: The incubation of the human carcinoma HEp2 cells 
involved 7500 cells per well in a Costar 96-well plate and permitted to grow for 48 h. Each ZnPc 
stock solution was prepared in DMSO at 32 mM and then diluted to 20 µM in medium (a 2X 
stock). Finally, a concentration of 10 µM with a maximum DMSO concentration of 1% was 
achieved via dilution into the 96-well plate. The cellular uptake was permitted to go on for 0, 1, 
2, 4, 8, 12 and 24 h, after which it was halted. This was achieved by removing the loading 
medium and washing the wells with PBS. The concentration of each compound was obtained 
using standard curves via intrinsic fluorescence. The fluorescence was measured using a BMG 
FLUOstar plate reader with a 355 nm excitation and a 650 nm emission filter. The cells were 
measured and their uptake expressed in nM compound concentration per unit cell, following a 





 Dark Cytotoxicity: The plating of HEp2 cells was achieved as described above. The ZnPcs 
were diluted to a final concentration of 400 µM in medium. Two-fold serial dilutions to 50 µM 
were prepared and the cells were incubated overnight. The cell toxicity was calculated using 
Promega’s Cell Titer Blue Viability assay according to the manufacturer’s directions. Cells that 
were not treated were considered 100% viable, while those treated with 0.2% saponin were 
considered to be nonviable (0% viability). The dose-response curves were used to calculate IC50 
values for each ZnPc. 
 Phototoxicity: The plating of HEp2 cells was achieved as described above. The ZnPc 
concentrations ranged between 6.25-100 µM. Following overnight loading, 50 mM HEPES pH 
7.2 replaced the initial medium. A NewPort light system with a 175 W halogen lamp  was used 
to irradiate the cells for 20 min. The light was filtered through a water filter to provide 
approximately 1.5 J/cm
2
 light dose required. The culture was kept on a 5 
o
C Echotherm 
chilling/heating plate (Torrey Pines Scientific, Inc.) to keep the cells cool. Subsequent to the 
light exposure, the plate was incubated overnight and the cell viability calculated as described for 
the dark cytotoxicity. 
Microscopy: The incubation of the cells was done in a glass bottom 6-well plate (MatTek) 
and permitted to grow for 48 h. The cells were then exposed to 10 µM of each ZnPc for 6 h. 
Tracers for different organelles were used at the shown concentrations: LysoSensor Green 50 
nM, MitoTracker Green 250 nM, ER Tracker Blue/white 100 nM, and BODIPY FL C5 ceramide 
1 µM. The cells were incubated concurrently with ZnPcs and then diluted with tracers for 30 min 
before washing them 3 times using PBS. A Leica DMRXA microscope with a 40× NA 0.8dip 
objective lens and DAPI, GFP and Texas Red filter cubes (Chroma Technologies) was used to 





5.4.4. Methods for Mouse Imaging 
 Nude mice were subcutaneously implanted on either side of the upper thigh with 1 x 10
6
 
HT-29 colon cancer cells suspended in DMEM media: Matrigel 4:1 (v/v).  Tumors were allowed 
to establish until visible (approximately 100 cm
3
).  One additional mouse had no implanted 
tumor but was used to evaluate the kinetics of tissue uptake, in addition to the retention of the Pc 
or PcCEA in normal subcutaneous tissue.  Mice were anesthetized using isoflurane to effect, and 
imaged for 20 seconds at 630 nm excitation/700 nm emission in a Kodak In Vivo FX imager to 
obtain a background image (0 hours), then given an intratumor administration of 80 µL of 100 
µM phthalocyanine only (Pc 5.44) on the right flank or ZnPc coupled with antiCEA (Pc-antiCEA 
5.45) in the left flank.  Mice were then returned to their boxes and re-imaged at times of 1, 6, 24 
and 96 hours.   
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APPENDIX B: BIOLOGICAL DATA FOR COMPOUNDS IN CHAPTER 3 
 
Figure B.1. Subcellular localization of Pc 3.4 in A431 cells at 10 µM for 6 h. (a) Phase contrast, 
(b) Overlay of 3.4 fluorescence and phase contrast, (c) ER Tracker Blue/White fluorescence, (e) 
MitoTrack green fluorescence, (g) BoDIPY Ceramide, (i) LysoSensor green fluorescence, and 






Figure B.2. Subcellular localization of Pc 3.4 in HEp2 cells at 10 µM for 6 h. (a) Phase contrast, 
(b) Overlay of 3.4 fluorescence and phase contrast, (c) ER Tracker Blue/White fluorescence, (e) 
MitoTrack green fluorescence, (g) BoDIPY Ceramide, (i) LysoSensor green fluorescence, and 







Figure B.3. Subcellular localization of Pc 3.4 in HT-29 cells at 10 µM for 6 h. (a) Phase 
contrast, (b) Overlay of 3.4 fluorescence and phase contrast, (c) ER Tracker Blue/White 
fluorescence, (e) MitoTrack green fluorescence, (g) BoDIPY Ceramide, (i) LysoSensor green 







Figure B.4. Subcellular fluorescence of Pcs in A431 cells at 10 µM for 6 h. (a) Phase contrast, 
(b) Pc 3.4, (c) Pc 3.9, (d) Pc 3.6, (e) Pc 3.5, (f) Pc 3.11. Scale bar: 10 µm. 
 
Figure B.5. Subcellular fluorescence of Pcs in HEp2 cells at 10 µM for 6 h. (a) Phase contrast, 
(b) Pc 3.4, (c) Pc 3.9, (d) Pc 3.6, (e) Pc 3.5, (f) Pc 3.11. Scale bar: 10 µm. 
 
Figure B.6. Subcellular fluorescence of Pcs in HT-29 cells at 10 µM for 6 h. (a) Phase contrast, 
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